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Abstract 
This study investigated some characteristics of dental pulp stromal/stem 
cells (DPSCs) isolated from healthy teeth (hDPSCs) compared to DPSCs 
isolated from teeth with shallow carious lesions (cDPSCs) with a view to the 
use of both cell types in hard tissue engineering strategies. Osteogenic 
differentiation was investigated using appropriate histochemical staining 
and osteogenic marker expression (ALPL, OC, RUNX-2). In addition, 
angiogenic (VEGFR-2, PECAM-1) and inflammatory gene markers (TLR-2, 
TLR-4) were investigated together with the secretion of the pro-
inflammatory cytokines (IL-6 and IL-8). The activity of the pro-osteogenic 
IGF axis was also investigated in hDPSCs and cDPSC cultures. cDPSCs 
exhibited significantly higher clonogenic potential, and possess a higher 
proportion of cell that express mesenchymal stem cell markers (CD146+, 
CD90+ and CD105+, CD45-, CD31-) compared with hDPSCs. Evidence 
also suggested that cDPSCs had a greater osteoblastic differentiation 
potential than hDPSCs. cDPSCs expressed higher levels of inflammatory 
markers than hDPSCs together with higher concentrations of IL-6 and IL-8 
in conditioned medium indicative of retention of a carious phenotype 
following cell isolation and culture. Finally functional examination of the IGF 
axis suggested a role for insulin-like growth factor binding proteins-2 and -3 
(IGFBP-2 and -3) in the osteogenic differentiation of DPSCs. Therefore 
cDPSCs are comparable to hDPSCs in terms of their osteogenic potential 
and the inflammatory environment of cDPSCs may offer a promising cell 
source for future mineralised tissue repair and regeneration. 
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 Literature Review 
1.1 General introduction 
Tissue engineering using the triad; scaffolds, stem cells and signals may 
provide an alternative method for pulp capping and root therapy, as well as 
for maxillofacial bone reconstruction [1-3]. Defects in the jaw bone (mandible 
or maxilla) happen due to trauma, inflammation or tumour and they remain a 
major clinical challenge [4]. The terms “tissue repair” and “tissue 
regeneration” have been used to describe the process of restoration of  
tissue morphology, structure and function after injury [5]. In vivo such 
processes are controlled by the differentiation of remaining vital cells or 
trans-differentiation of stem/progenitor cells located in or around the 
damaged tissue [5-7]. Mineralised tissue formation following noxious stimuli 
affecting the dentine-pulp complex, indicates that this distinctive tissue can 
adapt itself in early disease conditions to maintain vitality and essentially 
replace lost structure and function [8].  
1.2  Biology of dentine  
Dentine is thick mineralised tissue that forms the bulk of the tooth to protect 
the underlying non-mineralised pulp tissue. It is capped with the enamel 
(highly mineralised protective tissue in the crown part of the tooth, and in the 
root, it is covered by the cementum (a mineralised structure contributing to 
the attachment of the teeth to the surrounding bony socket). Generally, 
dentine is comprised of minerals (70% in weight), organic matrix (20% in 
weight) and water (10% in weight) [9].   
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1.2.1 Dentine structure and development  
The initial stage of tooth development starts with invagination of epithelial 
cells from stomodeum. These cells form the enamel organ, which consists of 
enamel epithelium, stratum intermedium, stellate reticulum and enamel 
matrix-secreting ameloblasts [10]. The enamel organ is surrounded by 
ectomesenchymal tissue that are derived from the neural crest, which later 
forms the dental papilla [11]. The outermost layer of dental papilla opposes 
the inner enamel epithelium (IEE) and is induced by it to differentiate into 
odontoblast. Odontoblasts are the principle cells involved in the synthesis of 
dentine matrix [9]. These cells produce dentine, and their cell bodies are 
located outside the pre-dentin/dentine layer; at the dentine-pulp interface. 
Odontoblastic processes cross the dentine layer and are located inside the 
dentinal tubules. The number of these tubules is higher in the inner third 
layer compared with the outer third layer of dentine [12]. In the outer layer of 
the tooth, dentine structure is atubular or contains thin and curved tubules; 
called mantle dentine (in the coronal region), and Tomes granular layer and 
hyaline Hopewell-Smith layer (in the root region). These peripheral layers 
are less mineralised and resilient to adapt for dissipating pressures or forces 
transported from the enamel, which otherwise would cause enamel cracks 
and consequently detachment of the fragmented enamel [9]. Again in the 
root region, the elasticity of peripheral dentine layer is crucial to resist the 
axial and lateral pressures [13]. The largest part of the dentine layer is 
formed by the circumpulpal dentine. This layer is mainly composed of 
intertubular dentine (prominent part) and peritubular (around the lumen of 
the tubules). Differences in the composition (non-collagenous protein), 
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structure and some crystallo-chemical specificities between the two types of 
dentine are well documented [14-17].          
Dentine deposition is a continuous function of odontoblasts and occurs at a 
consistent rate throughout the life of the tooth, although it is considerably 
diminished in rapidly progressing carious lesions [18]. Primary dentine is the 
earliest dentine secreted during tooth development [8] (Figure 1), and its   
deposition rate is approximately 4µm/day until the tooth becomes functional 
(antagonistic cusps become in contact) and the roots become completely 
formed [9].Then the formation of secondary dentine starts but the deposition 
rate decreases to approximately 0.4µm/day and it continues throughout the 
life of the tooth. Primary and secondary dentine share the same chemical 
composition and histological structure [8], however, they are different in their 
morphology [9]. Secondary dentine is physiologically secreted following 
tooth eruption and apical closure. It is responsible for narrowing the pulp 
canal as it  is deposited on the roof and lateral walls of the pulp chamber [8]. 
Tertiary dentine is secreted to protect the underlying pulp from possible 
injury in response to external stimuli such as abrasion, erosion and bacterial 
infection [8, 19]. Its secretion is regulated by bioactive molecules, which are 
sequestered in dentine matrix during tooth development [20-22]. In the early 
stages of pulp response to moderate external stimuli, pre-existing 
odontoblasts produce reactionary dentine (tertiary dentine) which becomes 
continuous with primary and secondary dentine structures [23, 24]. However, 
in the case of more intense external stimuli, localized odontoblastic damage 
occurs and odontoblast-like cells differentiate from dental pulp stem cells, 
which secrete reparative dentine (tertiary dentin) to form dentine bridging in 
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the area of pulp exposure. Many factors may be involved in localized 
odontoblasts damage including bacterial toxins or high levels of pro-
inflammatory mediators, which are secreted locally as a response to severe 
dental injury [25]. During inflammation, stem/progenitor cells are recruited to 
the site of injury where they differentiate into odontoblast-like cells and 
secrete tertiary reparative dentine. This protects the underlying pulp tissue 
from further bacterial attack [20].  
Odontoblast gene expression profile :   
Odontoblasts are formed as a layer of palisade cells at the dentine pulp 
interface (Figure 2). They are post-mitotic cells, which play a crucial role 
during dentine formation by secreting the organic matrix macromolecules 
(pre-dentine) and are actively involved in the mineralisation processes [26, 
27]. In earlier studies, a unique in vitro culture system of human dental pulp 
cells has been successfully investigated, which allow differentiation of these 
cells into odontoblast-like cells with comparable morphological and 
functional properties to that of native odontoblasts [28, 29]. Cultured 
odontoblast-like cells have been used to investigate the biological functions 
of these cells in vitro [30-32]. Moreover, successful isolation of mature native 
human odontoblasts from the pulp chamber allow researchers to profile the 
gene expression of these cells [33]. Interestingly, it has been observed that 
both cultured odontoblasts and mature native odotoblasts expressed the 
odontoblastic markers including DSPP, DSP, Hsp25 and nestin [34]. 
However, DSPP and DSP specificity to odontoblasts has been argued [33, 
35, 36]. As odontoblasts are hard tissue-forming cells contributing to dentine 
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formation, the expression of COL1A1 and Matrilin 4 has been observed by 
these cells [33].   
 
1.2.2 Dentine matrix 
Odontoblast are the key cells for extracellular matrix (ECM) formation. 
Depending on dentine type and location, dentinogenesis comprises three 
different mineralisation processes as follows: 1) dentine outer layer resulting 
from the cell-derived events involving the presence of matrix vesicles and 
their enzymatic equipment and 2) intertubular dentine formed as a result of 
active transformation of pre-dentine to dentine, which is a matrix controlled 
process, and 3) the peritubular dentine resulting from passive deposit of 
serum-derived molecules along the walls of the dentinal tubules [9].   
Biomineralisation is defined as a process by which hydroxyapatite (HA) is 
secreted in the extracellular matrix. Initiation and regulation of the 
mineralisation process are mediated by the extracellular matrix [37-39]. 
Table 1 summarizes the molecules that play a role in dentinogenesis 
processes.  
During dentine mineralisation; three components are needed to achieve 
proper mineralisation including collagen that forms the scaffold, non-
collagenous proteins that bind to the collagen scaffold and act as a mineral 
nucleator, and crystalline calcium phosphate that is deposited in a controlled 
manner [40]. The collagen fibrils and their associated proteoglycans are 
synthesized by odontoblasts in the proximal pre-dentine. These fibrils 
increase in diameter by end to end elongation and lateral aggregation. Then 
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they migrate throughout the pre-dentine, reaching the place where they 
undergo mineralisation [41-43]. This is followed by discharge of non-
collagenous phosphorylated proteins and mineral associated proteoglycans, 
which are secreted distally in the pre-dentine (near pre-dentine/dentine 
junction), where the mineralisation occurs [9]. Some matrix components 
follow the intercellular pathway and migrate directly from the serum to the 
dentine; albumin and phospholipids were observed to be involved in this 
process [44].  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: The key player components of ECM and their role in dentin     
formation and mineralization.  
ECM components Notes[9] 
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Type I collagen  Major protein found in dentine (~90% of the organic matrix) 
 Synthesized by odontoblasts 
 Provide an organised scaffold 
 Has self-aggregating properties that lead to the formation of 
calcospherites. 
Dentine Sialo 
Phospho Protein 
(DSPP) 
 SIBLINGs (small integrin-building ligand N-linked glycoproteins) 
 Immediately cleaved after secretion into DSP, DGP and DPP 
 Its mutation leads to different forms of dentinogenesis imperfecta 
Dentine Sialo 
Protein (DSP) 
 SIBLINGs (small integrin building ligand N-linked glycoproteins) 
 It is suggested to be less effective mineralisation mediator relative 
to other ECM molecules.  
 Inhibits the formation and growth of calcium phosphate mineral 
crystal   
Dentine Phospho 
Proteins (DPP) 
 SIBLINGs (small integrin building ligand N-linked glycoproteins) 
 Form more than 50% of the non-collagenous protein in dentine  
 Binds to calcium, hydroxyapatite and collagen 
 At low concentration, it causes nucleation 
 At high concentration it inhibits the crystal growth 
Dentine Matrix 
Protein-1 
(DMP-1) 
 SIBLINGs (small integrin building ligand N-linked glycoproteins) 
 Interacts with other molecules and regulates the transcription of 
DSPP gene 
 Has a calcium binding capacity and great affinity to collagen fibrils  
 Enhances the nucleation of calcium phosphate crystals and 
regulate their growth 
Bone Sialo Protein 
(BSP) 
 SIBLINGs (small integrin building ligand N-linked glycoproteins) 
 Initiate the formation of mineral crystals  
 Marker of osteogenic differentiation, it is also expressed in dentine 
but at lower level. It is intensifies collagen fibrillation 
 Initiates crystal nucleation and induce cell adhesion to the ECM 
Osteopontin  SIBLINGs (small integrin building ligand N-linked glycoproteins) 
 Mediates hydroxyapatite binding 
 Mediates cell attachments/signalling 
 Its phosphorylation is important in enhancing mineralisation  
Matrix Extracellular 
Phosphoglyco 
Protein (MEPE) 
 SIBLINGs (small integrin building ligand N-linked glycoproteins) 
 The central protein of MEPE (Dentoin) plays a role in initiating the 
differentiation of pulp cells into odontoblasts/osteoblasts.  
Osteoclacin (OCN)  Highly expressed in differentiating odontoblasts as it might be 
involved in glucose metabolism needed by these active cells 
Glycosaminoglycans 
(GAGs) 
 Identified as mineralisation inhibitor, need to be enzymatically 
modified at place where mineralisation should be initiated  
 Two distinct group;  
a) First group observed in the pre-dentine and involved in 
collagen fibrils moving from the proximal to the distal part of 
the pre-dentine 
b) Second group is secreted in dentin associated with 
mineralisation and they are stable, participated in dentine 
formation and become dentine component  
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Figure 1: Tooth development  
Teeth develop from both ectoderm and mesoderm.  Enamel develops from 
ectoderm of the primordial oral cavity, and all other tooth associated tissues 
develop from the associated mesenchyme. (a) Bud stage: localized growth of 
epithelial cells surrounded by proliferating mesenchymal cells. (b) Cap stage: the 
inner surface of each ectodermal tooth bud becomes invaginated by mesenchymal 
tissue called dental papilla, which gives rise to dentine and dental pulp. The 
ectodermal cap-shaped covering over the papilla is called an enamel organ and will 
produce the future enamel of the tooth. As the enamel organ and dental papilla 
form, the surrounding mesenchyme condenses forming the dental sac, which later 
forms the cementum and periodontal ligament. (c) Bell stage: The mesenchymal 
cells in the dental papilla, adjacent to the inner enamel epithelium, differentiate into 
odontoblasts, which produce pre-dentine, and deposit it adjacent to the inner 
enamel epithelium. The pre-dentin later calcifies to form dentine. As the dentin 
thickens, the odontoblasts regress toward the centre of the dental papilla but 
odontoblastic processes remain embedded in the dentine. Cells of the inner enamel 
epithelium near the dentine form ameloblasts, which produce enamel in the form of 
prisms or rods over the dentine layer and forms the outer layer of the tooth or the 
crown. As enamel increases, the ameloblasts regress. (d) Both enamel and dentine 
help to create the crown. (e)  Root development occurs during the later stages of 
enamel and dentine development. (f) As the teeth develop, the jaws ossify and the 
outer cells of the dental sac also become active in bone formation. Each tooth is 
surrounded by bone, except at its crown, and is held in its bony socket or alveolus 
by the periodontal ligament. 
(Adapted from http://dentallecnotes.blogspot.co.uk/2011/08/note-on-tooth-
developmentodontogenesisw.html)  
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Figure 2: Anatomical representation of enamel, dentine, pulp and 
odontoblasts 
Enamel: Tooth enamel is the hardest substance in the human body. It 
consists mainly of calcium phosphate and calcium carbonate. 
Enamel covers the crown of each tooth and is important because 
its hard structure protects the underlying dentine structure.  
Dentine: The main structure of the tooth, which is a calcified connective 
tissue. It is underlying the enamel and slightly softer than enamel, 
contains millions of dentinal tubules which filled with fluid and 
odontoblastic processes.     
  Pulp:   The soft connective tissue that includes blood vessels, nerves and 
lymphatic vessels. It is contained within the central part of the 
tooth called the "pulp cavity".  
 (adapted from: http://www.dentist-charlotte-north-carolina-nc.com/tooth-pain-
mechanism.html) 
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1.3 Biology of bone 
Bone is a highly vascularized and mineralised tissue, and it is back bone of 
the musculoskeletal system. It supports and protects the internal vital organs 
and acts as a storage area for minerals (such as calcium), and provides a 
protective environment for marrow tissue (where blood cells are produced). 
In the context of dental tissue physiology, important bone structures include 
the bone of the mandible, maxilla, zygoma, frontal and nasal bones, other 
facial bones and base of the skull [45].  
Bone tissue regeneration has been a major research topic for decades. 
Minimal damage in any of the facial bones, can lead to considerable 
deformities. Therefore, the tissue engineering of such bony defects, in 
particular the mandible and maxilla remains an area of great interest [4].    
 
1.3.1 Bone structure and development 
There are two distinct pathways of bone development; intra-membranous 
bone ossification and endochondral cartilaginous bone ossification, both of 
which are dependent on mesenchymal cellular condensation prior to 
subsequent bone formation [46]. Although, the two types of bone ossification 
are different, they share the same  key regulator molecules. These include, 
parathyroid hormone related protein (PTHRP), bone morphogenic proteins 
(BMPs), vascular endothelial growth factor (VEGF), and fibroblastic growth 
factors (FGFs) [47-52].  
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 Intra-membranous ossification 
The intra-membranous ossification occurs by condensation of mesenchymal 
tissue and differentiation of stem cells into osteoblasts, which is associated 
with vascular invasion. The mandible and many cranial bones are formed by 
this process [46].   
 Endochondral/cartilaginous ossification 
Endochondral/cartilaginous ossification occurs in regions of low vasculature 
at the site of bone formation. Cartilaginous precursor is first established and 
this is reformed into bone. Chondrocytes undergo apoptotic death followed 
by resorption of cartilage which is replaced by bone tissue [52]. All long 
bones of the body and spinal vertebrae formed through this type of 
ossification [46].  
Bone is also composed of bone lining cells (resting osteoblast or surface 
osteocytes), bone forming cells (osteoblasts), bone resorbing cells 
(osteoclasts), and bone matrix (organic and inorganic matrix components). 
 
Bone Cells  
 Bone lining cells  
These cells are flattened and located in the periosteum and endosteum. 
These cells may act to remove the bone matrix covering (osteoid), as a 
preparative stage before osteoclastic resorption. Other evidence suggests 
that these cells are pre-osteoblasts and contribute to crystal growth in bone 
development [47, 53].  
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 Osteoblasts  
These cells are derived from multipotent mesenchymal stem cells [54], and 
are regulated by various signalling pathways and physiological stimuli [55]. 
Particularly important in this respect is the transcription factor RUNX-2 which  
influences the expression of other genes responsible for matrix protein 
assembly such as osteocalcin, type 1 collagen and bone sialoproteins [56, 
57]. Osteoblasts themselves contribute to the production and secretion of 
bone matrix proteins [58], along with cytokines and other signalling proteins 
[48, 59].   
Osteoblast gene expression profile :   
Osteoblasts have three stages in their development cycle; differentiation, 
proliferation, and matrix formation/mineralisation, and a specific gene 
expression profile is associated with each of these stages [60]. The COL1 
gene is expressed very early by osteoblasts during the proliferation phase 
[61], and down-regulated when the mineralisation begins [62]. Alkaline 
phosphatase (ALPL) is an early post proliferative osteoblast differentiation 
gene and is up-regulated as mineralisation begins. It is down-regulated in 
highly mineralised mature or maturing bone matrix [61, 63, 64]. As indicated 
above, RUNX-2 encodes a crucial transcription factor for early stage 
osteoblasts differentiation [65] and function[66]. RUNX-2 binds to promotor 
regions of the genes, which encode other bone marker proteins such as 
osteopontin (OP), osteocalcin (OC) and type 1 collagen alpha chain 
(COL1A1) [67]. Osteocalcin is expressed post proliferatively [62, 64] and is 
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associated with mineralised nodule formation and bone mineralisation [60]. It 
is as a marker for osteoblast maturation and its expression is associated 
with advanced stages of differentiation [61, 68]. 
 Osteocytes 
When osteoblasts become entrapped within the mineralised bone matrix, 
they are defined as osteocytes and they are connected to each other by 
actin-rich cellular processes [48, 58]. These cells are sensitive to mechanical 
pressure and contribute to bone remodelling and metabolism [47, 48, 58]. 
 Osteoclasts 
These cells are characterized as giant multi nucleated bone resorbing cells, 
and play an important role in bone remodelling. Osteoclasts are derived from 
undifferentiated mesenchymal stem cells and monocytes [47, 48, 53, 58]. 
Osteoclasts are involved in demineralisation and degradation of inorganic 
and organic matrix of bone through their specialized morphology and 
enzymes secretion profile. The balance between osteoclastic and 
osteoblastic function is important for bone remodelling [47, 69, 70].  
 
1.3.2 Bone matrix 
Bone matrix comprises 70% inorganic component, 20% organic component 
and 10% water. The inorganic component of bone extracellular matrix is 
composed mainly of carbonated calcium phosphate mineral in the form of 
extremely small hydroxyapatite crystals. These crystals are found to align in 
parallel layers in a collagenous organic framework. Collagen and 
hydroxyapatite together are the essential bone matrix building blocks [71-
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73]. The organic component of bone extracellular matrix is composed of 
90% collagens and 10% non-collagenous proteins (Figure 3 and Table 2). 
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Figure 3: Classification of the main organic component found in the bone   
extracellular matrix [74]  
        * Next table summarise the main role of ECM components in bone 
formation and mineralization    
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Collagens
Collagen type I
Collagen type III
Non-collagenous
Proteoglycans:
These proteins are 
present in the 
extracellular matrices 
of connective tissue 
including bone 
Decorin
Biglycan
Glycoproteins:
These proteins are 
present in the 
extracellular 
matrices of all body 
tissues and play a 
role in cellular 
attachment and 
response to stimuli  
Osteonectin 
Osteopontin
Bone sialoprotein
Matrix extracellular 
protein 
Alkaline 
phosphatase
Vitamin K-
dependant/gla 
matrix proteins
Matrix gla protein 
Osteocalcin 
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Table 2: A summary of the key organic components of bone ECM and their 
role in bone formation and mineralization [74] 
 
Protein type Notes 
Collagen type I  Main structural protein in organic matrix  
 Forms organic scaffold of the bone 
Collagen type 
III 
 Structural protein  
 Co-expressed with collagen type I  
 Associated with the walls of blood vessels and peripheral 
nerves  
Decorin  Highly expressed in bone matrix 
 Its expression is associated with osteoblast proliferation, during 
early matrix formation and bone mineralisation  
 Member of small leucine-rich proteoglycan family (SLRPs) 
 Binds collagen type I and growth factors  
 Regulate fibrillogenesis and mineralisation  
Biglycan  Highly expressed in bone matrix 
 Its expression is associated with osteoblasts proliferation, 
during late matrix formation and bone mineralisation  
 Member of small leucine-rich proteoglycan family (SLRPs) 
 Binds collagen type I and growth factors 
 Regulate fibrillogeneis and mineralisation   
Osteonectin  Binds to collagen, hydroxyapatite and growth factors 
 Regulate cell proliferation and angiogenesis  
 Has a regulatory role in bone turnover  
Osteopontin  SIBLING (small integrin binding ligand N-linked glycoprotein) 
 Expressed in kidney, liver, bone, vascular and immune system. 
 Has mineral binding sites 
 Regulate cell attachment and proliferation 
 Initiate intracellular signalling   
 Promote osteoclast migration  
Bone 
sialoprotein 
 Has mineral binding sites 
 Associated with initiation of mineralisation  
 Act as crystal nucleator   
Matrix 
extracellular 
protein 
 SIBLING (small integrin binding ligand N-linked glycoprotein) 
 Associated with mineralisation and bone remodelling 
Alkaline 
phosphatase 
 Present in body tissues (liver, intestine) and known as non-
specific alkaline phosphatase 
 In bone, it is known as bone specific and found within vesicles 
on the extracellular membrane of osteoblasts 
 Act as calcium binding protein  
 Play a role in mineralisation  
 Considered as an early osteoblastic marker 
Matrix gla 
protein 
 Act as calcium binding protein  
 Play a role in regulation and inhibition of mineralisation  
Osteocalcin  One of the most abundant proteins in bone 
 Frequently used as a biochemical marker for bone formation 
 Act as a calcium binding protein 
 Play a role in mineralisation and bone turnover 
 Has direct effect on the growth and maturation of 
hydroxyapatite crystals in bone  
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1.4 Dentine and bone  
There are similarities between bone and dentine but there are also some 
specific differences in detailed structure and molecular profile. Both tissues 
have mesodermal embryonic origin. In bone, osteoblasts are responsible for 
matrix formation and become osteocytes when embedded in bone canaliculi.  
However, odontoblasts are responsible for dentin formation then remain at 
the dentine-pulp interface with cell processes extending through dentin and 
occupying the lumen of dentinal tubules (Figure 2). In contrast with bone, 
dentine is not vascularized. In addition, bone formation also undergoes a 
constant remodelling, while dentine is a quite a stable structure. Despite this 
both osteoblasts and odontoblasts show similarities in behaviour at various 
stages of their life cycles [8, 9].  
 
1.4.1 Dentine repair and regeneration 
As indicated above, signalling cues from the enamel epithelium induce 
dentine formation by specialized odontoblasts [75]. In addition, 
demineralised dentine as well as bone extracts, enhance mineralisation 
when applied directly at sites of pulp exposure [76, 77]. Bone morphogenetic 
proteins (BMPs), combined with collagen-based matrices, bone sialoprotein 
(BSP) and growth/differentiation factor 11 (Gdf11) stimulate reparative 
dentine formation and dentine regeneration [77-83], and this occurs when 
these agents are in direct contact with dental pulp [84]. However in the case 
of inflamed pulp, these mechanisms are compromised [85]. On the other 
hand, autologous transplantation of stem cells derived from human-extracted 
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teeth into dentine and periodontal defects, with existence of appropriate 
signals was observed to partially regenerate dentine and periodontal tissues 
[86]. Therapeutic agents including Trioxide aggregates and Calcium 
hydroxide induce dentine deposition at the pulp/dentine interface, and this 
protects the pulp from further bacterial attack [87, 88]; however, this 
treatments did not show 100% successful clinical outcome. New therapeutic 
agents targeting the cells and molecules responsible for dental pulp 
inflammation are therefore necessary to increase healing capacity, 
counteract inflammation and maintain tissue vitality [89]. The reparative 
tissue induced by therapeutic reagents may on occasion lack appropriate 
structural integrity [87, 88], although they are able to enhance 
dentinogenesis under non-inflammatory conditions [85]. The control of the 
inflammatory context is essential for dental pulp healing . Such control needs 
to be exerted as early as possible as pulp tissue can quickly and irreversibly 
be damaged as a result of inflammation [90].    
 
1.4.2 Bone repair and regeneration  
Following bone fracture,  repair occurs by similar processes and molecules 
that are involved in both intramembranous and endochondral bone formation 
(Section1.3.1). It is exclusively heals without formation of any scar tissue 
[91, 92]. Bone injury leads to hematoma formation which is associated with 
the inflammatory response and leads to recruitment of essential cells and 
signalling molecules that regulate bone repair. These include pro-
inflammatory cytokines (TNF-α, interleukins) and other essential growth 
factors (FGFs, PDGF, VEGF) that will be discussed further in Section1.5.3. 
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For many years, simple autogenic, allogenic or xenogeneic bone grafts have 
been used for general tissue regeneration [93]. These include techniques 
such as free tissue transfer with microvasculature re-anastomosis of 
vascularized flaps from various body sites [94, 95]. Although these 
procedures have proven reliable and show effective outcomes, they need 
extended hospitalization and the donor site is associated with high rates of 
morbidity and complications. Tissue engineering can be considered as an 
alternative as it offers various potential advantages over other approaches 
including; decreased technical complexity and morbidity , as well as an 
ability to mimic the in vivo microenvironment [93]. However, more advanced 
approaches are needed for large bone defects to regenerate functionally 
sensitive tissue like maxillofacial tissue. Current regenerative approaches for 
bone reconstruction are summarized in (Table 3). 
In summary, mineralised tissue repair and regeneration are largely 
dependent on the extent of the inflammatory response, which influences the 
release of essential signalling molecules to achieve new mineralised tissue 
formation. It also depends on the balance between the damage and the 
regeneration induced by inflammation. Clinical intervention (mainly 
transplantation) in critical bone defects has shown a wide range of success. 
However, these techniques are not ideal because of their associated 
complications, and improved techniques and methodologies are required 
[46]. Hence cell-based tissue engineering therapies show great promise.   
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Table 3: Summery of commonly used regenerative approaches for bone 
repair and reconstruction  
Regenerative approach Overview 
Autologous bone 
reconstruction 
 Current gold standard approach [46, 96] 
 Contains essential components to achieve osteoinduction , 
osteoconduction and osteogenesis[97]  
 Use bone from rib, iliac crest of the same patient [96] 
 Its availability is limited with considerable postoperative 
complications [96, 98, 99] 
 Vascularized grafts have higher osteogenic potential. 
 Easily incorporated without immunogenic responses [100]   
Allogenic/Xenogenic 
bone reconstruction 
 It is available in various forms; demineralised bone matrix, 
cancellous chips, cortico-cancellous, cortical grafts, 
osteochondral, and whole-bone segments [46, 101] 
 Lower osteoinductivity with no cellular component  as grafts 
are devitalized during preparation [46]   
 Immunoreactions issues and transmissions of infections [46, 
102]  
Synthetic scaffolds 
 Wide range of alloplastic scaffolds used clinically such as 
ceramics and polymers [100] 
 Some synthetic polymers such as polycaprolactone, polylactic, 
polyglycolic acid and polylactic-co-glycolic acid scaffolds has 
been approved for use in craniofacial applications or as bone 
pins/screws [103] 
Gene therapy 
 Application of exogenous cytokines and growth factors, 
essential factors for bone regeneration such as bone 
morophogenic proteins, fibroblast growth factor, insulin-like 
growth factors, vascular endothelial growth factor and platelet 
derived growth factor [103, 104]    
 Can enhance cell adhesion, proliferation, migration, as well as 
osteogenic differentiation [104]  
 Combinations of growth factors have been demonstrated 
considerably greater bone healing compared to single growth 
factor treatment [105] 
Prefabricated bone 
engineering 
 Construction of tissue with similar characteristic as possible to 
the defect to be restored [106] 
 Well- established procedure in plastic reconstructive surgery 
that adapts to complex geometry of the defect [107]   
Cellular approach Section 1.5 
Autologous cells and 
others [46] 
Bone marrow aspirate concentrate  
Platelet-rich plasma 
Bioreactors 
Vascularization techniques 
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1.5 Cell-based mineralised tissue engineering  
Tissue engineering is a multidisciplinary field that holds hope and promise 
for tissue regeneration therapies. In order to understand the tissue 
engineering approach for regeneration therapy, three main pillars need to be 
investigated (scaffold, stem cells, and growth factors) to allow growth, 
differentiation and regeneration of tissues in 3D structures [108].   
 
1.5.1 Scaffold 
Three-dimensional scaffolds offer the necessary platform for cell growth, 
proliferation, and maintenance of differentiation. Scaffolds physically support 
deposited extracellular matrix and vascular ingrowth until the entire bone 
function is restored [109, 110]. Scaffold architecture determines the eventual 
shape of the new bone and cartilage. Several reviews have been published 
on the general properties and design features of biodegradable polymers 
and scaffolds [46, 111-116].  
 
1.5.2 Cells used in mineralised tissue engineering 
Early implantation of an effective cell type in the area where mineralised 
tissue regeneration is required leads to secretion of essential osteogenic and 
vasculogenic regulators as well as other key growth factors. Transplanted 
cells are able to recruit host cells and together form the vascularized tissue 
[46]. One of the most common challenges facing mineralised tissue 
regeneration is to define an appropriate source of cells that can be 
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successfully differentiated into mineralised tissue as well as neo-vasculature. 
[117, 118].    
 Stem cells 
Stem cell identification, function and therapeutic applications is an area of 
ongoing interest to many researchers. Stem cells were discovered in the 
early 1900s, and described as undifferentiated, primitive cells which can be 
used as building blocks for different tissues due to their ability to differentiate 
into other lineages and produce various cell types. During embryonic life, 
stem cells are described as totipotent and can differentiate to become any 
other cell type. With subsequent embryogenesis, cells are restricted by 
lineage and adopt a phenotype usually described as pluripotent [119] (Figure 
4). 
One of the well characterised adult somatic stem cells is the mesenchymal 
stem cell population which has been isolated from bone marrow and specific 
dental tissues [119]. Stem cells are often present together in special tissue 
compartments called niches and contain cells that may be used in the 
development and repair of body tissues. In these stem cell niches, stem cell 
proliferation, division, survival, migration and aging are regulated by cell-cell 
interaction and specific bioactive molecules. Stimulation of the stem cell 
niche(s) can occur during pathological conditions to repair tissue damage 
[120, 121]. 
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Figure 4: Embryonic and adult stem cell differentiation  
Stem cells can be differentiated into different types of tissue such as: 
adipose, cartilage, bone, cardiac, and neural tissues.  
(Adapted from wateverailsyou.blogspot.com) 
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1.5.2.1.1 Embryonic stem cells (ESCs) 
ESCs are formed following the fertilization up until the ninth week of 
gestation. ESCs are pluripotent with a high proliferative capacity and are 
used as a multi-lineages cell source. They can differentiate into vascular 
cells, nerve cells and mineralised tissue regeneration cells [122], and have 
therefore found application in bone tissue engineering [46]. ESCs are 
located in the inner cell mass of blastocytes and are distinct from adult stem 
cells which usually reside in the various adult somatic tissues. Research and 
clinical therapies using embryonic stem cells have been limited due to 
ethical and political issues; for example, issues around the destruction of 
human embryos for the sake of regenerative medicine, cloning of human 
embryos and violation of human dignity and privacy have all been raised 
[123]. Another cell type of comparable versatility is the induced pluripotency 
stem cells (iPSCs), which are pluripotent stem cells generated from non-
pluripotent somatic cells by transfection of appropriate genes artificially. 
iPSCs were first described in 2006, and were created via retroviral delivery 
of four transcription factors (Oct4, Sox2, Klf4, and Myc) into mouse 
fibroblasts [124]. iPSCs are similar to ESCs in morphology, gene expression 
profile, surface antigen presentation, and differentiation potential [125]. 
However, the clinical use of ESCs and iPSCs is still considered a potential 
risk due to their potential to form teratomas and other tumours [126]. In 
comparison and as an alternative to these cells, adult stem cells have been 
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investigated, which are present in many parts of the human body and their 
isolation does not involve the destruction of life or tumorigenesis [126].  
 
1.5.2.1.2   Adult / postnatal stem cells  
The identification of adult / postnatal stem cells has opened up new 
opportunities for stem cell research. These cells were investigated in a 
variety of postnatal tissues; for example, bone marrow, adipose tissue, cord 
blood, peripheral blood, and most important for the current project, they were 
also investigated in various dental tissues [127-136].   
Dental tissue-derived stem cells: 
More relevant to our studies, stem cells have been isolated from dental 
structures including periodontal tissue (PDLSCs) [137], apical papilla 
(SCAP) [138], dental follicle (DFSCs) [139], and dental pulp stem cells 
isolated from adult (DPSCs) and deciduous teeth (SHED) [140] (Figure 5).   
As dental tissues developed from oral ectoderm and neural crest derived 
mesenchyme, they contain pluripotent stem cell populations which display a 
developmental potential similar to ESCs and are able to differentiate into 
different lineages [141, 142]. Different cell types from different portions of the 
tooth germ (dental pulp, periodontal ligament, apical papilla, and dental 
follicles) share special features related to their neural crest origin; they also 
express mesenchymal stem cell-markers along with their pluripotent 
differentiation capacity. Typically they display a fibroblast-like morphology 
with associated high efficiency for adherent colony formation and high 
proliferative potential [143]. 
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Figure 5: Location of Dental Stem Cells 
 
TGPCs: Tooth Germ Progenitor Cells; DFSCs: Dental Follicle Stem 
Cells; SCAP: Stem Cells of Apical Papilla; DPSCs: Dental Pulp 
Stem Cell; PDLSCs: Periodontal Ligament Stem Cells; SHED: Stem 
cells from Human Exfoliated Deciduous teeth.    
(Adapted from: http://www.slideshare.net/hamedgholami104/dental-
stem-cells-18007596) 
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 Periodontal ligament stem cells (PDLSC):  
Periodontal ligament contributes to tooth anchorage, nutrition, homeostasis 
and repair. PDLSCs can differentiate into cementoblasts, osteoblasts, 
chondrocytes and adipocytes and are characterised by a high rate of 
proliferation [137, 144].   
 Stem cells derived from apical papilla (SCAP): 
SCAP are a distinct type of dental stem cells which are positioned at the root 
tips during development before the tooth appears in the oral cavity [145]. 
These cells can undergo odontogenic, osteogenic, adipogenic, 
chondrogenic, and neurogenic differentiation [146]. 
 Dental follicle-derived stem cells (DFSCs): 
The dental follicle defines the sac that surrounds the un-erupted tooth, and 
controls bone remodelling during the process of tooth eruption [147]. DFSCs 
are usually isolated from impacted third molars and studies showed the 
potential of DFSCs to differentiate into osteogenic, adipogenic, and 
neurogenic lineages [139] . 
 Dental pulp stem cells (DPSCs) 
These are the cells which were used exclusively in our studies and therefore 
a short description of the biology of this tissue is provided. 
Biology of the dental pulp 
The dental pulp organ originates mainly from the neural crest and first 
branchial arch mesoderm [148, 149]. Human dental pulp is the core 
connective tissue that occupies the centre of the tooth, surrounded by 
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dentine in the crown area and by cementum in radicular area. The 
condensed connective tissue of the pulp contains a mixed population of cells 
that are embedded in a fibrous vascular stroma [150]. Dental pulp has an 
inherent regenerative ability as it is a highly vascularized tissue containing 
stem/progenitor cells [108, 151]. Dental pulp contains many different types of 
cells including fibroblasts, lymphocytes, macrophages, dendritic cells, nerve 
cells, pericytes, endothelial cells and undifferentiated mesenchymal cells, 
each of which has unique functions [8, 150]. Odontoblast progenitor cells 
differentiate to odontoblasts, which are mesenchymal cells that are densely 
packed at dentine/pulp interface and which participate in synthesis and 
deposition of type I collagen-rich matrix known as pre-dentine which is 
subsequently mineralised to form dentine [152]. Odontoblast cytoplasmic cell 
processes run through the dentinal tubules, which interconnect the dentine 
pulp complex (Figure 2). Mature odontoblasts are not mitotically active  [153, 
154] and as they are situated at pulp-dentine interface, they act as first line 
of defence against bacterial infection [89, 155, 156].   
Dental pulp possesses stem/progenitor cells that are involved in dentine 
repair following damage by noxious stimuli [151, 157]. DPSCs undergo self-
renewal and multi-lineage differentiation but also interact appropriately with 
engineered scaffold. They are easily accessible and easily banked, and can 
therefore be used for autologous regenerative therapies including the 
generation of mineralised tissue [83, 151, 157-163]. In this respect they have 
proved of value for maxillofacial reconstruction and periodontal ligament 
tissue regeneration [2, 3, 164]. 
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DPSCs isolation and characterization: 
DPSCs express various stem cell markers such as mesenchymal stem cell 
marker CD146, CD105, CD90 and STRO-1, as well as OCT4, which is an 
embryonic stem cell marker [157]. DPSCs proved to be a generic source of 
mesenchymal stem cells [159], retaining the characteristic stem cell feature 
of high proliferative ability after prolonged culture [140, 165]. Transplantation 
of DPSCs into immune-suppressed mice resulted in formation of functioning 
dentine/pulp-like tissue architecture [157]. Moreover, these cells were able to 
differentiate into odontoblasts, adipocytes, chondrocytes, and osteoblasts in 
vitro [166, 167]. They can also differentiate into functioning neurons, and 
have been considered a source of material for treatment of various neural 
diseases [168, 169]. Third molars are often extracted for clinical reasons and 
subsequently discarded. However, they provide an excellent source of 
dental stem cells [170]. Development of these teeth starts at 5-6 years with 
calcification between 7-10 years and complete root development by 18- 25 
years. Stem cells from this source proliferate well [157], form pulp-like tissue 
with well-established vascularization [171]. 
Dental pulp stem cells from adults (DPSCs) versus deciduous (SHED) 
teeth:  
In the context of tissue engineering, stem cells from deciduous dental pulp 
tissue are less affected by genetic and/or environmental factors, and may 
have advantages for cell-repair and regeneration. In general, the anatomical 
and functional differences between adult and deciduous teeth affect stem 
cell differentiation potential [143]. Although the isolation technique for 
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DPSCs and SHED are similar, SHED tend to grow in clusters with higher 
proliferation rates and higher number of colony forming units (CFUs) 
compared with DPSCs [140, 172].  
DPSCs isolated from healthy versus carious teeth: 
Dental caries is one of the most prevalent chronic diseases worldwide [173]. 
It is a result of complex interaction over time between acid-producing 
bacteria and fermentable carbohydrate, and other host factors including 
saliva [173]. Penetration of oral bacteria into the dentine layer trigger 
inflammatory responses in the dental pulp [25], which responds to injury or 
inflammation according to the severity of infection (mild versus deep caries). 
The inflammatory process is characterized by inflammatory cell infiltrate, and 
immature progenitor cells recruitment [174]. Dental pulp cell biology is 
known to be affected by caries, but further studies are needed to determine 
in details the causative molecular mechanisms. DPSCs themselves have 
immunomodulatory effects and they have been successfully isolated from 
inflamed dental pulps [175]. Interestingly these cells showed high expression 
levels of some MSCs markers [176] although there is some controversy in 
relation to their differentiation potential in comparison with cells isolated from 
normal pulps [177, 178]. The rate of dentine repair/regeneration is closely 
related to the population size of remaining vital odontoblasts or newly 
differentiated odontoblast-like cells. If the inflammation is not too severe 
and/or is  rapidly controlled, then innate pulp repair mechanisms can 
generally suffice for regeneration of the tissue(s) [25]. Carious teeth are 
usually extracted and discarded; however, as indicated above these cells 
are also a potential source of DPSCs [175, 179, 180]. 
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1.5.3 Growth factors  
The third factor which plays a role in mineralised tissue engineering is 
signalling molecules, which control cellular activity. Growth factors are 
amongst the most important of these agents. They are proteins secreted 
extracellularly, which bind to specific cell receptors to influence cell function. 
Growth factors regulate cell adhesion, proliferation, migration and 
differentiation, all of which are involved in tissue regeneration. In mineralised 
tissue healing and regeneration amongst the most important factors are the 
pro-inflammatory cytokines, bone growth factors, angiogenic growth factors 
and insulin-like growth factors [181, 182].  
 Pro-inflammatory cytokines   
This includes interleukins-1 (IL-1), IL-6, IL-7 and IL-8 and TNF-α. They are 
released by inflammatory cells and cells of mesenchymal origin. In 
mineralised tissue regeneration, they stimulate cell recruitment (chemotaxis), 
extracellular matrix synthesis, angiogenesis, and fibrinogenesis at the site of 
injury. At a later stage, they also contribute to bone resorption and  
remodelling [181, 182]. 
 Bone and angiogenic growth factors 
Osteoblasts and endothelial cells secrete growth factors that influence 
growth, migration and differentiation of both cell types [183, 184]. These 
growth factors are released during blood vessel formation and are 
expressed during angiogenic response to the injury although they also play a 
key role during bone repair/regeneration [101, 185]. These growth factors 
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included members of TGF-β, BMP, FGF, PDGF, and VEGF families. The 
contribution of  these various growth factors  is summarised in Table 4. 
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Table 4: Key player bone and angiogenic growth factors  
Growth 
factors 
Notes 
 
TGF-β 
 Produced from degranulating platelet in hematoma and  
extracellular matrix at the site of injury 
 Enhances recruitment, proliferation and differentiation of  
mesenchymal cells into bone forming cells [186-188]  
 
BMPs 
 Osteoinductive molecules [189, 190] 
 Enhance the differentiation of mesenchymal stem cells [191] 
 BMP-2, BMP-4, BMP-7  have been investigated widely for 
osteogenic applications [192-194] 
 BMP induce the production of VEGF from osteoblasts [195] 
 
FGF 
 Stimulate mitogenesis of endothelial cells and osteoblasts 
[196, 197] 
 Basic FGF (bFGF) influences secretion of Matrix 
Metalloproteinases and VEGF [198] 
 Initiate expression of bone markers (ALP, RUNX-2 and OC) 
[199] 
 Stimulates the production of VEGF from osteoblasts 
PDGF  Secreted by platelets [200] 
 Angiogenic factor that modulate the expression of VEGF 
[201] 
 
VEGF 
 Has five isoforms; VEGF-A, -B, -C, D, E [202] 
  Major angiogenic regulator stimulating blood vessel 
formation [202]  
 Enhances the proliferation and migration of endothelial cells 
[202] 
 Plays a crucial role in recruitment, migration and 
differentiation of osteoblasts [203-205]  
 Mediates the osteoinductive factors (BMP-2, FGF-2 and IGF) 
[206, 207] 
  A key regulator between angiogenesis and osteogenesis 
during bone tissue repair [208, 209]   
IGF See Section “Insulin-like growth factor (IGF) axis” 
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Insulin-like growth factor (IGF) axis 
As a significant portion of the experimental work, this thesis describes the 
potential role of the IGF axis in the osteogenic differentiation of DPSCs.The 
IGF axis plays an important role in tissue regeneration. It comprises two 
peptide hormones IGF-1 and IGF-2, with corresponding cell surface 
receptors; IGF-1R and IGF-2R together with six circulating high affinity 
binding proteins (IGFBP 1-6)  [210, 211]. Most components of the IGF axis 
are expressed in human dental pulp stem cells [212]. 
 IGF axis components 
 Insulin-like growth factor -1 and -2 
IGF-1 is a 70 amino acid polypeptide (7.5 KDa) hormone that has similar 
structure to human pro-insulin. It is present in serum largely bound to 
IGFBPs, the free form representing only 1% of total IGF-1. Total 
concentration in plasma is of the order of 150-400ng/ml. IGF-1 is secreted 
mainly from the liver under the control of pituitary growth hormone (GH), but 
it is also secreted by extra-hepatic tissues including skeletal muscle, bone, 
and cartilage. IGF-1 acts to control cell development, proliferation, 
differentiation and migration as well as exhibiting anti-apoptotic actions [213, 
214]. Many IGFs actions are considered to operate via autocrine and 
paracrine mechanisms [215]. IGF-1 is reported to regulate the differentiation 
of osteoblasts and subsequent bone formation [119], and is also involved in 
the differentiation and proliferation of osteoblasts from mesenchymal cells 
during the process of fracture healing [216, 217]. IGF-1 transcription in 
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osteoblasts is modulated by oestrogen and glucocorticoids [177, 216]. IGF-1 
acts mainly through IGF-1R, although it also binds the insulin receptor (IR) 
but with lower affinity, a consequence of homology between IGF-1R and IR 
[218]. 
IGF-2 is a 67-amino acid polypeptide hormone. IGF-2 concentrations peak 
during foetal growth and then decline in adult life. IGF-2 expression is not 
dependent on pituitary growth hormone [219, 220]. IGF-2 stimulates 
osteotypical matrix deposition and osteodentine formation [221]. Growth 
hormone and both IGFs act in concert to regulate skeletal growth, 
maturation, and maintenance [119].  
 Insulin-like growth factor-1 and -2 receptors 
IGF activity is mediated via their respective cell surface receptors; IGF-1R 
and IGF-2R [222]. IGF-1R is a heterotetrameric transmembrane tyrosine 
kinase receptor [223]. It is composed of two extracellular α-subunits that 
contain the growth factor binding domain and which are connected by 
disulphide bonds to two transmembrane β-subunits that contain tyrosine 
kinase catalytic activity [221, 224, 225]. When the receptors are occupied  by  
ligand, they undergo conformational changes that trigger the tyrosine kinase 
activity, leading to activation of downstream signalling molecules by protein 
phosphorylation [215]. Among these are the SRC homology 2 domain-
containing protein (SHC) and insulin receptor substrate family of proteins 
(IRS1-4). These signalling intermediates play an important role in activation 
of the phosphoinositide 3 kinase (PI3K) and mitogen-1 activated protein 
(MAPK) kinase pathways [225]. IGF-1R has higher binding affinity for IGF-1 
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than IGF-2. IGF-2R is a mannose- 6- phosphate receptor and binds both 
IGF-1 and IGF-2 although with a higher affinity for IGF-2 compared with IGF-
1 [220]. IGF-2R  is a key player in IGF-2 turnover and degradation [226].  
 Insulin-like growth factor binding proteins 
Insulin-like growth factor binding proteins (IGFBPs) are secreted by several 
tissues and are soluble proteins [215]. IGFBP-3 and -5 are commonly found 
in a ternary complex with an acid labile subunit (ALS) [227, 228]. IGFBPs 
have higher affinity for IGFs than the cell surface receptors. IGFBPs are 
considered as a reservoir for IGFs as  99% of circulating IGFs are bound to 
IGFBPs [229]. IGFBPs regulate the circulating IGFs levels either by 
sequestering IGFs from IGF-IR and IGF-2R or by releasing them into the 
circulation to bind and activate their receptors [215, 230]. IGFBPs affinity for 
IGFs can be affected by post-translational modifications of these proteins 
and particularly by proteolysis [222, 230].  
IGFBP-1 stimulates cell motility, adhesion and migration. It binds specifically 
to the α₅β₁ integrins [230, 231], and is present at very high concentrations in 
placenta and there are higher levels in female plasma compared to male 
plasma [232]. IGFBP-1 expression is inversely regulated by insulin and 
phosphorylation of IGFBP-1 reduces IGF affinity [230]. 
IGFBP-2 levels increase with age [233].  IGFBP-2 is crucial to transport 
IGFs, and IGFBP-2 serum levels correlate with normal bone formation and 
bone remodelling [234]. IGFBP-2 has been considered as a negative 
regulator of bone formation induced by IGF-1, including IGF-1 stimulation of 
osteoblast proliferation, collagen secretion and bone formation [235]. 
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However, growing evidence indicates the anabolic effect of IGFBP-2 on 
bone density [236, 237]. Recently, a unique heparin-biding domain (HBD) 
has been identified in IGFBP-2, which is suggested to mediate the anabolic 
effect of IGFBP-2 [238]      
IGFBP-3 is the most abundant IGFBP in serum and reaches highest levels 
during the puberty. IGFBP-3 provides 75-80% of the IGF carrying capacity in 
serum, and binds IGFs in high affinity complexes. The IGF1-IGFBP3 
complex forms a tripartite complex with a third protein known as acid labile 
subunit (ALS) and this prolongs the circulating half-life (~16 hours) of bound 
IGF-1 compared to free growth factor (<15 minutes) [215] . Around 90% of 
IGFBP-3 and 55% of IGFBP-5 circulate in a trimeric complex with ALS 
during adult life [239]. Interestingly and pertinent to the current study, IGF 
activity on osteoblasts is enhanced by IGFBP-3 [240]. 
IGF-1 can regulate IGFBP-4 and IGFBP-5 expression and can also activate 
the IGFBP-4 specific protease. This forms a positive feedback loop releasing 
IGFs from IGFBP-4 to act locally on tissues. However in some tissues, IGF-1 
increases IGFBP-5 expression and this may serve as a negative feedback 
mechanism regulating growth factor activity. Clearly regulation of IGF action 
is a complex process and it remains an area of intense study [218, 241, 
242]. In bone, IGFBP-5 potentiates the proliferative action of IGF-2 and 
during bone remodelling processes IGFs are released from IGFBP-5. 
IGFBP-5 is therefore considered to have an enhancing effect on IGF action 
in bone tissue [243].  IGFBP-5 affinity for IGF-1 is decreased by association 
with extracellular components including collagen, laminin, and fibronectin 
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and this may lead to IGF release into the local tissue environment [231]. 
Although the studies described above suggested an osteogenic function for 
IGFBP-5, this area remains controversial and IGFBP-5 may also inhibit bone 
formation by sequestration of IGFs from their receptors on the osteoblasts 
surface [244].There are relatively few studies on the function of IGFBP-6. 
IGFBP-6 showed the ability to inhibit the IGF-2 actions as it has higher 
affinity for IGF-2 than IGF-1 [245]. A diagrammatic representation of the IGF 
axis is shown in Figure 6.   
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Figure 6: Insulin-like growth factor (IGF)  axis 
IGF axis comprises two related polypeptide growth factors IGF-1 and IGF-2, 
two cell surface receptors IGF-1R and IGF-2R, and six soluble binding proteins 
(IGFBP1-6). Some IGFBPs can bind to extracellular matrix (ECM) and IGFBP-3 
circulates in serum bound to an acid labile subunit (ALS). IGFBPs show similar 
affinity for IGF-1 and IGF-2 with the exception of IGFBP-6 which has a 20-fold 
higher affinity for IGF-2 than IGF-1. Most IGFBPs can be proteolysed by 
specific IGFBP proteases. IGF-1 and IGF-2 can also bind to both A and B 
isoforms of the insulin receptor and to the hybrid IGF-1R/IR receptors. Finally 
IGFBPs have direct effects independently of IGFs and these may be mediated 
by specific IGFBP receptors (adapted from Igf-society.org). 
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 IGF axis in dental tissue 
IGF-1 is suggested to have a role in pulp repair/regeneration as it induces 
proliferation and differentiation of dental pulp cells to form odontoblast-like 
cells. There is evidence that IGFs are trapped in the matrix during dentine 
formation and that soluble growth factor can be released into dental pulp 
following demineralisation of dentine [20-22]. IGF-1 has been used as a pulp 
capping material in rat molars and enhanced reparative dentinogenesis in 
this experimental model. Caviedes et.al (2004), demonstrated higher 
expression of IGF-1R in dental pulp derived from human teeth having 
incomplete roots compared with complete roots. This might be as a result of 
increased cell proliferation during root formation and suggests a role for 
IGFs in this process [212]. Gotz  et al. (2001), demonstrated the expression 
of IGF axis components during reparative processes in periodontal 
connective tissue with IGF axis proteins found in both the cellular and 
acellular compartments of extrinsic fibres of cementum. Cementoblasts and 
periodontal ligament fibroblasts express IGF-1R. IGF-1 induces the 
accumulation of amelogenin and ameloblastin suggesting that this growth 
factor plays a role in enamel bio-mineralisation as ameloblasts also express 
IGF-1R [246]. 
 IGF axis during angiogenesis 
Endothelial cells (ECs) express several components of the IGF axis 
including IGF-1,  IGFBP-2, -3, -4 and -6 [247-249]. Expression of the IGF 
axis in ECs is modulated by several factors including cell density [250], 
hypoxia [251], TGF-β, VEGF [252], and  IGF-1 itself [253]. IGF-1 stimulates 
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endothelial cell migration and angiogenesis, as well as inflammatory and 
vasodilatory responses in these cells [254-256]. IGF-1 acts via the PI3K 
pathway and cross talk with other growth factors and hormones (e.g. 
ostradiol), also occurs through this signalling pathway to regulate responses 
such as vasodilation [257, 258]. IGF-1 is important for initiating angiogenesis 
and neovascularization. An earlier study demonstrated that an IGF-1R 
antagonist inhibits retinal neovascularization in vivo [259, 260]. IGF-1 also 
act as a chemo-attractant to increase cytokine release further stimulating 
angiogenesis with associated production of extracellular matrix [261]. In 
addition, IGF-1 administration increases circulating levels of VEGF and TGF-
β [262-265].  
         
1.6 Pulp response to injury 
Cariogenic bacterial populations release acids that progressively 
demineralize enamel, which normally protects the dentine/pulp complex [89, 
266], and dentine layer of the tooth [267]. Dentine demineralisation releases 
bioactive molecules from the dentine matrix, which diffuse towards the 
dental pulp where they can stimulate and signal the repair processes, and 
trigger appropriate inflammatory and immune responses in the dental pulp 
[90, 267, 268]. DPSCs respond to the noxious stimuli by many different 
routes, and carious lesions may cause localized odontoblastic damage and 
activate DPSCs to differentiate into odontoblast-like cells that contribute to 
tertiary/reparative dentine formation [269]. Odontoblast differentiation during 
development and repair appeared to be similar processes [270]; however, a 
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more complex and variable signalling environment modulated by infection 
may exist following severe dental injury [271].  
In the case of mild inflammation, bacterial insult initiates dentine repair 
accompanied by mineralised tissue formation at the pulp/dentine interface. 
Untreated severe and rapidly progressing inflammation reaches the pulp and 
cause irreversible damage, pulp necrosis, infection of the root canal system 
and periapical disease [90, 267]. In shallow and moderate dentine carious 
lesions, Gram positive bacteria are the predominant microorganisms [267]. 
While in deep carious lesion, the loads of Gram positive aerobic bacteria 
decrease and the Gram negative anaerobic species increases; including 
Fusobacterium, Prevotella, and Tannerella SPP [266].   
 
1.7 Inflammation and regeneration   
Most tissue injury is followed by inflammatory processes as a fundamental 
part of early healing events. These modulate the final repair/regeneration  
outcome according to severity of trauma/insult [272]. Two of the most 
important molecular axes involved in the response to dental pulp infection 
and tissue damage are the Toll-like receptor (TLR) family and the interleukin 
(IL) family. As a part of the experimental work subsequently reported in this 
thesis describes the expression and activities of these inflammatory markers 
in carious dental pulps, a short description of the members of these 
molecular axes along with a brief synopsis of their activities is provided. 
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1.7.1  Inflammatory markers 
 Toll-like receptors (TLRs) 
 Innate immunity depends on the recognition of microbial pattern products by 
a set of germ-line encoded receptors termed pattern recognition receptors 
(PRRs) [273]. The PRRs are responsible for recognition of pathogen-
associated molecular patterns (PAMPs), found in the bacterial cell wall 
components including lipopolysaccharide (LPS), peptidoglycan, Lipoteichoic 
acid (LTA), as well as bacterial and viral nucleic acids including single- and 
double-stranded RNA and DNA. The TLR family constitutes an important 
class of PAMP recognition receptors [274, 275]. TLRs are type I integral 
transmembrane glycoproteins with an extracellular domain containing 
numbers of leucine-rich repeat (LRR) motifs responsible for agonist 
recognition and a cytoplasmic domain homologous to the interleukin-1 
receptor responsible for intracellular signal transduction [274, 276]. The TLR 
family comprises ten functional TLRs (TLR-1-10) with various critical roles in 
the recognition of different PAMPs and subsequent activation of innate 
immune responses through the NF-kB pathway [277-280]. Depending on 
TLR cellular localisation and PAMP ligands, they are classified into extra-
cellular and intra-cellular receptors. Extra-cellular receptors essentially 
recognise microbial membrane components including lipids, lipoproteins 
(TLR-1, TLR-2, TLR-6), lipopolysaccharide (TLR-4) and flagellin (TLR-5). 
The intra-cellular TLRs recognise double-stranded RNA (TLR-3), single-
stranded viral RNA (TLR-7 and TLR-8), in addition to un-methylated CPG-
DNA of viruses and bacteria (TLR-9) [275]. TLRs regulate the migration, 
proliferation, differentiation and immunosuppressive activities of MSCs [281]. 
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They also activate the effector phase of the innate immune response 
including release of pro-inflammatory cytokines that recruit inflammatory 
cells [282-284], and maturation of antigen presenting dendritic cells (DCs) 
[285]. Maturation of DCs leads to initiation of an adaptive immune responses 
and therefore TLRs have a pivotal role in coordinating innate and adaptive 
immunity [277]. 
TLR-4 is expressed on various cell types including endothelial cells [286], 
cardiac myocytes [287] and cells of the central nervous system (CNS) [288]. 
TLR-2, -3, and -4 are expressed on stem and progenitor cells in various 
tissues [289-293], including dental follicle-derived stem cells [272, 294]. 
TLR-4 is expressed in human stem cells isolated from apical papilla [295], 
and all TLRs except TLR-7 are expressed in periodontal ligament stem cells 
[291, 296]. All TLR family members are also expressed on dental pulp stem 
cells [272, 297, 298]. Such wide range of expression suggests a broad range 
of activities not limited to immune responses. Indeed recent research 
demonstrated that TLR-4 function in central nervous system homeostasis 
[299], learning and memory [300], and neurodegeneration as well as 
neuroprotection after ischemic preconditioning [301]. TLR-4 signalling may 
also be involved in cancer development and progression [302]. TLR-4 
activity is mediated by two main signalling pathways: (1) MyD88-dependent 
and NF-kB-driven, and (2) MyD88-independent and IRF3-driven pathways 
[303]. The NF-kB pathway is also activated independently of MyD88, 
although this is a minor pathway and exhibits different dynamics and kinetics 
[304]. The balance between MyD88-dependent and MyD88-independent 
pathways may regulates apoptosis, proliferation, differentiation and 
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migration of cells, although data is not conclusive and further research is 
required [304]. Activation of NF-kB signalling by the TLR-4 complex 
(containing a complex of TLR-4, MD-2, CD14) involves degradation of 
inhibitor kB allowing the subsequent nuclear translocation of NF-kB and 
regulation of transcription of target genes [305, 306]. Responses to PAMPs 
are dependent not only on TLRs but also the presence of potential co-factors 
as well as the levels of each PAMP [307]. Some TLRs act in combination to 
stimulate or inhibit the cellular response to selective agonists [308, 309].         
Different dental pulp cells express a range of TLRs [89, 155, 298]. TLR-2 is 
expressed on odontoblast and can be activated by LTA to stimulate the 
nuclear translocation of NF-kB [155]. This signalling pathway can also be 
stimulated by LPS in DPSCs or odontoblast like-cells [297, 310, 311], 
possibly via crosstalk with the MAPK signalling pathway [310, 312, 313]. 
Both of these pathways have crucial roles in innate immunity [314, 315]. 
Various factors modulate the  immunostimulatory or immunotolerance 
function of TLRs. These can include the nature and load of bacterial 
invasion, and degree of penetration into the dental tissue (shallow or deep 
caries). The developmental stage of the tooth (un-erupted or erupted) may 
also be important, other sources of contamination from the resident oral 
bacteria may also be involved [316]. TLR expression is low in non-
inflammatory situations and this prevents unnecessary inflammatory 
responses [317, 318].    
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 Interleukins 
Carious pulp tissue shows up-regulation of several interleukins; including IL-
4, IL-6, IL-8, and IL-10 [319-321]. IL-8 plays a crucial role in immune 
responses, particularly in the activation of neutrophils, which are usually the 
first immune cell type to appear at the site of injury [322]. Most cytokines 
also use p38 MAPK and NF-kB signalling pathways to activate responsive 
cells [323]. During bacterial infection of dental pulp, many cytokines show 
pleiotropic actions; for example, IL-6 has antibacterial and 
immunomodulatory properties but also plays a stimulatory role in 
angiogenesis and the mineralised tissue reparative process [324]. IL-6 and 
IL-8 in addition to chemokines are secreted mainly as a result of TLRs 
activation and ligation [274, 285, 325]. IL-6 is secreted by a variety of 
immune and non-immune cells and mediates various aspects of the immune 
response [326]. IL-6 and  IL-10 levels increase following bacterial stimulation 
of TLR-2 in odontoblasts [327, 328], and this provides a mechanism for 
regulating the intensity of the immune response as the immunosuppressive 
cytokine IL-10 regulates the immune response through negative feedback of 
IL-6 and IL-8 expression [327], to inhibit inflammation-associated immune 
responses and minimize host damage [329]. Also, relevant to these 
observations is the biphasic response of dental pulp cells to pro-
inflammatory signalling molecules. Therefore, low levels of cytokines and 
growth factors show stimulatory effects on these cells whilst higher levels of 
these molecules appeared to cause cell damage [330-333].    
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1.7.2  Inflammation and mineralised tissue regeneration  
During the initial phase of dental pulp immune responses, various 
coordinated mechanisms are stimulated to down-regulate both pre-dentine 
matrix secretion and mineralisation [89]. TLRs expressed by odontoblasts 
influence the production of extracellular matrix proteins [89, 334], and 
increase the synthesis of dentine, decorin and initiate odontoblast 
differentiation [334]. LPS-induced TLR-4 activity accelerates synthesis of 
ameloblastin mRNA [335]. The role of TLRs in osteogenic differentiation of 
human MSCs is controversial and may depend on the tissue of origin of 
MSCs [336]. Although TLR-4 stimulates the production of tertiary dentine, 
the TLR-4 receptor expression is decreased during the mineralisation of 
murine odontoblast-like cells [156, 337, 338], and this may be mediated  by 
inhibition of ALP activity [339]. In a similar vein, LTA down-regulates type I 
collagen, the major pre-dentine structural component and activation of the 
NF-kB pathway inhibits the expression of α 1 (I) and α 2 (I) collagen [340, 
341]. Moreover, LPS significantly down-regulates DSPP, a glycoprotein that 
plays a critical role in the pre-dentine mineralisation process [342]. Many of 
the TLR activated signalling pathways are also involved in the BMP 
mediated osteogenic differentiation of rat dental follicle stem cells [343]. 
Critically as outlined above the activation of NF-kB signalling pathway is 
important in regulating the immune response to infection but also is involved 
in differentiation of stem cells from various sources [344, 345], and this 
provides a focus for cross talk between inflammatory and differentiative 
pathways. There are also issues associated with dosage effects. Thus LPS 
(10µg/ml) treatment showed a significant inhibitory effect on the human 
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DPSCs growth (after 14 days) and proliferation (after 24h), although at 0.1 
µg/ml LPS showed a significant stimulatory effect after the same period of 
time [297]. Such effects may reflect different responses dependant on 
severity of bacterial challenge as indicated previously. LPS has been 
reported to promote the odontogenic differentiation of human DPSCs via the 
TLR-4, ERK and p38 MAPK signalling pathways. While the NF-kB signalling 
pathway does not appear to have a role in LPS-induced odontogenic 
differentiation [297]. LPS treatment of human DPSCs enhanced mineralised 
nodule formation in a time-dependent manner. Thus DSPP and DMP-1 were 
increased on day 7 and day 14 after LPS treatment but  ALP and OCN 
expression was up-regulated on day 14 and 21 [297]. Conversely in a 
separate study, LPS inhibited the expression of ALP, DSPP and RUNX-2, 
and supressed mineralisation nodule formation in a rat dental papilla-derived 
cell line [342]. 
 
1.7.3 Inflammation and angiogenesis 
Vasculogenesis is defined as the formation of the primary vascular plexus 
from pre-existing vascular precursor cells in the new embryo while 
angiogenesis is the formation of new blood vessels from pre-existing 
vessels. The latter is accountable for the greater part of blood vessel 
formation in normal physiological tooth development and healing pulp injury 
[346-349]. Angiogenesis is stimulated by hypoxia and limited nutrient supply, 
and is controlled by growth factors, cytokines, endogenous angiogenesis 
inhibitors, transcription factors, adhesion molecules and components of 
extracellular matrix [350-354]. Generally, inflammation induces the 
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expression of mitogenic and proangiogenic factors including VEGF, FGF 
and PDGF in human pulp and gingival fibroblast [347, 355, 356]. The 
integrity of the vital pulp tissue is dependent on the process of angiogenesis 
at the site of injury [357], and up-regulation of angiogenic signalling during 
inflammation may also aid survival and differentiation of DPSCs into mature 
odontoblast-like cells at the site of trauma and angiogenic signalling 
pathways together with inflammatory cytokines secreted during bacterial 
infection are crucial for reparative dentinogenesis [358]. Thus angiogenesis 
provides blood supply, oxygen nutrition and stem/progenitor cells essential 
for healing processes [359], and indeed VEGF directly stimulates the 
proliferation and differentiation of DPSCs [360]. In the case of caries-induced 
inflammation, the number of capillaries in the pulp under the lesion increases 
and these capillaries extend into the odontoblast layer [90]. Chronic 
exposure of dental pulp tissue to an inflammatory environment results in 
vasodilation and increased vascular permeability with increases in the blood 
flow [154, 361]. LPS  stimulates VEGF expression in DPSCs via NF-kB [310, 
362], and as is evident from discussions above NF-kB acts as a master 
transcription factor modulating a range of pro-inflammatory cytokines and 
angiogenic factors in dental pulp cells and oral epithelial cells [85, 363, 364]. 
LTA stimulates the production of the pro-angiogenic chemokine CXCL2 that 
binds its receptor CXCR2. This receptor  is abundantly expressed on 
endothelial cells and increases vascularization under inflammatory 
conditions  [365]. IL-6 is implicated in oedema  following continuous intra-
dentinal diffusion of Gram positive bacteria also resulting in increased 
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vascular permeability [327]. Chemokines in addition to their role in cell 
locomotion also induce  angiogenesis  [366, 367]. 
TLR-4 expression has been reported in adult pericytes located close to 
vasculature [304], and  activated TLR-4 was reported to stimulate 
proliferation  of endothelial progenitor cells [290]. Stem cells express 
proangiogenic factors and differentiate directly into endothelial cells. DPSCs 
express VEGF, monocyte chemotactic protein-1 (MCP-1) [368], FGF-2, 
PDGF, IGFs, TGF-β and IL-8. These factors regulate endothelial cell 
migration via PI3K/AKT and MEK/ERK signalling pathways and initiate the 
tubulogenesis seen in these cells [347, 356, 360, 369, 370]. 
 
1.7.4 Inflammation and IGF axis 
Many growth factors are sequestered within the dentine matrix as it is 
secreted by odontoblasts during tooth development [25]. During dentine 
demineralisation these factors may be released and modulate both repair 
and regenerative processes [25]. In general, inflammatory cells are the 
source of most growth factors/cytokines that contribute to wound healing 
[371]. In the area of inflammation, all types of wound cells including 
macrophages, fibroblast and endothelial cells express IGF-1  [372]. IGF-1 
plays an important role in healing and typically establishes responsive 
conditions in which other growth signals undertake reparative roles. In 
cystic fibrosis, inflammation acts as an important modulator of the IGF axis 
causing a decrease in IGF bioactivity and there may be a reciprocal 
relationship between cytokines and the IGF axis in cystic fibrosis. Patients 
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have been described with  high serum concentration of IL-1β, TNF-α, and 
IGFBP-2 compared to significantly low concentrations of IGF-1 and IGF-2 
[373]. In non-diabetic patients with cardio-metabolic risk factors, plasma 
IGF-1 and IL-6 are inversely related to each other. Clinical and 
experimental data showed that IGF-1 acts as an anti-inflammatory molecule 
inhibiting IL-6 expression. Also IL-6 decreases IGF-1 levels by enhancing 
its clearance [374]. This is also seen in chronic inflammation where high IL-
6 concentrations are correlated with significant decrease in IGF-1 and 
IGFBP-3 levels [375]. On the other hand, IGF-1 stimulates IL-17-induced 
expression of inflammatory cytokines and chemokines. Insulin/IGF-1 
signalling pathway crosstalk with IL-17 occurs via activated NF-kB [376]. 
IGF-1 expression in intestinal epithelial cells stimulates the expression of 
IL-10 and inhibited IFN-Ɣ and TNF-α in immunosuppressive monocytes 
[377].  
TLR-2 deficiency is associated with a significant decrease in IGF-1 levels, 
and compromised innate immune responses in the brain resulted from TLR-
2 deficiency leading to reduced IGF-1 levels [378]. In skeletal muscle injury, 
the expression of IGF-1 affects the expression of the inflammatory 
cytokines involved in the recruitment of monocytes/macrophages. In 
general, it appears that following appropriate modulation of inflammatory 
responses, IGF-1 expression provides a suitable environment for effective 
repair and regeneration of damaged tissue response [379].  
…………………………….  
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 Aim and Objectives 
The main aim of this thesis was to characterise the dental pulp stromal/stem 
cells isolated from teeth with shallow caries (cDPSCs) for the purpose of 
future use in mineralised tissue (bone/dentine) regeneration.  
 
This aim was addressed via a series of specific experimental objectives, 
summarized as follows:  
1- Isolation, characterisation and comparison of dental pulp 
stromal/stem cells from healthy (hDPSCs) and carious teeth with 
shallow caries (cDPSCs). This included investigation of colony 
forming ability and identification of stem cell surface markers.   
2- Comparing the osteogenic potential of cDPSCs to those of hDPSCs 
in monolayer cultures.  
3- Comparing the changes in the expression of osteogenic, angiogenic 
and inflammatory markers under basal and osteogenic conditions in 
hDPSCs and cDPSCs in monolayer cultures, in order to examine the 
effect of inflammatory environment on the expression of these 
regenerative molecules. 
4- Investigating the expression of insulin-like growth factor (IGF) axis 
during the osteogenic differentiation of hDPSCs and cDPSCs.       
5- Investigating the potential role of insulin-like growth factor axis during 
osteogenic differentiation of hDPSCs 
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…………………………………….      
……….………………….…………………      …………………………..
Clinical Rational:  
1- cDPSCs can be banked and used as candidates for cell 
based hard tissue regeneration therapies. 
2- Investigating low-grade inflammation and regeneration for 
future development of endodontic and conservative dental 
regeneration therapies.  
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 Materials and Methods 
3.1 Materials 
3.1.1 Cell culture 
Alpha-Modified Minimum Essential Medium (α-MEM) catalogue number 
(#)BE12-169F and phosphate buffered saline (PBS) # BE17-516F were from 
Lonza BioWhittaker, UK. Penicillin/Streptomycin (Pen Strp) #P4333, Foetal 
bovine serum (FBS) #F9665, L-glutamine #G7513, 0.25% (w/v) Trypsin-
EDTA solution #T4049, Trypan blue solution, 0.4% (w/v) #T8154, dimethyl 
sulfoxide (DMSO) #276855, dexamethasone #31375, L-ascorbic acid 
#A4403, Naphthol AS-MX phosphatase solution 0.25% (w/v) #855-20mL, 
fast violet B salt #F1631, Alizarin red stain #A5533 were from Sigma-Aldrich, 
UK. Collagenase type I #17100-017 was from GIBCO™. Dispase II neutral 
protease, grade II #114662200 was from Roche, Germany. Tissue culture 
plastic including 15mL centrifuge tubes #430790, 50mL centrifuge tubes 
#430828, T-25 cm2 tissue culture flasks #430639, T-75 cm2 tissue culture 
flasks #430641, T-175 cm2 tissue culture flasks #431080, 10cm Petri dishes 
#353803, 6 well tissue culture plates #18341 and Stripette were from 
Corning®, UK. Additional items included pipette tips (Starlab, Tip one, UK) 
Syringes #SS* 05SE1 (TERUMO, UK) ,syringe filters #16532 (Sartorius - 
UK) 70μm strainer #352350 (Falcon, USA) and Pasteur pipettes #PIP4105 
(SS Scientific lab supply, UK).   
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3.1.2 Flow cytometry  
Human umbilical vein endothelial cells (HUVECs) were generously provided 
by Gary Grant from Leeds Institute of Cancer and Pathology and the U937 
myeloid cell line was generously provided by Dr Gina Doody from Leeds 
Institute of Cancer and Pathology and Sophie Stephenson from section of 
Experimental Haematology, Leeds Institute of Cancer and Pathology. 
Human large vessel endothelial cell growth medium package #ZHM-2953 
was from Cellworks, UK. RPMI 1640 medium for U937 culture #R0883 was 
from Sigma-Aldrich 
Fluorochrome-labeled mouse anti-human monoclonal antibodies against cell 
surface markers of interest were from BD Biosciences, UK (Table 5). Fixable 
Viability Stain #564406, human BD Fc block™ #564220, Stain Buffer BSA 
#554657, Brilliant Stain Buffer #563794, BD™ CompBeads #552843 were 
also from BD Biosciences, UK. 5mL polystyrene round-bottom tubes for flow 
cytometry (12x75mm) #352054 were from Falcon, UK. 
Data was acquired on an LSRII FACS analyser (BD Biosciences) using 
405nm, 488nm and 640nm laser excitations. Analysis of acquired data was 
performed using both FACS DivA software (BD Biosciences) and FlowJoV10 
(Tree Star). 
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Table 5: List of antibodies and isotypes used in flow cytometry 
Antibody against Description Isotype 
CD146 
 
PE-Cy7 
Mouse Anti-Human 
(Cat# 562135) 
 
PE-CY7  Mouse 
IgG1,k Isotype Control 
(Cat# 557872) 
 
 
CD90 
 
PerCP-Cy™5.5 
Mouse Anti-Human 
(Cat# 561557 ) 
PerCP-Cy™5.5 Mouse 
IgG1,k Isotype Control   
(Cat# 550795 ) 
CD105 
BV421 
Mouse Anti-Human 
(Cat# 563920) 
BV421 Mouse 
IgG1, k Isotype Control 
(Cat# 562438) 
CD45 
APC-Cy7 
Mouse  Anti-Human 
(Cat# 557833) 
APC-Cy7 Mouse 
IgG1,k Isotype Control 
(Cat# 557873) 
 
CD31 
 
 
FITC 
Mouse Anti-Human 
(Cat# 555445) 
FITC Mouse 
IgG1,k Isotype Control 
(Cat# 555748 ) 
Fixable Viability dye 
BV510 
(FVS 510) 
 
(Cat# 564406) 
 
-------------------- 
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3.1.3 Quantitative real time polymerase chain reaction (qRT-PCR)  
RNeasy® mini kit #74104 was from (Qiagen, UK. β-mercaptoethanol 
#A4338,0100 was from Applichem panreac, UK, absolute ethanol (200 
Proof, Molecular Bi-ology Grade) #BP2818- 500 was from Scientific 
Laboratory Supplies Ltd, UK. Ultrapure DNAse/RNase-free distilled water 
#10977035, RNase-free tubes #AM12400 and lens cleaning tissue 
#FB13067 were from Thermo Fisher Scientific, UK. DNase I Amplification 
Grade #18068015 was from  Invitrogen, UK. Optical adhesive seal #P3-0300 
was from Geneflow Ltd, UK. High Capacity RNA to cDNA kit #4387406, 
master mix #4369016 and TaqMan probes (see   Table 6 for further 
information) were from Applied Biosystems (ABI), UK. PCR tubes (0.2mL flat 
cap) #TFI0201 were from Bio-Rad, UK. Non-stick RNA-free 1.5mL microfuge 
tubes #AM12450 were from Ambion ®, Mexico. 96 well PCR microplates 
(LightCycler type) #I1402-9909 were from Starlab, USA. Thermal cycler 
(PTC-100 Peltier -version 9) Roche LC480 Light Cycler was used to 
generate data.  
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    Table 6: Details of Taqman® gene expression assays used in qRT-PCR 
Gene Name Gene Description 
Taqman ® gene 
expression assay 
number 
Glyceraldehyde-3-phosphate 
dehydrogenase 
(GAPDH) 
House-keeping gene 
(Control) 
Hs99999905-m1 
Alkaline phosphatase, 
Liver / kidney / bone 
( ALPL) 
Bone marker 
(Gene of interest) 
Hs01029144-m1 
Runt-related transcription 
factor-2 
(RUNX-2) 
Transcription factor, bone 
marker 
(Gene of interest) 
Hs00231692-m1 
Bone gamma-
carboxyglutamic acid-
containing protein 
(BGLAP)/ 
Osteocalcin 
(OC) 
 
Select calcium binding 
protein, bone marker 
(Gene of interest) 
 
 
Hs00609452-g1 
 
 
Insulin like growth factor-1 
(IGF-1) 
 
Naturally-occurring 
polypeptide protein 
hormone 
(Gene of interest) 
Hs01547656-m1 
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Insulin like growth factor-2 
(IGF-2) 
Naturally-occurring 
polypeptide protein 
hormone 
(Gene of interest) 
Hs04188276-m1 
Insulin like growth factor-
1receptor 
(IGF-1R) 
Protein found on the 
surface of human cells 
(Gene of interest) 
Hs00609566-m1 
Insulin like growth factor-2 
receptor 
(IGF-2 R) 
Protein found on the 
surface of human cells 
(Gene of interest) 
Hs00974474-m1 
Insulin like growth factor 
binding protein-1 
(IGFBP-1) 
Carrier protein for IGFs 
(Gene of interest) 
Hs00236877-m1 
Insulin like growth factor 
binding protein-2 
(IGFBP-2) 
Carrier protein for IGFs 
(Gene of interest) 
Hs01040719-m1 
Insulin like growth factor 
binding protein-3 
(IGFBP-3) 
Carrier protein for IGFs 
(Gene of interest) 
Hs00426289-m1 
Insulin like growth factor 
binding protein-4 
(IGFBP-4) 
Carrier protein for IGFs 
(Gene of interest) 
Hs01057900-m1 
Insulin like growth factor 
binding protein-5 
(IGFBP-5) 
Carrier protein for IGFs 
(Gene of interest) 
Hs00181213-m1 
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Insulin like growth factor 
binding protein-6 
(IGFBP-6) 
Carrier protein for IGFs 
(Gene of interest) 
Hs00181853-m1 
Vascular Endothelial Growth 
Factor Receptor 
(VEGFR-2) 
Angiogenic marker 
(Gene of interest) 
Hs00911700-m1 
Platelet/ endothelial  Cell 
Adhesion Molecule 
(PECAM-1) 
Angiogenic marker 
(Gene of interest) 
Hs01065279-m1 
Toll- Like Receptor-2 
(TLR-2) 
 
Inflammatory marker 
(Gene of interest) 
Hs01014511-m1 
Toll- Like Receptor-4 
(TLR-4) 
Inflammatory marker 
(Gene of interest) 
Hs00152937-m1 
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3.1.4 Western and ligand blot 
Precision Plus protein dual colour standards #1610374, 10x Tris-buffered 
saline (TBS) #1706435,  Mini-protean® 4 -15% (30 µl) TGX stain-free™ gels 
# 456-8083, Mini-protean® 12% (50µL) TGX stain-free™ gels #456-8044, 
Trans-Blot Turbo transfer pack 7x 8.5cm #1704156, Trans-Blot® Turbo 
transfer system (transfer pack mini format 69 BR007547) and ChemiDoc 
imager were all from BioRad, UK. Electrophoresis sample buffer 2% #Sc-
45085 was from Insight Biotechnology, UK. β-mercaptoethanol #A4338 was 
from Application Panreac, UK. Tween® 20 #BPE337-500 was from Fisher 
Scientific Ltd, UK. Bovine albumin Faction V #160069 was from MP 
Biomedicals, UK. Tergitol solution type NP-40 70% solution #NP40S-1 and 
Corning gel-loading tips (0.2MM)  #CLS4884-400EA were from Sigma-
Aldrich, UK. Monoclonal mouse antibodies to hIGFBP-2 #MAB6741, 
hIGFBP-3 #MAB305, hIGFBP-4 #MAB8041, hIGFBP-5 #MAB8751 and 
hIGFBP-6 #MAB8761 were from R&D Systems, UK. Anti-mouse HRP 
conjugate secondary antibody #ab97046 was from Abcam, UK. Super-
Signal® West Femto Maximum Sensitivity Substrates #34095 was from 
Fisher scientific, UK. Mono-biotinylated human IGF-2 receptor Grade #ABB-
AM01 was from GroPep, Australia. Round gel-loading tips #I1022-0810 were 
from Starlab, UK. 
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3.1.5 Enzyme linked immunosorbent assay (ELISA)  
Human IGFBP-3 Quantikine ELISA kit #DGB300, IGFBP-2 Duo Set #DY674 
wash buffer #WA126, Reagent Diluent #DY004, normal goat serum #DY005, 
streptavidin- horseradish peroxidase (HRP) #890803, Substrate Solution: 
colour reagent A (H2O2), colour reagent B (Tetramethylbenzidine) #DY999 
and stop solution -2 N H2SO4 #DY994 were from R&D Systems, UK. The 96 
well ELISA plates #S1837-9600 were from Starlab, UK. Absorbance was 
determined with a Thermo-Scientific Varioskan Flash type 300 
spectrophotometer. 
 
3.1.6 Human inflammatory cytokines quantification  
CBA Human Inflammatory Cytokines Kit  #551811 was from BD 
Biosciences, UK. 
A 4 Laser LSRII flow cytometer, (BD Biosciences) using 405nm violet 
laser, 488nm blue laser, 355nm UV and 640nm red laser excitations 
was used a high through-put plate arm (HTS) to run the cytokine bead 
array. Flow cytometry analysis software: Flow Cytometric Analysis 
Program (FCAP) Array software (BD Biosciences)  
 
3.1.7 In vitro bioassay 
p-Nitrophenol  #100-02-7, Alkaline buffer solution  #A9226-100mL, and  p-
Nitrophenyl Phosphate Liquid Substrate System # N7653 were from Sigma-
Aldrich, UK. 
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3.1.8 Gene knockdown   
IGFBP-2 shRNA plasmid #sc-37195-SH, control shRNA plasmid-A #sc-
108060, copGFP control plasmid #sc-108083, Puromycin #CAY13884-25, 
shRNA plasmid transfection medium #sc-108062, shRNA plasmid 
transfection reagent #sc-108061 were all from Santa Cruz Biotechnology, 
UK. Electroporation cuvettes (0.2mm) #Ep-102 were from Cell Projects, UK. 
A Gene Pulser Xcell™ electroporation system was from Bio-Rad, UK. Axio 
observer research microscope was from ZEISS. 
 
3.2 Methods  
3.2.1 Isolation of dental pulp stromal cells  
Healthy and carious third molar teeth were used to study the expression of 
osteogenic, angiogenic and inflammatory markers in addition to IGF axis 
components under basal conditions and during differentiation of dental pulp 
stromal/stem cells (DPSCs) into osteogenic lineages. Freshly extracted 
healthy and carious fully erupted third molars were collected from adult 
patients (20-40 years of age) at the out patients dental clinic of Leeds Dental 
Institute. Teeth were obtained through Leeds Dental and Skeletal tissue 
bank (LDI Research Tissue Bank; 130111/AH/75), with  patients’ informed 
consent. The age and gender of patients were recorded (Table 7). Carious 
lesions in this study was chosen based on the depth of the decay in the 
dentine layer, and assessment of this group was made during the sectioning 
of the teeth. Teeth with more than 2mm of sound dentine measured from the 
edge of carious lesion to the pulp tissue, were included in this study and 
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categorized as shallow caries [380, 381] (Figure 7A). This was assessed 
visually and by the use of a WHO periodontal probe (Figure 7B). External 
tooth surfaces were washed using sterile PBS and surrounding soft tissue 
attachments were removed using a sterile scalpel. External tooth surfaces 
were washed again with sterile PBS and were cracked open using a 
decontaminated vice to access the pulp tissue. Pulp tissue was gently 
separated by sterilized tweezers from the crown and root chambers, 
avoiding the apical third of the pulp tissue to prevent cross contamination 
with periodontal tissues. Isolated tissues were minced using a sterile scalpel 
before being digested in a solution of 5mL α-MEM, 3mg/mL collagenase 
type I and 4mg/mL dispase. The tissue- enzyme mixture was incubated for 1 
h at 37° C and was continuously mixed using a shaker inside the tissue 
culture incubator. The tissue-enzyme mixture was regularly checked at 15 
mins intervals to avoid over-digestion. The enzymatic reaction was stopped 
with 20% (v/v) FBS after complete dissociation of the pulp tissue. Cell pellets 
were obtained by centrifugation at 1000 g for 10 minutes. The supernatant 
was carefully aspirated and discarded. The pelleted cells were re-suspended 
in proliferation medium consisting of α-MEM, supplied with 20% (v/v) FBS, 
100 unit/mL Pen Strep, and 200mM L-glutamine. The cell suspension was 
passed through a 70μm strainer and seeded into T-25 cm² flasks and 15cm 
Petri dishes. The cultures were incubated at 37°C and 5% CO2 in 
proliferation medium. 
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Table 7: Details of all donors isolated during the current study  
* donors included and investigated in the current study 
Dental pulp stromal/stem cells isolated from healthy teeth (hDPSCs)  
Dental pulp stromal/stem cells isolated from carious teeth (cDPSCs)  
Cell type Age Gender tooth Type 
hDPSCs 11 Female First molar 
hDPSCs 11 Female First molar 
hDPSCs 9 Male First molar 
hDPSCs 40 Male Third molar 
hDPSCs 31 Female Third molar 
hDPSCs 31 Female Third molar 
hDPSCs 14 Female Second premolar 
hDPSCs 14 Female Second premolar 
hDPSCs 14 Male Second premolar 
*hDPSCs 
(H2) 
35 Female Third molar 
hDPSCs 35 Female Third molar 
hDPSCs 23 Male Third molar 
hDPSCs 9 Female First molar 
hDPSCs 19 Female Second premolar 
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hDPSCs 19 Female First premolar 
hDPSCs 19 Female First premolar 
hDPSCs 18 Male Third molar 
hDPSCs 18 Male Third molar 
hDPSCs 18 Male Third molar 
hDPSCs 34 Male Third molar 
hDPSCs 23 Male Third molar 
hDPSCs 31 Female Third molar 
hDPSCs 22 Female Third molar 
*hDPSCs 
(H1) 
20 Female Third molar 
*hDPSCs 
(H3) 
24 Female Third molar 
*cDPSCs 
(C1) 
40 Male Third molar 
cDPSCs 40 Male Third molar 
cDPSCs 8 Female First molar 
cDPSCs 10 Male First molar 
cDPSCs 10 Male First molar 
cDPSCs 9 Male First molar 
*cDPSCs 
(C3) 
24 Female Third molar 
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cDPSCs 24 Female Third molar 
cDPSCs 17 Female First molar 
cDPSCs 17 Male First molar 
cDPSCs 34 Male Third molar 
cDPSCs 34 Male Third molar 
*cDPSCs 
(C2) 
36 Female Third molar 
cDPSCs 36 Female Third molar 
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Figure 7 : Assessment of Dental Caries 
Carious lesions in this study were chosen based on the depth of 
the decay in the dentine layer, and assessment of this group was 
made during the sectioning of the teeth. Teeth with more than 
2mm of sound dentine measured from the edge of carious lesion 
to the pulp tissue, were included in this study and categorized as 
shallow caries [380, 381] .This was assessed visually and by the 
use of a WHO periodontal probe 
A:Illustrates carious lesion affecting enamel and superficial dentine 
(Adapted from: http://patient.info/health/tooth-decay)  
B: WHO probe used to measure the caries depth  
(Adapted from: intelligentdental.com). 
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3.2.2 Cell culture and expansion 
Isolated DPSCs from healthy (hDPSCs) and carious teeth (cDPSCs) were 
sub-cultured in T-175 cm² flasks, and media were changed every 5 days 
until cells reached 80% confluence. Monolayers were then washed with 
sterile cold PBS, and detached using 0.25% (w/v) Trypsin-EDTA solution for 
5 minutes. Twenty percent FBS was added to neutralize the trypsin, then the 
cell suspension was transferred to a  50mL universal tube and centrifuged at 
1100 g for 5 minutes [63]. The supernatant was discarded and the cell pellet 
was re-suspended in fresh proliferation media and cultured in the tissue 
culture flasks or plates according the experimental requirements. Cells were 
counted using a haemocytometer after staining with 0.01% (w/v) Trypan blue 
to exclude dead cells. Cells were seeded with the required densities 
according to the experimental plan. 
 
3.2.3 Stem cell characterization  
  Colony Forming Unit Fibroblast (CFU-F) Assay 
hDPSCs (n=3) and cDPSCs (n=3) were isolated and seeded in 15cm Petri 
dishes for 14 days, then fixed with absolute ethanol for 20 minutes after 
washing with PBS. Cells were stained with 10% (v/v) Trypan blue for 5 
minutes and washed gently with distilled water to remove any unbound 
stains. Aggregates of 50 cells or more were defined as a colony. All colonies 
were counted and recorded under the light microscope. 
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 Flow cytometric analysis of cell surface epitopes 
Flow cytometric analysis was used to characterise the surface phenotypic 
profile of cDPSCs versus hDPSCs. For this purpose, hDPSCs (n=3) and 
cDPSCs (n=3) were expanded to passage 4, then 1X106 cells were stained 
following the manufacturer’s instructions. Required antibody concentration 
for each marker was determined by titration (Section 3.2.3.2.1). Cells were 
stained with Fixable Viability Stain (FVS 510) in sodium azide and protein-
free Dulbecco’s Phosphate Buffered Saline (1x DPBS) in 5mL FACS tube at 
4⁰C for 30-60 minutes in dark. One µL of FVS510 stock solution for each mL 
of cell suspension (1:1000) was then added. Cells were washed twice with 
2mL of staining buffer (BSA) and centrifuged at 400 g for 5 minutes. After 
washing, 5µL of human Fc block was added per 1x106 cells, which blocked 
the Fc receptors (receptors of immunoglobulin) to minimize non-specific 
binding. Fc receptors are found on the surface of some immune cells; the 
fragment crystallisable region (Fc region) is the tail region of an antibody that 
interacts with these receptors [382]. After this, cells were incubated for 10 
minutes at room temperature and stained with the following pre-titrated 
fluorochrome-conjugated antibodies (Table 8): CD146/PE-Cy7, 
CD90/PerCP-Cy5.5, CD105/BV421, CD45/APC-Cy7, CD31/FITC,  in 100µL 
of staining buffer (BSA) and incubated at 4º C for 30-60 minutes.  Brilliant 
stain buffer was added (50µL/1x106 cells) to reduce the reagent interactions 
between the polymer based brilliant violet dyes, and to improve the staining 
quality when two or more dyes were used in the same experiment. Finally, 
the cells were washed twice in 2mL staining buffer and centrifuged (4°C, 400 
g for 5 minutes). The cells were re-suspended gently in 500µL staining 
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buffer, and analysed on an LSRII digital flow cytometer. Single colour 
stained CompBeads were used for purpose of compensation 
(Section 3.2.3.2.2). Unstained cells, cells labelled with mouse IgG1 Isotype 
(Table 8) and fluorescence minus one (FMO) was used as a control for each 
stain (Section 3.2.3.2.3).  
 
3.2.3.2.1 Antibody /Isotype titration 
An important step in optimization of flow cytometry experiments is titration of 
antibodies and isotype controls to use both of them at a level that saturates 
all the binding sites for that specific antibody. This is to ensure appropriate 
enumeration of protein expression and to maximise resolution between 
differentially stained fractions. The isotype controls are antibodies 
(immunoglobulin, Ig) available in different classes (IgA, IgG, IgD, IgE, or 
IgM), and these are used as one of the control measures to show the degree 
of non-specific binding of the antibody of interest (test antibody). Both test 
antibody and its isotype control should be used with the same class of 
immunoglobulin, matched with the host species, conjugated to the same 
fluorochrome and used at the same concentration in the staining procedure. 
Following the standard protocol for the flow cytometry experiment including 
the use of viability dye and blocking steps, we stained a known amount of 
cells (1X106) with serial antibody and isotype control dilutions. Cells 
recommended by the company were used for the titration and they were 
known to express the surface markers that were included in this study 
(Figure 8). The degree of binding is defined by the relative median 
fluorescence shift of the given antibody concentration compared to the same 
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concentration of its corresponding isotype control (Figure 8).The antibody 
and isotype control dilutions that were used in this study are listed in (Table 
8).  
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Figure 8: Antibody/Isotype control titration of positive stem 
cells markers 
Saturation occurs at the point where the ratio of the median intensities of  
antibody and its isotype (antibody/isotype) is the greatest; known as the 
Relative Median Fluorescent Shift. HUVECS: human umbilical vein 
endothelial cord cells, U937: model cell line were isolated from the 
histiocytic lymphoma of a 37-year-old male patient 
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Table 8: List of titrated test antibodies and their corresponding isotype 
antibodies that were used in this study  
 
Test Antibody Dilutions Isotype control Dilutions Supplier 
PE-Cy7 
Mouse Anti-Human 
CD146 
1:40 
PE-CY7 
Mouse IgG1, κ 
1:80 
BD 
Biosciences 
PerCP-Cy™5.5 
Mouse Anti-Human 
CD90 
1:20 
PerCP-Cy™5.5 
Mouse IgG1, κ 
1:40 
BD 
Biosciences 
BV421 
Mouse Anti-Human 
CD105 
1:5 
BV421 
Mouse IgG1, κ 
1:6 
BD 
Biosciences 
APC-Cy7 
Mouse Antihuman 
CD45 
1:20 
APC-Cy7 
Mouse IgG1, κ 
1:20 
BD 
Biosciences 
FITC 
Mouse Anti-Human 
CD31 
1:4 
FITC 
Mouse  IgG1, κ 
1:4 
BD 
Biosciences 
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3.2.3.2.2 Compensation controls  
Compensation is as a mathematical process by which we correct multi-
parameter flow cytometric data for spectral overlap (spill over). Spill over 
occurs whenever the fluorescence emission of one fluorochrome is detected 
in a detector designed to measure signals from another fluorochrome [383]. 
To correct this spectral overlap, a single-stained (SS) sample was run on the 
flow cytometer for the viability dye and CompBeads were run for other 
fluorochrome-labelled antibody (Table 9). CompBeads set provides two 
populations of polystyrene micro particles, which are used to optimize 
fluorescence compensation setting for multicolour flow cytometric analysis;  
the CompBeads anti-Mouse Ig, κ particles which bind any mouse κ light 
chain-bearing immunoglobulin, and the CompBeads negative control, which 
has no binding capacity. When mixed together with fluorchrome-conjugated 
mouse antibody, the CompBeads provide a clear bright and negative stained 
populations to suitably determine the spectral overlap for each given 
antibody marker without using valuable tissue samples. Compensation 
controls allow to investigate the bleeding of one dye on all other dyes. 
Compensation settings were adjusted until only a single colour was seen in 
each channel and no spill over of one colour into another colour’s channel 
was detected .  
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Table 9:  Single-stained (SS) compensation controls for flow cytometry 
 
 PE-Cy7 
CD146 
PerCP-Cy™5.5 
CD90 
BV421 
CD105 
APC-Cy7  
CD45 
FITC  
CD31 
Fixable 
viability 
dye 510 
Unstained Χ Χ Χ Χ Χ Χ 
SS- 
CompBeads 
 Χ Χ Χ Χ Χ 
SS- 
CompBeads 
Χ  Χ Χ Χ Χ 
SS- 
CompBeads 
Χ Χ  Χ Χ Χ 
SS- 
CompBeads 
Χ Χ Χ  Χ Χ 
SS- 
CompBeads 
Χ Χ Χ Χ  Χ 
SS- DPSCs Χ Χ Χ Χ Χ  
   
 
 
 
 
 
          : Included in the experiment 
  X  : not included in the experiment  
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3.2.3.2.3 Fluorescence minus one (FMO) controls 
Fluorescence minus one (FMO) is one of the control measures used  to 
optimise flow cytometry experiments. In this method, cells were stained with 
all fluorochromes that were used in the experiment except one (Table 10), in 
order to determine the exact range of the negative population for this 
particular fluorochrome [383]. This identifies the gate where the negative 
data spread due to the multiple fluorochromes in the panel used in this 
study. In the FMO controls, one specific fluorochrome from the panel was 
excluded each time and replaced it by its corresponding fluorochrome-
conjugated isotype control (Table 10). The corresponding isotype control 
was used to determine the background of non-specific binding in the 
presence of other cell phenotype markers which allows accurate 
determination of cell populations of interest.  
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 Table 10: Fluorescence minus one (FMO) controls for flow cytometry 
 
FMO control 
PE-Cy7 
CD146 
BV421 
CD105 
PerCP-Cy™5.5 
CD90 
APC-Cy7  
CD45 
FITC  
CD31 
Fixable 
Viability 
Stain  510 
Tube 1 
 
Unstained 
------- ------- ------------ --------- ------- --------- 
Tube 2 
 
PE-Cy7 
FMO 
PE-Cy7 
relative 
isotype 
CD105 CD90 CD45 CD31 FVS 510 
Tube 3 
 
BV421 
FMO 
CD146 
BV421 
relative 
isotype 
CD90 CD45 CD31 FVS 510 
 
Tube 4 
 
PerCP-Cy5.5 
FMO 
CD146 CD105 
PerCP-Cy5.5 
 
relative 
isotype 
CD45 CD31 FVS 510 
Tube 5 
 
APC-Cy7 
FMO 
CD146 CD105 CD90 
APC-Cy7 
 
relative 
isotype 
CD31 FVS 510 
Tube 6 
 
FITC 
FMO 
CD146 CD105 CD90 CD45 
FITC 
 
relative 
isotype 
FVS 510 
Tube 7 
 
Fixable 
viability stain 
510 
FMO 
CD146 CD105 CD90 CD45 CD31 --------- 
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3.2.4 Osteogenic differentiation of DPSCs  
hDPSCs and cDPSCs at passage 4 were cultured in 6-well plates at 1X105 
cells/well under basal conditions (α-MEM supplemented with 20% (v/v) FBS, 
200mM L-glutamine, and 100unit/mL Pen Strep). When the cells reached 
80% confluence, they were cultured in triplicate under basal or osteogenic 
conditions  (basal medium + 10nM dexamethasone and 100μM of L-ascorbic 
acid). Cultures were terminated at 1 and 3 weeks for further investigation of 
changes in gene expression using qRT-PCR for detection of relative 
changes in the expression of osteogenic, angiogenic, and inflammatory 
markers,  as well as changes in the IGF axis gene expression. Histological 
staining (Alkaline Phosphatase (ALP) and Alizarin red stains), as well as IGF 
protein expression were also investigated. Experiments were performed on 
cells derived from three healthy and three carious donors and triplicate wells 
were used for each time point and each culture condition; basal and 
osteogenic. 
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3.2.5 Quantification of gene expression using quantitative real 
time polymerase chain reaction (qRT-PCR)  
 
 Extraction of mRNA from hDPSCs and cDPSCs cultured in 
monolayers under basal and osteogenic conditions 
hDPSCs and cDPSCs cultured for 1 and 3 weeks under basal and 
osteogenic conditions were detached as described above and counted to 
determine the amount of cell lysis buffer required. mRNA extraction was 
performed according to manufacturer’s instructions using Qiagen’s 
RNAeasy® min kit summarised in Table 11. 
 
 mRNA quantification 
A NanoDrop spectrophotometer (ND 1000) was used to quantify the yield 
and purity of mRNA. Two μL of  the extracted mRNA was used and 
quantities were recorded as ng/μL. A260/280 ratios were also recorded as 
an indication of mRNA purity and were typically 1.8 - 2.0. 
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Table 11: Steps of RNA extraction using RNAeasy mini kit 
Reagents 
The amount needed to perform 
the reaction 
Buffer RLT 
1- Add sufficient buffer RLT and 
mix. 
2- Transfer lysed cells to nuclease 
free Eppendorf and mix on the 
vortex for 1 min. 
3- Add 70% ethanol at 1:1 (v/v) 
with buffer RLT 
4- Transfer up to 700μL of the mix 
to RNeasy spin column placed in 
2mL collection tube 
Number of pelleted 
cells 
Volume of 
buffer RLT 
(μL) 
˂ 5 X 106 350 
5 X 106   to  1 X 107 600 
More than 1 X 107 Not suitable 
5- Add RW1, centrifuge, and 
discard the flow through. 
700μL 
6- Add buffer RPE, centrifuge, and 
discard the flow through. 
7- Repeat step no. 6, and use new 
collection tube. 
500μL 
8- Add nuclease free water, 
centrifuge and collect the RNA 
elutes in a new tube. 
30μL 
 
 
 
Chapter 3: Materials and Methods 
 
82 
 
 DNase treatment  
To ensure that the mRNA was pure and clear of any genomic DNA, DNase I 
amplification grade kit was used according to the manufacturer’s 
instructions. Briefly, a mixture of DNase I buffer, enzyme, and mRNA sample 
(up to 1μg) were mixed in a 10μL reaction volume and incubated at room 
temperature for 15 minutes. The reaction was stopped by adding 1μL EDTA 
(25 mM) to the mix, then the mix is incubated at 65°C for 10 minutes in the 
PTC-100 thermal cycler. 
 
 Reverse transcription  
 Reverse transcription was carried out to generate single stranded cDNA 
from the mRNA by preparing 20μL reaction volume using the ABI high 
capacity RNA to c-DNA kit. Briefly, 10μL of buffer were added to 1μL of 
enzyme, and 9μL of mRNA sample, and then incubated in the PTC-100 
thermal cycler for 1 hour at 37°C followed by 5 minutes at 95°C. Negative 
controls for the experiment were generated during this step, by removing the 
mRNA template in one reaction and reverse transcriptase enzyme in the 
other. 
 
 qRT- PCR 
Quantitative real time PCR was performed using a Roche LC480 light cycler. 
The experiment was performed in a 20μL reaction volume composed of 
10μL gene expression master mix, 1μL Taqman gene expression assay 
specific for each gene, 8μL nuclease free water and 1μL c-DNA sample. The 
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20μL mix was added into each well of 96 well PCR reaction plate in 
triplicate. In addition, triplicates of non-template negative control and RT 
negative control were included in each plate. The plate was sealed securely 
and centrifuged for 10 second before starting the amplification procedure 
using the light cycler. Amplification was carried out according to Applied 
Biosystems’ (AB) recommendations for Taqman® probes  (Figure 9).  
 
 
 
Figure 9: qRT-PCR amplification program  
recommended by Applied Biosystems for the Taqman® probes  
 
 
 
 
 
1st   
stage 
•Pre-incubation cycle:
• 5 minutes at 95 ºC
2nd 
stage
•45 amplification cycles compising of:
•1- 95 ºC for 5 seconds
•2- 65 ºC for 1 minutes
3rd    
stage
•Final cooling:
•4 ºC for 30 seconds
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 Data analysis  
For each gene, relative expression levels were calculated using the 2-ΔΔCt 
method [384, 385]. In brief, the threshold cycle (Ct) value was determined for 
each gene of interest in triplicate. Technical replicates were averaged, then 
normalized to that of the house-keeping gene GAPDH. This is referred to as 
the ΔCt value. The ΔΔ Ct values were determined by normalizing the ΔCt 
value for each treated sample (under osteogenic conditions) to the 
appropriate control samples (under basal conditions) at each time point to be 
able to determine the relative changes in gene expression of interest 
(osteogenic, angiogenic, inflammatory and IGF axis) following osteogenic 
induction of hDPSCs and cDPSCs. The relative changes in gene expression 
were calculated using the 2-ΔΔct equation. In all cases, the 2-ΔΔct values for all 
markers were compared in both hDPSCs and cDPSCs. Changes in the gene 
expression levels were plotted as 2-ΔΔct ± SD. 
 
 House-keeping gene optimization  
The selected house-keeping gene (HKG) should have constant expression 
regardless the changes in cell culture conditions. Expression of GAPDH, a 
commonly used HKG, was measured under basal and osteogenic culture 
conditions at different time points. Data were analysed using Students’ t-test 
and P-values were determined (Figure 10). No statistically significant 
differences were found between all samples at different time points and 
under different culture conditions, which indicated that GAPDH was a 
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suitable HKG for this study; because it did not undergo any changes in 
response to different culture conditions or time points (Figure 10). 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Validation of GAPDH as house-keeping gene 
GAPDH expression was analysed under basal and osteogenic 
conditions for different samples; no significant difference in GAPDH 
expression was apparent after osteogenic differentiation. P-value = 0.83 
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3.2.6 Protein expression 
 hDPSCs and cDPSCs were cultured under both basal and osteogenic 
conditions for 1 and 3 weeks as described previously, changing media was 
performed once every week. One mL of conditioned medium was collected 
from each medium change, and was either freeze-dried and stored at -20ºC 
or directly stored at -80ºC without freeze-drying. 
 
 Optimization of protein detection method:   
Western blotting 
In western blotting, 1mL of medium conditioned by hDPSCs cultured under 
basal and osteogenic conditions was collected, and freeze-dried. Freeze-
drying is a process used to remove the water from the sample by freezing 
then drying it under a vacuum at very low temperatures. Powdered media 
were then dissolved in 1X SDS-polyacrylamide (SDS-PAGE) sample buffer 
containing β-mercaptoethanol (1:20, v/v) and loaded onto 15% (w/v) SDS-
polyacrylamide pre cast gels (30μL /well ). Suitable molecular weight 
markers (5µL of dual colour standards, 10 -250 kDa) were loaded  in a lane 
next to the samples to be able to determine molecular weight of the target 
proteins. Gels were run at 120V for 1 hour then proteins were transferred to 
PVDF semi dry membranes using the Trans-Blot Turbo device (BioRad) for 
10 minutes. After blotting, the membrane was rinsed three times with 
distilled water (dH2O) and incubated for 1hour with gentle agitation at room 
temperature in blocking solution, which comprised 5% bovine serum albumin 
(BSA) in Tris-buffered saline containing Tween-20 (TBS-T, 0.05%, v/v). After 
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blocking, the membrane was washed three times for 5 minutes using 0.05% 
(v/v) TBS-T then incubated overnight at room temperature with one of the 
following primary antibodies: anti- IGFBP-2, anti- IGFBP-3, anti- IGFBP-4, 
anti-IGFBP-5 or anti-IGFBP-6 reconstituted (1:1000, v/v) in 0.05% (v/v) TBS-
T. Next day, the membrane was washed three times for 5 minutes using 
0.05% (v/v) TBS-T then incubated with the appropriate streptavidin 
horseradish peroxidase (HRP) conjugated secondary antibody reconstituted 
(1:10000, v/v) in 5% (w/v) BSA in 0.05% (v/v) TBS-T for 1 hour with gentle 
agitation at room temperature. The membrane was washed three times, 
each for 15 minutes using 0.05% TBS-T, and was developed with ultra-
sensitive enhanced chemiluminescent (ECL) substrate (A and B, 1:1 v/v) 
and images were obtained and recorded on the ChemiDoc imager. 
Ligand blotting 
For ligand blotting, 1mL of medium conditioned by hDPSCs cultured under 
basal and osteogenic conditions was collected, and freeze-dried. Freeze-
dried medium was re-suspended in non-reducing SDS-PAGE sample buffer. 
Electrophoresis and blotting were performed as described in the previous 
section for Western blot analysis. After the blotting step, the membrane was 
incubated; first in 3% Tergitol solution type NP40 in TBS for 30 minutes, and 
incubated in blocking solution (3% (w/v) BSA in TBS) for 2 hours. Lastly, the 
membrane was incubated in 0.1% (v/v) TBS-T for 10 minutes with gentle 
agitation at room temperature. After that, the membrane was incubated 
overnight at 4°C with 20ng mono-biotinylated IGF-2 in 1mL of 1% (w/v) BSA 
and 0.1% (v/v) TBS-T. Next day, the membrane was washed three times, 
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each for 15 minutes in 1% (w/v) BSA in 0.1% (v/v) TBS-T. The membrane 
was then incubated in streptavidin-HRP reconstituted (1:2000, v/v) in 1% 
(w/v) BSA in 0.1% (v/v) TBS-T for 1 hour with gentle agitation at room 
temperature. Finally, the membrane was washed three times, each for 15 
minutes in 0.1% (v/v) TBS-T then developed using ECL substrate (A and B, 
1:1 v/v) and images were obtained and recorded on the ChemiDoc imager. 
Enzyme-linked immunosorbent assay (ELISA) 
hDPSCs and cDPSCs were grown under basal and osteogenic conditions 
for 1 and 3 weeks. Conditioned medium (1mL) was collected from  each 
culture at 1 and 3 week time points under basal and osteogenic conditions.  
IGFBP-2 and IGFBP-3 concentrations in conditioned media were determined 
by ELISA using human IGFBP-2 Duo Set ELISA kit and human IGFBP-3 
Quantikine ELISA Kit according to the manufacturer’s protocol. Briefly, for 
IGFBP-2, diluted capture antibody (mouse anti-human IGFBP-2) at 2μg/mL 
in PBS was plated in 96 well microplate (100μL/well) and incubated 
overnight at room temperature. On the following day, the plate was washed 
with 300μL of 1:25 (v/v) diluted washing buffer (0.05% (v/v) Tween-20 in 
PBS) four times. Plates were blocked using 300μL of the 1:5 (v/v) reagent 
diluent (5% (v/v)Tween -20 in PBS, 0.2µm filtered) and incubated for 1 hour 
at room temperature. After washing four times with 400μL washing buffer, 
100μL of the samples, and appropriately diluted standards (representative 
standard curve is shown in Figure 11A) were added  to the 96 well plate and 
incubated for 2 hours at room temperature. Plates were washed as above 
and 100μL of the detection antibody (biotinylated goat anti-human IGFBP-2) 
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were added at 200ng/mL in reagent diluent with 2% (v/v) heat activated goat 
serum for 2 hours at room temperature. After washing, 100μL of working 
dilution of streptavidin-HRP (1:200, v/v) was added for 20 minutes and 
plates were incubated at room temperature in the dark. Finally the plates 
were washed and 100μL of substrate solution (colour reagent A: H2O2 and 
colour reagent B: Tetramethylbenzidine, 1:1 v/v) were added and the plate 
was incubated for 20 minutes at room temperature in the dark. 50μL of stop 
solution (2 N H2SO4) was added and absorbance was determined 
immediately using a microplate reader (Thermo-Scientific Varioskan Flash 
type 300 spectrophotometer) at 450nm. 
For IGFBP-3, the Quantikine ELISA kit was used. The assay was performed 
following the manufacturer’s instructions. In brief, 100µL of assay diluent 
RD1-62 (buffer with blue dye) was plated in a 96 well plate. Next, 100μL of 
the samples, and appropriately diluted standards (recombinant human 
IGFBP-3 in buffer) in calibrator diluent RD5P (buffered protein base) were 
added to  the assay diluent RD1-62 and incubated for 2 hours at 2-8ºC, 
representative standard curve is shown in (Figure 11B). The plate was 
washed with 400μL of 1:25 (v/v) washing buffer (buffered surfactant) three 
times. Then 200µL of chilled IGFBP-3 polyclonal anti-IGFBP-3 HRP 
conjugate was added per well and incubated for 2 hours at 2-8ºC. The plate 
was washed as above and 200µL of substrate solution were added per well 
(colour reagent A: stabilized H2O2, colour reagent B: stabilized 
Tetramethylbenzidine, 1ː1, v/v) and incubated for 30 minutes at room 
temperature in the dark. Finally, 50μL of stop solution (2 N H2SO4) was 
Chapter 3: Materials and Methods 
 
90 
 
added and absorbance was determined immediately using a microplate 
reader at 450nm. 
 
There was evidence of serum interference in immunoblotting techniques, 
which reflects the relative lack of sensitivity of such techniques in this study. 
Therefore, ELISA was used for any further investigation of protein level, to 
be able to calculate the accurate protein concentration as ELISA was more 
accurate with high throughput. 
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Figure 11: Representative standard curves for standards 
used in ELISA quantitative analysis of IGFBPs 
(A) IGFBP-2 standard curve 
(B) IGFBP-3 standard curve  
 
 
0
0.5
1
1.5
2
2.5
0 1000 2000 3000 4000 5000
pg/ml
IGFBP-2 standards
standards
A
0
0.5
1
1.5
2
2.5
0 10 20 30 40 50 60
ng/ml
IGFBP-3 standards
standards
B
Chapter 3: Materials and Methods 
 
92 
 
 Inflammatory cytokine assay 
The BD ™ CBA Human Inflammatory cytokines kit was used to quantify the 
following cytokines; interleukin-8 (IL-8), interleukin- 1β(IL-1β), interleukin-6 
(IL-6), interleukin-10 (IL-10), tumour necrosis factor (TNF), and interleukin-
12p70 (IL-12p70) protein levels in media conditioned by hDPSCs and 
cDPSCs grown under basal and osteogenic conditions for 1 and 3 weeks. 
This assay was performed in 96 well plates following the manufacturer’s 
protocol. Briefly, the mixed capture beads were vortexed, and then 50µL 
were added to each well. The standard dilutions were added (50µL) to the 
control wells, representative standard curves are shown in Figure 12. 
Likewise, 50µL of each of our samples (basal and osteogenic conditioned 
media) from both hDPSCs and cDPSCs were added to the 96 well plate 
followed by 50µL of the PE detection reagent. The plate was incubated for 
three hours, at room temperature in the dark. After that, the plate was 
washed twice using 250µL of washing buffer (centrifuged at 400 g for 2 
minutes). Finally, 120µL of washing buffer was added to re-suspend the 
beads and the plate was ready for acquisition on the flow cytometer (LSR II 
4 Laser). The data were analysed using flow cytometry analysis program 
(FCAP) array software.  
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Figure 12: Representative standard curves for standards used in CBA  
quantitative analysis of (IL12p70, TNF, IL-10, IL-6, IL-8, IL-1β)  as 
labelled 
Data were generated using flow cytometer LSRII 4 Lasers, BD Biosciences 
equipped with 4 lasers (405nm violet laser, 488nm blue laser, 355nm UV laser 
and 640nm red laser) and analysed using flow cytometric analysis program 
(FCAP) Array software (BD Biosciences)  
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3.2.7 In vitro bioassay  
hDPSCs were grown to 80% confluence and incubated in osteogenic 
medium (Section 3.2.4) with a fixed concentration of IGFBP-2 and IGFBP-3 
at (10nM), and varying concentrations (0nM, 1nM, 10nM, 100nM) of IGF-1 or 
IGF-2. Medium was changed at day 4, 7, 10 and cultures were terminated at 
day 14. ALP enzyme activity has been examined as an osteogenic marker. 
Alkaline phosphatase activity was measured by the ability of alkaline 
phosphatase enzyme to convert the colourless substrate p-
nitrophenylphosphate (pNPP) into yellow p-nitrophenyl (pNP) as previously 
described [386]. Briefly, cells were washed twice with PBS, and lysed by 
200µL of 0.1% (v/v) Triton™x-100 followed by three cycles of freezing and 
thawing. Lysates were centrifuged (1000g) for 5 minutes and 20µL of the 
supernatants were used in ALP activity assay. Standards were prepared by 
diluting pNP in buffer, provided with the pNPP substrate as a kit, at 
concentrations of 5, 25, 50, 100, 150 and 200 nmol/mL. A 100μL of each 
standard was added to the wells of a 96 well plate (n=3). A 90μL of pNPP 
substrate was then added to 10μL of sample lysates in triplicates in 96 well 
plates. The plate was then incubated at 37 ºC for 30 minutes in the dark. The 
reaction was stopped by adding 100μL of 1M NaOH. The sample 
absorbance was measured at 405nm using a microplate reader. Alkaline 
phosphatase specific activity was expressed as nmoles of p-Nitrophenol/µg 
DNA of the sample.   
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3.2.8  Cell transfection 
 Puromycin optimisation  
A puromycin selection system was used to select stably transfected 
hDPSCs. hDPSCs were seeded at a concentration of 1x105 cells/well in 6 
well plate in antibiotic free growth medium one day prior to addition of 
puromycin (experiments were done in duplicate). Freshly prepared medium 
containing puromycin at 0-10 µg/mL was added to 80% confluent cells in 
duplicate wells. Medium was replaced every three days for up to a week. 
Cultures were examined by light microscopy for signs of cell death to 
determine the lowest puromycin concentration, which resulted in 100% cell 
death. This concentration was subsequently used in selection of stably 
transfected cells.  
 
  Lipid- based transfection 
Small or short hairpin RNA (shRNA)- based strategy has been used 
attempting to knock down the IGFBP-2 expression in hDPSCs, which will be 
discussed later in this study (Chapter 7). Dental pulp stromal/stem cells were 
isolated from healthy pulp tissue, seeded at passage 4 at 1x105 cells/mL  in 
6 well plates in proliferation medium (α-MEM, 20% (v/v) FBS, 200mM L-
glutamine, 100 unit/mL  Pen Strep) and grown under basal conditions until 
cells reached 70% confluence. Cells were transfected according to the 
manufacturer’s protocol (Santa Cruz Biotechnology, Inc). Briefly, cells were 
washed with 1mL of  transfection medium and incubated for 6 hours with 
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either negative control (control shRNA plasmid) or IGFBP-2 shRNA plasmid 
in the presence of 0.5-3% (v/v) lipid based transfection reagents and 
transfection medium in a final volume of 1mL. After 6 hours, 1mL of antibiotic 
free- proliferation medium was added to each well and incubation continued 
overnight. Next day, media were replaced with 2mL of antibiotic free-
proliferation medium containing the selected concentration of puromycin. 
Media were changed every 2 days. Dead cells were removed with medium 
changing, and puromycin resistant cells should have been able to grow for 
3-4 weeks. Unfortunately, successful transfection for hDPSCs was not 
achieved and no viable living cells were observed even after 4 weeks. 
 
 Electroporation- based transfection  
As an alternative to the lipid based transfection, electroporation based 
methodology was used. Electroporation creates transient pores in the 
cellular membrane that allow nucleic acid to pass into the cells [387]. The 
protocol was adapted from a previous study, which optimised the 
electroporation conditions for transfection of dental pulp stem cells [388]. 
Briefly, hDPSCs were isolated from healthy pulp tissue, seeded at passage 
4 in a T-175 flask in proliferation medium under basal conditions until cells 
reached 70% confluence. Cells were passaged, counted and 1X106 cells/mL 
were brought together with either positive control (copGFP control plasmid), 
negative control (control shRNA Plasmid) or IGFBP-2 shRNA plasmid in 
electroporation buffer (α-MEM medium without any additives). The 
transfection mix was transferred to the 0.2mm electroporation cuvettes then 
exposed to 100V for 20msec using a one-pulse square- wave method. 
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Electroporation was performed using a Gene Pulser Xcell main unit. After 24 
and 48 hours, the positive control cells (copGFP control plasmid) were 
imaged using an Axio Observer Research microscope. 
3.3 Statistical analysis  
All experiments were carried out in triplicate from three different donors in 
each group; hDPSCs and cDPSCs. Flow cytometry, qRT- PCR, and ELISA 
results were analysed using Students’ t-test and one way analysis of 
variance (ANOVA) followed by Bonferroni multiple comparison tests. P-
values were determined, and P ˂ 0.05 was considered significant. The 
statistical analyses were carried out using the Graph Pad Prism software (v 
6). ………………  ………………………..
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  Results   
Dental pulp stem cells in healthy and carious teeth 
4.1 Introduction 
Stem/progenitor cells have been identified and isolated from dental pulp. 
However, it is not clear if pulp cells isolated from carious teeth (cDPSCs) 
express stem cell markers and whether they retain the same regenerative 
abilities as the well characterised dental pulp stem cells isolated from 
healthy teeth (hDPSCs) [3, 151, 157, 389-392]. A number of  mesenchymal 
stem cell (MSC) surface markers have been reported in the literature (Table 
12) and the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy have suggested a set of standards 
to define human MSCs for both laboratory-based scientific investigations 
and pre-clinical studies. They defined the MSCs as cells able to grow as 
adherent cells, differentiate into bone, cartilage and adipose cells, and 
express the stem cell surface markers including CD105, CD73 and CD90, 
but not hematopoietic or endothelial markers such as CD45, CD34, CD11b 
and CD19 [393-395]. Putative MSCs were first isolated from dental pulp 
tissue and partially characterized in 2000 [151]. Subsequent studies 
demonstrated that dental pulp cells possessed stem cell properties, 
including the expression of known stem cell surface markers, adhering to 
plastic and the ability to differentiate into multiple lineages [3, 393, 396]. 
Interestingly, studies also noted the high proliferative capacity of such cells 
isolated from third molars (also the source of dental pulp cells described in 
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this current study) with the ability to undergo osteogenic and chondrogenic 
differentiation. However, no cartilage tissue formation has been reported 
[390]. Adipogenic differentiation of hDPSCs  has also been observed under 
appropriate conditions [160, 390, 391] although some reports suggested that 
this effect is less pronounced [151, 389]. Dental pulp stem cell populations 
showed comparable properties to those of MSCs, including  the ability to 
self-renew and multi-lineage differentiation capability although with higher 
potential toward odontogenic lineages and dental pulp regeneration [397]. 
The broad capacity for differentiation of DPSCs could be related to their 
developmental origin, which includes neural crest derived cells [398], and 
complete pulp regeneration has been reported in pulpectomised adult canine 
teeth after transplantation of autologous pulp stem/progenitor (CD105+) cells 
with stromal cell-derived factor-1 (SDF-1) into a root canal [399].  
Dental caries is one of the most common oral diseases and is characterized 
by pulp inflammation due to bacterial infection. In contrast to healthy dental 
pulp, there are few data regarding the properties of stem cells isolated from 
cDPSCs. However, the dental repair process occurring following carious 
lesions confirm the presence of a stem cell population in the pulp tissue 
[400]. This has led to an ongoing interest in cDPSCs especially with regard 
to distinctive stem cell characteristics and whether or not they retain tissue 
regeneration potential. Previous studies have demonstrated that DPSCs 
isolated from deeply carious teeth retain the characteristics of mesenchymal 
stem cells, including self-renewal proliferation and multi-lineage 
differentiation capability [175, 177]. Alongi et al. (2010), isolated DPSCs from 
teeth affected with irreversible pulpitis which showed higher levels of stem 
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cell markers STRO-1, CD90 and CD146 compared to DPSCs isolated from 
unaffected teeth using immunohistochemical analysis, while CD146 
demonstrated moderate to high expression levels in both DPSCs isolated 
from non-inflamed and inflamed dental pulps using flow cytometry analysis 
[175]. In a later study, DPSCs were isolated from third molars affected by 
deep caries and the phenotype pattern was compared with DPSCs isolated 
from unaffected third molars using flow cytometry. Flow cytometry analysis 
indicated higher expressions of STRO-1, CD90, CD105 and CD29 in 
cDPSCs when compared to hDPSCs [177].  
The present study was designed to investigate the changes in stem cell 
characteristics including expressed stem-cell markers, clonogenic ability and 
osteogenic differentiation of dental pulp stromal/stem cells isolated from 
teeth with shallow caries. Investigations of the characteristics of cDPSCs will 
give us information about the ability of cDPSCs to be involved  in 
regeneration therapies. Three donors were studied in each group. hDPSCs 
were isolated from fully erupted third molars without caries or pulp disease, 
while the cDPSCs were isolated from teeth with shallow caries.  
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Table 12: Selection markers for mesenchymal stem cells 
Positive Biological role References 
CD146 Stem cell marker including MSCs 
derived from periodontal ligament, 
bone marrow, placenta and adipose 
tissue. Correlates with multi-potency 
and clonogenic ability. 
[401], [402], [403], 
[404], [405], [392], 
[406], [3], [151] 
CD90/Thy1  Wound repair, cell-cell and cell-matrix 
interactions. 
[407], [408], [393], 
[392], [3] 
CD105/Endoglin Cell adhesion molecule, vascular 
homeostasis. 
[407], [408], [393], 
[392], [3] 
STRO-1 Putative stem cell marker. Successfully 
used to enrich CFU-Fs from human 
bone marrow 
[407], [392], [406], [3]  
CD73 Cell adhesion molecule. Expressed in 
mesenchymal stem cells 
[408], [393], [409], [3] 
Negative Used to exclude  References 
CD45 Leukocytes 
[407], [408], [393], 
[392], [406], [3], [151] 
CD31 Endothelial cells [407], [408],  
CD34 
Primitive hematopoietic cells and 
endothelial cells 
[408], [393], [392], 
[151] 
CD11b and 
CD14 
Monocytes and macrophages [408], [393] 
CD79 alpha and 
CD19 alpha 
B cells [393] 
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4.2 Results 
4.2.1 Colony forming unit fibroblast assay (CFU-F) in dental pulp 
cells isolated from carious versus healthy teeth 
 
Colony forming units (CFUs) were counted in primary basal cultures of 
hDPSCs (n=3) and cDPSCs (n=3) isolated from third molars. Colonies were 
identified as clusters of 50 cells or more. DPSCs derived from healthy and 
carious teeth showed the ability to form colonies. hDPSCs showed an 
average of 60 ±10 colonies, whereas cDPSCs showed an average of 100  
±7.6. cDPSCs displayed a significant increase in CFUs when compared to 
hDPSCs (Figure 13) suggesting an increased colony forming efficiency in 
these cells. 
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Figure 13: Colony Forming Unit Fibroblast assay (CFU-F)  
 
An image showing colony forming units arising from hDPSCs (A)  and 
cDPSCs; (B) after 14 days of basal culture, cells were stained with 10% 
Toluidine blue. Scale bar = 5 cm. (C) Comparing the number of colony units 
formed by DPSCs derived from 3 healthy and 3 carious teeth. The data are 
presented as the mean of biological replicates (n=3) ±SD. Data were 
analysed using Student’s t test (P =0.0034). 
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4.2.2 Expression of stem cell surface markers in dental pulp cells 
isolated from carious versus healthy teeth 
 
Flow cytometric analysis was used to characterize the surface phenotypic 
profile of cDPSCs versus hDPSCs. hDPSCs and cDPSCs were cultured at 
passage 4 under basal conditions (α-MEM, supplied with 20% (v/v) FBS, 
100 unit/ml Pen Strep, and 200mM L-glutamine) then subjected to flow 
cytometric analysis to investigate the expression of stem cell surface 
markers on both hDPSCs and cDPSCs. The expression of putative stem cell 
markers was investigated in both cell types. Positive stem cell markers 
included CD146 (melanoma cell adhesion molecule, MCAM), CD90 (Thy-1, 
cell adhesion molecule), CD105 (Endoglin, cell adhesion molecule) and 
negative stem cell markers included CD45 (haematopoietic cell marker, 
leukocyte common antigen) and CD31 (platelet endothelial cell adhesion 
molecules, PECAM-1) (Table 12). An example of the gating strategy that has 
been used in the analysis of the collected data  is demonstrated in Figure 
14. 
Fluorescence minus one (FMO) with antibody isotype controls were used as 
negative control in the analysis presented in this study (Chapter 3, Methods, 
Section 3.2.3.2.3). Negative control gate was set where 98% of the 
population falling beneath this gate, making any movement of the positive 
stain beyond this point represents more than three standard deviations away 
from the mean of the negative control, which considered statistically 
relevant. 
Flow cytometric results showed that all positive stem cell markers (CD146, 
CD90 and CD105) appeared to be expressed by both hDPSCs and cDPSCs  
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but with variable percentages (Figure 15 , Figure 16, and Figure 17). 
Interestingly, the expression of CD146 was higher by 20% in cDPSCs 
(43.5% ±17.14) compared with hDPSCs (23.2% ±22.6) (Table 13). On the 
other hand, as shown in Table 13, flow cytometric analysis revealed almost 
the same expression level of CD90 positive populations in both hDPSCs 
(98.9% ±1.2) and cDPSCs (99.70 % ±0.36). Moreover, 99.60% ±0.08 of 
cDPSCs expressed CD105 compared to 97.8% ±1.6 of hDPSCs; giving 
approximately 2% increase in CD105 expression by cDPSCs compared with 
hDPSCs. Negative stem cell markers (CD45 and CD31) showed negative or 
very little expression in both cell populations. CD45 was expressed in about 
5% ±4.94 of hDPSCs and 0.72% ±0.31  of cDPSCs, while CD31 was 
expressed only in 0.04% ±0.03 of hDPSCs and 0.10% ±0.05 of cDPSCs.  
On an individual basis, two donors of hDPSCs expressed low levels of 
CD146 (H1- 3.76% and H3- 11%), while 54.9% of H2 expressed CD146. 
However, two donors of cDPSCs showed a moderate expression of CD146 
(C2- 28.4% and C3- 34.7%), while C1 expressed 67.5% of CD146 (Figure 
15). Interestingly, it is apparent from Figure 16 and Figure 17 that more than 
95% of hDPSCs and cDPSCs expressed CD90 and CD105. What is more, a 
noted observation to emerge from these data was the expression of the 
leukocyte precursor marker CD45, which was expressed at a range of 
0.85%  to 12.1% in hDPSCs. While CD31 expressed at a range of 0% to 
0.17% in both hDPSCs and cDPSCs.  All in all, the results of this study did 
not show any significant differences between cells isolated from healthy and 
carious wisdom teeth in expressing positive and negative stem cell markers 
(Table 13). 
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 In order to further analyse the stem cell population from both hDPSCs and 
cDPSCs, another gating strategy was used (Figure 20). In this strategy, dead 
cells were excluded using fixable viability dye, the CD90 positive 
subpopulation of DPSCs was gated, CD105 against CD45 was plotted from 
selected CD90+ subpopulation, then CD146 against CD31 was plotted from 
selected CD105+/CD45- subpopulation. The final gated population was 
assumed to be enriched stem cell population(s) (Figure 20). Flow cytometric 
results of the previous gating strategy showed that the cDPSCs expressed 
higher percentage of stem cell population (CD90+/CD105+/CD45-
/CD146+/CD31-); about 34% ±16.6 compared with18.5% ±19.31 expressed 
by hDPSCs (Figure 21).  
Regarding the individual analysis of both DPSC subpopulations using the 
previous gating strategy, hDPSCs showed low to moderate expression 
levels  as H1 and H3 expressed 2.35% and 7.41%  respectively, while H2 
expressed about 45% of the same markers. However, cDPSCs showed 
moderate  expression levels as C2 and C3 expressed 19.6% and 27% of 
stem cell markers respectively, while C1 expressed about 57.9% of the 
same markers (Figure 20).  
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Figure 14: Example of gating strategy used to analyse single stem cell 
surface marker  
Flow cytometry analysis of stem cell surface marker expression in DPSCs under 
basal conditions (CD90 was used as an example). (A) Representative dotplot of 
intact cellular bodies gating in DPSCs by excluding scattered very small nuclear 
debris . (B) Representative dotplot of living cells gating in DPSCs using FMO 
control relative to fixable viability dye (BV510). (C) Representative dotplot of the 
negative control (FMO + antibody isotype) relevant to CD90 (PerCP-Cy5.5). (D) 
Representative single-parameter histogram plot for the negative control (FMO + 
antibody isotype) relevant to CD90 (PerCP-Cy5.5), where the gate is positioned at 
98% of the negative control and any movement of the positive stain beyond that 
point is statistically relevant . 
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Figure 15: Expression of CD146 in hDPSCs and cDPSCs under basal 
conditions using flow cytometry.  
Representative diagrams are single- parameter histograms showing the 
expression of CD146 in hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) cultures 
under basal conditions. The grey coloured histograms represent the negative 
control (FMO+ antibody isotype) relevant to CD146 (PE-Cy7), where the gate is 
positioned at 98% of the negative control and any movement of the positive stain 
beyond that point is statistically relevant. The blue coloured histograms represent 
positive CD146 population in hDPSCs and the bright red coloured histograms 
represent positive CD146 population in cDPSCs. * Gating strategy following what 
has been demonstrated in Figure 14. 
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Figure 16: Expression of CD90 in hDPSCs and cDPSCs under basal 
conditions using flow cytometry.  
Representative diagrams are single- parameter histograms showing the 
expression of CD90 in hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) cultures 
under basal conditions. The grey coloured histograms represent the negative 
control (FMO+ antibody isotype) relevant to CD90 (PerCP-5.5), where the gate is 
positioned at 98% of the negative control and any movement of the positive stain 
beyond that point is statistically relevant. The blue coloured histograms represent 
positive CD90 population in hDPSCs and the bright red coloured histograms 
represent positive CD90 population in cDPSCs. * Gating strategy following what 
has been demonstrated in Figure 14. 
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Figure 17: Expression of CD105 in hDPSCs and cDPSCs under basal 
conditions using flow cytometry.  
Representative diagrams are single- parameter histograms showing the 
expression of CD105 in hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) cultures 
under basal conditions. The grey coloured histograms represent the negative 
control (FMO+ antibody isotype) relevant to CD105 (BV421), where the gate is 
positioned at 98% of the negative control and any movement of the positive stain 
beyond that point is statistically relevant. The blue coloured histograms represent 
positive CD105 population in hDPSCs and the bright red coloured histograms 
represent positive CD105 population in cDPSCs. * Gating strategy following what 
has been demonstrated in Figure 14. 
 
 
 
 
Chapter 4: Results 
 
111 
 
 
 
 
 
Figure 18: Expression of  CD45  in hDPSCs and cDPSCs under basal 
conditions using flow cytometry.  
Representative diagrams are single- parameter histograms showing the 
expression of CD45 in hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) cultures 
under basal conditions. The grey coloured histograms represent the negative 
control (FMO+ antibody isotype) relevant to CD45 (APC-Cy7), where the gate is 
positioned at 98% of the negative control and any movement of the positive stain 
beyond that point is statistically relevant. The blue coloured histograms represent 
positive CD45 population in hDPSCs and the red coloured histograms represent 
positive CD45 population in cDPSCs. * Gating strategy following what has been 
demonstrated in Figure 14. 
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Figure 19: Expression of  CD31 in hDPSCs and cDPSCs under basal 
conditions using flow cytometry.  
Representative diagrams are single- parameter histograms showing the 
expression of CD31 in hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) cultures 
under basal conditions. The Grey coloured histograms represent the negative 
control (FMO+ antibody isotype) relevant to CD31 (FITC), where the gate is 
positioned at 98% of the negative control and any movement of the positive stain 
beyond that point is statistically relevant. The blue coloured histograms represent 
positive CD31 population in hDPSCs and the bright red coloured histograms 
represent positive CD31 population in cDPSCs. * Gating strategy following what 
has been demonstrated in Figure 14. 
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Table 13: Stem cell marker expression (%) in DPSCs isolated from healthy 
and carious teeth  
Data presented as means of expression of the biological replicates (n=3)  ± SD in 
each group. No statistical difference was observed in the expression of all 
markers between hDPSCs and cDPSCs using Student’s t-test.   
 
 
 
 
 
 
GROUP 
Positive stem cell markers Negative stem cell markers 
CD146 CD105 CD90 CD45 CD31 
hDPSCs 
 
23.2%  
±22.6 
 
98.9% 
±1.2 
 
97.8% 
±1.6 
 
5.2% 
±4.94 
 
0.04% 
±0.03 
cDPSCs 
 
43.5%    
±17.14 
 
99.70% 
±0.36 
 
99.60% 
±0.08 
 
0.72% 
±0.31 
 
0.10% 
±0.05 
 
P-value 
 
(0.372) 
 
( 0.451) 
 
(0.254) 
 
(0.329) 
 
(0.202) 
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Figure 20: Stem cell population in dental pulp cells isolated from 
healthy and carious teeth  
Flow cytometry analysis of stem cell surface markers expressed in DPSCs 
isolated from healthy (H1, H2, H3) and carious (C1, C2, C3) teeth under basal 
conditions. (A) Representative dotplots of intact cellular bodies gating in 
DPSCs. (B) Representative dot plots of living cells gating in DPSCs using 
fixable viability dye. (C) Representative dotplots of CD90+ cells gating in 
DPSCs. (D) Representative of dotplots of CD105 (Y axis) against CD45 (X 
axis) surface markers from selected CD90+ subpopulation. (E) 
Representative dotplots of CD146 (Y axis) against CD31 (X axis) surface 
markers from selected CD105+ /CD45- subpopulation in the previous plot (D).  
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Figure 21: Stem cell population (%) in hDPSCs and 
cDPSCs. 
 
The graph represent the mean percentage of stem cell 
population markers (CD90+/CD105+/CD45-/CD146+/CD31-) 
expressed in DPSCs derived from 3 healthy and  3 carious 
teeth. Data are presented as the mean of expressions of the 
biological replicates (n=3) ± SD in each group. Data were 
analysed using Student’s t-test. P=0.414 
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4.3 Discussion 
These results demonstrated the ability of both hDPSCs and cDPSCs to 
express mesenchymal stem cell surface markers, adhere to plastic surfaces, 
and their ability to form colonies. The behaviour of hDPSCs in this study is 
similar to that previously reported with regard to mesenchymal stem cell 
surface markers expression, colony forming and differentiation ability [151, 
389, 396]. Colonies of cDPSCs occurred at higher frequency in comparison 
to hDPSCs, in agreement with previous observations showing a higher 
clonogenic potential on cDPSCs isolated from third molars (n=10) with deep 
caries [177]. Caries as a pathologic microenvironment is able to evoke 
different responses of the stem cells and other supportive cells in the pulp 
tissue through bacterial toxins that can reach the pulp through the dentinal 
tubules. Therefore, increased clonogenic potential of cDPSCs might possibly 
be a sign of early dentinal repair, in response to these pathological stimuli.  
The surface markers on hDPSCs and cDPSCs have been analysed to 
confirm the presence of stem cells in these two groups and to characterise 
the different cell subpopulations within these mixed stromas based on the 
percentage of stem cell markers expression. In the present study, CD146 
was expressed in 23.2% ±22.6 of the hDPSCs. This varied from the report of 
Bakopoulou et al. (2011), in which more than 80% of DPSCs expressed 
CD146 [406]. High expression of CD146 in their study may be related to the 
stage of root development as they isolated the DPSCs from impacted third 
molars of three donors aged 16-18 years. High vascularity was needed in 
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order to complete root formation in the eruption stage (18-25 years old) and 
CD146 is known to be expressed in perivascular MSCs [410]. CD90 and 
CD105 expressions in hDPSCs in the present study are largely in agreement 
with other studies, which reported high expression (˃95%) of both CD90 and 
CD105 in dental pulp tissues isolated from normal healthy teeth [389, 407].  
Interestingly, the present study showed the mesenchymal stem cell marker 
CD90 was comparably expressed in both hDPSCs (98.9% ±1.2) and 
cDPSCs (99.70% ±0.36). Similarly, CD105 showed also parallel expression 
in cDPSCs  (99.60% ±0.08) compared with hDPSCs (97.8% ±1.6). Ma et al. 
(2012), demonstrated significantly higher expression of STRO-1, CD90, 
CD105 and CD29 in cDPSCs compared to hDPSCs [177], although the 
absolute levels of expression of both CD90 and CD105 in the previous study 
were far less compared to the current study. Ma et al. (2012), mentioned that 
they isolated hDPSCs and cDPSCs from pulp chambers only, while in the 
present study, DPSCs have been isolated from the pulp chamber and upper 
2/3rd  of the root canal, which might include different stem cell populations in 
the current study expressing higher percentages of stem cell markers. 
Furthermore, Ma et al. (2012), isolated DPSCs from teeth affected with deep 
caries as opposed to here, where DPSCs were isolated from teeth with 
shallow caries. In the case of deep caries with severe injury, odontoblasts 
can undergo cell death, perhaps leading to increased differentiation of stem 
cells into odontoblasts-like cells as a consequence of cariogenic challenge. 
This process depends on a cascade of events that involve stem cell 
proliferation, migration, and differentiation into odontoblasts-like cells [411]. 
Therefore, a more differentiated/lower stem cell pool in cells derived from 
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deep carious lesions may explain a lower expression of CD90 and CD105 
compared with the current study where DPSCs have been isolated from 
shallow carious lesion; stem cell proliferation and migration may be 
occurring but differentiation may not yet be extensive. However this 
hypothesis clearly requires further experimental validation. 
Another important study performed by Alongi et al. (2010), concluded  that 
cells isolated from pulp tissue of third molars affected by irreversible pulpitis 
(DPSC-IPs) showed distinct characteristics compared with normal dental 
pulp stem cells (DPSC-NPs). The authors stated that: although in vitro some 
stem cell characteristics from DPSC-IPs pulp may be lost, these cells still 
demonstrated the capacity to form dentine/pulp complex in vivo. In addition, 
they claimed that DPSC-IPs might have the potential to be used as a cell 
source for pulp and dentine regeneration rather than discarding them as 
medical waste. Using immunohistochemistry, both DPSC-NPs and DPSC-
IPs stained positively for STRO-1, CD90, CD105 and CD146. The results 
showed significantly higher antibody staining in the DPSC-IPs compared 
with DPSC-NPs [175]. Similarly, the current study showed a trend of 
cDPSCs to express higher levels of CD146 compared with hDPSCs (Table 
13). However, the present study showed a higher expression levels of 
CD146, CD90 and CD105 in both groups compared with what has been 
demonstrated by Alongi et al. (2010). This might possibly be related to the 
criteria of irreversible pulpitis and degree of inflammation that were 
investigated in their study compared with shallow caries that has been 
targeted in the current study. Higher expression of CD146 in cDPSCs 
compared with hDPSCs can be attributed to the nature of CD146, which is 
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known to be associated with the blood vessels and higher vascularity that is 
expected to be associated with inflammation [412]. Additionally, CD146 
showed strong staining during the initial inflammatory stages of dental pulp, 
which also may explain the higher expression of CD146 in cDPSCs 
compared to hDPSCs [412].  
A comparison of DPSCs isolated from carious deciduous teeth (SCCD) with 
normal exfoliated deciduous teeth (SHED) indicated that both cell types 
positively expressed (˃98%) CD29, CD73, and CD90. Furthermore, CD14, 
CD34, CD45 and HLA-DR were essentially negative in both populations 
[413]. Moreover, a similar study comparing SHED to deciduous teeth with 
inflamed pulps (SCIDs) showed no significant differences in proliferation, 
differentiation and MSC surface markers expression (CD146, CD90, 
CD105). SHED and SCIDs had a much higher CD146 (97.97% and 99.98%, 
respectively) expression compared with the current findings in hDPSCs and 
cDPSCs (23.2% and 43.5% respectively). However, SHED and SCIDs 
expressed less CD90 (54.56% and 78.17%, respectively) compared to 
hDPSCs and cDPSCs (98.9% and 99.70%, respectively) in the current study 
[414]. Kim et al. (2014), isolated DPSCs from inflamed pulp tissue of 
deciduous teeth and concluded that these cells had similar stem cell 
markers expression to those isolated from non-inflamed pulp tissue. Both 
populations showed positive expression of CD146 and CD90 while both 
were negative for CD45. The expression of CD146 was higher in both non-
inflamed (70.54%) and inflamed (67.93%) populations [415], compared with 
the current study. Higher CD146 expressed by deciduous dental pulps 
compared with adult dental pulp tissues might be related to greater 
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proportion of stem cell population known to reside in deciduous teeth 
compared with adults [416]. However, a subsequent report suggested that 
cells isolated from inflamed pulp tissue of deciduous teeth (SCDIP) failed to 
show typical MSC characteristics compared with healthy pulp tissues (SCD). 
The authors reported that SCD derived cells showed faster proliferation 
rates and time to confluency compared with SCDIP during early passages. 
Interestingly, CD34 and CD45 were absence in both cell types and there 
was no much difference in the expression of CD73, CD90 and CD166 
between SCD and SCDIP [417].  
 In the present study, both hDPSCs and cDPSCs demonstrated mild 
positivity for the hematopoietic stem cell marker CD45 (leukocyte common 
antigen). The average expression of CD45 in both hDPSCs and cDPSCs 
was 5.2% ±4.94 and  0.72% ±0.31, respectively. Previous data indicated that 
DPSCs were either negative for CD45 [3, 407, 418, 419] or expressed this 
marker at a very low concentration ˂1-2% of the cell  population [389]. It was 
reported that leukocytes represent ˂1% of dental pulp cell populations after 
enzymatic digestion harvesting [420]. It might be that early passages 
(passage 4) of heterogeneous stromal cell populations of hDPSCs still 
contains traces of CD45 positive population. The DPSCs might be 
challenged by different stimuli through the apical foramen or even through 
the surrounding periodontal ligament, which might increase the leukocyte 
population in the dental pulp. hDPSCs and cDPSCs failed to react with 
endothelial cell marker CD31 and this agrees broadly with the findings of 
other studies [407, 421]. 
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In the present study, flow cytometric results showed that cDPSCs expressed 
higher percentages (34.87% ±16.57) of stem cell population that co-
expressed CD90, CD105, and CD146 (CD90+/CD105+/CD146+), but not 
expressing CD45 and CD31 (CD45-/CD31-), compared with hDPSCs 
(18.45% ±19.31) (Figure 21). Other studies have reported various surface 
markers co-expression in DPSCs. For example, DPSCs co-expressed 
CD271 and CD90  (CD271+/CD90+) were represent 0.72% ±0.19% of total 
hDPSCs population isolated from normal impacted third molars [422]. 
Moreover, published data showed that 0.5% of hDPSCs negative for CD34 
co-expressed with STRO-1 and c-kit (CD34-/STRO-1+/c-kit+), whereas 20% 
of hDPSCs positive for CD34 co-expressed with STRO-1 and c-kit 
(CD34+/STRO-1+/c-kit+) [423]. Caries-induced inflammation may be able to 
influence the stem cell characteristics of cDPSCs, which might have the 
potential to be used as future source of stem cells. …………………  
……………………………………………………………….. 
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 Results 
 
Expression of regenerative markers in dental pulp cells 
isolated from carious versus healthy teeth 
5.1 Introduction   
The dental pulp has a fundamental regenerative potential in response to 
noxious stimuli including caries-induced inflammation. Inflammatory 
processes induce mineralised tissue regeneration, and are critical for healing 
processes, which are regulated by wide range of signalling molecules and 
growth factors [21, 22]. Dental pulp stem cells (DPSCs) are multipotent and 
have a proven ability to differentiate down different lineages; including 
odontoblast and osteoblast phenotypes [74, 151, 424]. Both odontoblasts 
and osteoblasts are accountable for manufacturing hard tissues. Although 
dentine and bone are chemically similar, they are very different structurally. 
The ability of DPSCs to differentiate into functional osteoblasts and produce 
mineralised matrix have been reported in many in vitro studies [425, 426], 
whereas, in vivo studies reported that DPSCs were able to reconstruct bony 
structures [427, 428] with comparable behavior to human bone marrow stem 
cells [74]. It has been reported that dentine can be formed in in vivo models 
when subjected to reciprocal induction from epithelial cell sources 
(subcutaneous implantation, implantation within the kidney capsules) [157, 
429]. In response to noxious stimuli in human teeth, DPSCs respond by 
differentiation into odontoblast-like cells and try to wall off the damage by 
forming reparative dentine, which is very similar in structure to woven bone.   
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Mineralised tissue regeneration requires vascularization [430]. With the 
dental pulp being essentially considered to be the neuro-vascular part of the 
tooth, and with its heterogeneous cell population, it is considered an ideal 
source for MSCs that can regenerate vascularized hard tissue [431]. The 
dental pulp MSCs population isolated from healthy (hDPSCs) and carious 
teeth (cDPSCs) have been successfully characterized and compared in 
Chapter 4 of this thesis.  
The aim of this chapter was to evaluate the effect of inflammation on the 
regenerative potential of DPSCs and to investigate the alterations of the 
inflammatory environment during the osteogenic induction of cDPSCs. This 
may offer some understanding of how we can make use of low-grade 
inflammation in enhancing repair and regeneration of bone, dentine and 
other mineralised tissues. In order to achieve this, the expression of 
inflammatory markers were investigated in cDPSCs and hDPSCs cultured 
under basal and osteogenic culture conditions at different time points (1 and 
3 weeks). These markers were: Toll-like receptors (TLR-2 and TLR-4) and 
their activation products, including IL-6 and IL-8. Furthermore, the 
expression of osteogenic and angiogenic markers were also investigated in 
both cell types under basal and osteogenic conditions. Correlation between 
the expression of these regeneration markers and the inflammatory markers 
was carried out in an attempt to deduce the effects that inflammation might 
have on the expression of these markers under different culture conditions. 
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5.2 Results   
5.2.1 Confirmation of osteogenic differentiation in hDPSCs and 
cDPSCs using histochemical staining 
 
Near confluent monolayers (80%) of hDPSCs and cDPSCs were cultured 
under osteogenic conditions as described in Chapter 3, Methods, 
Section 3.2.4; by treatment with osteogenic medium containing 
dexamethasone and ascorbic acid for 1 week and 3 weeks. 
 
A: Alkaline phosphatase (ALP) staining of hDPSCs and cDPSCs 
cultured under basal and osteogenic conditions  
Results of the current study showed positive ALP staining in cultures from all 
donors in hDPSCs and cDPSCs groups under basal and osteogenic 
conditions at 1 and 3 weeks (Figure 22). However, the results clearly 
indicated more intense ALP staining in all osteogenic cultures at 1 and 3 
weeks compared with basal cultures (Figure 22). Interestingly, cDPSCs also 
showed increased ALP staining under osteogenic conditions at 1 and 3 
weeks compared with hDPSCs under the same conditions (Figure 22). One 
donor from each group is presented in Figure 22 and similar results were 
obtained using DPSCs from other donors. 
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Figure 22: ALP staining of hDPSCs and cDPSCs  
ALP staining of hDPSCs (A) and cDPSCs (B) 
cultured in monolayers under basal and 
osteogenic conditions for 1 and 3 weeks as 
labelled. Scale bar = 5 cm  
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B: Alizarin red staining of hDPSCs and cDPSCs cultured under basal 
and osteogenic conditions  
Alizarin red positively stained mineralised nodules in both hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks compared 
with basal cultures. This confirmed the ability of both DPSCs to form calcium 
nodules under osteogenic culture conditions. However, cDPSCs showed 
more Alizarin red stained nodules under osteogenic conditions at 1 and 3 
weeks compared with hDPSCs under the same conditions (Figure 23). One 
donor from each group is presented in Figure 23 and similar results were 
obtained using DPSCs from other donors. 
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Figure 23: Alizarin red staining of hDPSCs and cDPSCs  
Mineralised nodules are stained positively (red) with Alizarin 
red stain in hDPSCs (A) and cDPSCs (B) cultured in 
monolayers under osteogenic conditions for 1 and 3 weeks as 
labelled. Scale bar = 100 µm. 
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5.2.2 Gene expression  
The changes in gene expression of osteogenic, angiogenic and 
inflammatory markers in hDPSCs and cDPSCs cultured under basal and 
osteogenic  conditions for 1 and 3 weeks were investigated using qRT-PCR 
as previously described (Chapter 3, Methods, Section 3.2.5).  
 
A: Baseline expression of osteogenic, angiogenic and inflammatory 
marker genes 
The osteogenic gene markers investigated were alkaline phosphatase 
(ALPL), osteocalcin (OC) and Runt-related transcriptional factor (RUNX-2). 
Angiogenic markers were Vascular Endothelial Growth Factor Receptor-2 
(VEGFR-2), and Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1). 
Inflammatory markers were Toll-Like receptors (TLR-2, TLR-4), and 
interleukins (IL-6, IL-8). The expression of these markers in hDPSCs and 
cDPSCs cultured under basal conditions were investigated to determine the 
baseline expression of those markers under healthy and inflamed conditions. 
The expression of the genes of interest in both hDPSCs and cDPSCs 
cultured under basal conditions were normalised to the house keeping gene 
GAPDH, and the results were presented as the means of ΔCt±SD to show 
the expression of these genes at the two time points (1 and 3 weeks). All 
experiments were repeated three times from three different donors in each 
group; hDPSCs and cDPSCs. Results from individual donors (individual 
analysis) as well as the average results of all donors together in each group 
(global analysis) were plotted for all genes. 
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B: Relative changes in the expression of osteogenic, angiogenic and 
inflammatory marker genes 
The relative changes in the expression of osteogenic, angiogenic and 
inflammatory markers in both hDPSCs and cDPSCs cultured under 
osteogenic conditions were carried out to determine the changes in the 
expression of these genes in both cell types under osteogenic culture 
conditions, compared with their baseline expression under basal conditions. 
The expression of the genes of interest in both hDPSCs and cDPSCs 
cultured under osteogenic conditions were normalised to controls from the 
same cells, cultured under basal conditions. The ∆∆Ct method was used to 
calculate the relative change in the gene expression (Chapter 3, Methods, 
Section 3.2.5.6). The means 2-∆∆ct  ±SD were plotted (Log 10 scale) to show 
the relative changes in gene expression at the both time points (1 and 3 
weeks). Fold changes in gene expression were calculated. All experiments 
were repeated three times from three different donors in each group; 
hDPSCs and cDPSCs. Results from individual donors (individual analysis) 
as well as the average results of all donors together in each group (global 
analysis) were plotted for all genes of interest. 
Statistical analysis: 
Statistical analysis was carried out for individual donors and for global gene 
expression data using one way ANOVA followed by Bonferroni multiple 
comparison tests, using Graph Pad Prism software (v 6). Differences were 
considered significant when P values were ˂0.05.  
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 Expression of osteogenic marker genes in hDPSCs and cDPSCs  
The gene expression of bone markers (ALPL, OC and RUNX-2) were 
investigated in hDPSCs (n=3) and cDPSCs (n=3), both cultured in 
monolayers under basal and osteogenic conditions for 1 and 3 weeks. 
5.2.2.1.1 Comparing the changes in ALPL gene expression in hDPSCs 
and  cDPSCs  
 
A: Baseline expression of ALPL gene in hDPSCs and cDPSCs 
ALPL was expressed at moderate levels in both hDPSCs and cDPSCs 
cultured under basal conditions for 1 and 3 week time points (Figure 24). 
However at 1 week under basal conditions, cDPSCs from the first donor 
(C1) showed higher levels of ALPL expression compared with hDPSCs from 
the first and third donors (H1, H3) under the same conditions (Figure 24A). 
cDPSCs from the second donor (C2) showed higher levels of ALPL 
expression compared with hDPSCs from all three donors (Figure 24A). 
At 3 weeks under basal conditions, cDPSCs from two out of three donors 
(C1, C2) showed higher levels of ALPL expression compared with hDPSCs 
from the first and second donors (H1, H2) under the same conditions (Figure 
24A). The levels of ALPL expression in cDPSCs from the third donor (C3) 
was lower compared with hDPSCs from all three donors at 3 weeks under 
basal conditions, with only hDPSCs from the third donor (H3) reaching 
statistical significance (Figure 24A). 
The levels of ALPL expression were higher in both hDPSCs and cDPSCs at 
3 weeks compared with 1 week under basal conditions, in all three donors  
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(Figure 24A). Statistical significance between 1 and 3 weeks was 
demonstrated in hDPSCs isolated from the third donor (H3) and in two out of 
three donors in the cDPSCs group (C1, C2) under basal conditions (Figure 
24A).  
The global analysis showed that ALPL levels were significantly increased in 
hDPSCs and cDPSCs at week 3 compared with week 1 under basal 
conditions (Figure 24B). cDPSCs showed a slightly higher levels of ALPL 
expression at both time points compared with hDPSCs under basal 
conditions (Figure 24B). 
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Figure 24: Baseline expression of ALPL gene in hDPSCs and cDPSCs 
cultured under basal conditions for 1 and 3 weeks  
ALPL gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, C2, 
C3) cultured in monolayers under basal conditions for 1 and 3 weeks. A: Individual 
analysis: showing the levels of ALPL gene expression in individual donors. The 
expression of ALPL was normalised to the house-keeping gene (GAPDH). Data are 
presented as means ∆Ct ±SD of three technical replicates from each donor. B: 
Global analysis: showing an averaged expression of ALPL from the three donors in 
each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P ˂0.001. 
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B: Relative changes in ALPL gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions  
In hDPSCs and cDPSCs,  the levels of ALPL expression were up-regulated 
at week 1 under osteogenic conditions compared with control cells cultured 
under basal conditions, in all three donors in both cell types (Table 14 and 
Figure 25A). 
Comparing both cell types, the level of ALPL expression was higher at week 
1 under osteogenic conditions, in hDPSCs from the first and third donors 
(H1, H3) compared with cDPSCs from the first and second donors (C1, C2), 
the only statistically significant difference was between hDPSCs from the 
first donor (H1) and cDPSCs from the second donor (C2). While the level of 
ALPL expression was higher at week 1 in cDPSCs from all donors compared 
with hDPSCs from the second donor (H2), only cDPSCs from the third donor 
(C3) reached statistical significance under osteogenic conditions (Table 14 
and Figure 25A). 
At 3 weeks, the levels of ALPL were down-regulated in hDPSCs from all 
three donors. Similarly, cDPSCs from the third donor (C3) showed down-
regulation of ALPL under osteogenic conditions compared with basal 
conditions. However, cDPSCs from the first and second donors (C1, C2) 
showed up-regulation of ALPL under osteogenic conditions compared with 
basal controls (Table 14 and Figure 25A). There was a significant difference 
comparing cDPSCs cultured for 3 weeks with 1 week from the third donor 
(C3) (Table 14 and Figure 25A). ALPL levels were significantly higher at 
week 1 compared with week 3 in hDPSCs from all three donors under 
osteogenic conditions (Table 14 and Figure 25A). 
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The global analysis showed that ALPL levels were significantly down-
regulated in hDPSCs compared with cDPSCs at week 3 under osteogenic 
conditions (Figure 25B). Furthermore, hDPSCs showed significant down-
regulation of ALPL levels at week 3 compared with week 1 under osteogenic 
conditions (Figure 25B). 
 
 
 
Table 14: Fold changes in ALPL gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions compared with cells 
cultured under basal conditions at 1 and 3 weeks 
Duration 
of cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week   ↑ b 3   ↑ 1.1 ↑  2.5 ↑ 1.7   ↑ 1.5 ↑ 2.5 
3 weeks ↓1.7         ↓ 2 ↓ 1.3 ↑ 1.4 ↑ 1.2 ↓1.1 
               
           a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
  b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 25: Relative changes in ALPL gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in ALPL gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in ALPL gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in ALPL gene expression from the three 
donors in each group of hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
Chapter 5: Results 
 
136 
 
5.2.2.1.2 Comparing the changes in OC gene expression in hDPSCs 
and cDPSCs  
 
A: Baseline expression of OC gene in hDPSCs and cDPSCs  
OC was expressed at moderate levels in both hDPSCs and cDPSCs 
cultured under basal conditions for  1 and 3 weeks (Figure 26). However at 
week 1 under basal conditions, cDPSCs from the first donor (C1) showed a 
trend to express higher levels of OC compared with hDPSCs from the first 
donor (H1) (Figure 26A). cDPSCs from the second donor (C2) showed a 
higher levels of OC expression compared with hDPSCs from all three donors 
at 1 week under basal conditions. The OC expression level at week 1 under 
basal conditions was higher in cDPSCs from the third donor (C3) compared 
with hDPSCs from the first and second donor (H1, H2) (Figure 26A).  
At 3 weeks under basal conditions, two out of three donors in the cDPSCs 
group (C1, C2) showed higher OC expression levels compared with 
hDPSCs from the first and third donors (H1, H3) under the same conditions 
(Figure 26A). cDPSCs from the third donor (C3) showed a trend to express 
higher OC compared with hDPSCs from first donor (H1) at 3 weeks under 
basal conditions . Only differences comparing the first donor from each 
hDPSCs and cDPSCs group (H1 with C1) reached statistical significance at 
3 weeks under basal conditions (Figure 26A). 
The levels of OC expression were higher at 3 weeks culture compared with 
1 week culture, in two out of three donors in both hDPSCs (H2, H3) and 
cDPSCs (C1, C2) under basal conditions (Figure 26A).   
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The global analysis showed a higher OC expression in cDPSCs compared 
with hDPSCs at both time points, and generally a higher expression at 3 
weeks compared with 1 week under basal conditions. However, the results 
of global analysis did not reach statistical significance (Figure 26B). 
 
 
 
 
. 
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Figure 26: Baseline expression of  OC gene in hDPSCs and cDPSCs cultured 
under basal conditions for 1 and 3 weeks  
OC  gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, C2, C3) 
cultured in monolayers under basal conditions for 1 and 3 weeks. A: Individual 
analysis: showing the levels of OC gene expression in individual donors. The 
expression of OC  was normalised to the house keeping gene (GAPDH). Data are 
presented as means ∆Ct ±SD of three technical replicates from each donor. B: 
Global analysis: showing an averaged expression of OC from the three donors in 
each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P ˂0.001. 
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B: Relative changes in OC gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions  
At week 1, OC was up-regulated under osteogenic conditions compared with 
basal conditions in two out of three cDPSCs donors (C1, C3) and was down-
regulated in two out three hDPSCs donors (H1, H2) (Table 15 and Figure 
27A). At week 3, OC levels were up-regulated in both hDPSCs and cDPSCs 
cultured under osteogenic conditions compared with cells grown under basal 
conditions (Table 15 and Figure 27A). A general trend of higher OC 
expression was observed at both time points in cDPSCs compared with 
hDPSCs except in cDPSCs from the second donor (C2) at 1 week and from 
the first donor (C1) at 3 weeks. Statistical significance was demonstrated at 
the 3 week time point, comparing cDPSCs from the second donor (C2) and 
hDPSCs from the second and third donors (H2, H3) (Table 15 and Figure 
27A). 
The levels of OC expression under osteogenic conditions were higher at 3 
weeks compared with 1 week, in hDPSCs from all three donors and in two 
out of three of cDPSCs donors (C2, C3), with only cDPSCs from the second 
donor (C2) reached statistical significance (Figure 27A).   
The global analysis showed that OC expression levels were significantly 
higher at 3 weeks compared with 1 week in hDPSCs and cDPSCs grown 
under osteogenic conditions (Figure 27B). cDPSCs showed a trend to higher 
expression of OC compared with hDPSCs at both time points under 
osteogenic conditions (Figure 27B).    
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Table 15: Fold changes in OC gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions compared to cells 
cultured under basal conditions at 1 and 3 weeks 
Duration 
of 
cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week   ↓b 1.5 ↓ 1.3 ↓1.03 ↑ 1.7   ↓ 1.8   ↑ 2 
3 weeks  ↑ 2.1        ↑ 2    ↑  2 ↑ 1.4 ↑ 3.8 ↑ 2.6 
          
              a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
     b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 27: Relative changes in OC gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in OC gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in OC gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in OC gene expression from the three 
donors in each group of hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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5.2.2.1.3 Comparing the changes in RUNX-2 gene expression in 
hDPSCs and cDPSCs 
  
A: Baseline expression of RUNX-2 gene in hDPSCs and cDPSCs  
 RUXN-2 was expressed by both cell types at both time points under basal 
conditions, in cells from all donors (Figure 28). There was a notable 
variability in RUNX-2 expression levels when comparing hDPSCs with 
cDPSCs. At 1 week under basal conditions, cDPSCs from two out of three 
donors (C1, C3) showed lower levels of RUNX-2 expression compared with 
hDPSCs from all three donors (Figure 28A). However at 3 weeks under 
basal conditions, cDPSCs from the second donor (C2) showed significantly 
higher RUNX-2 expression levels compared with hDPSCs from all three 
donors. While cDPSCs from the third donor (C3) showed a trend to express 
higher RUNX-2 levels compared with hDPSCs from the first and third donors 
(H1, H3) (Figure 28A). 
The levels of RUNX-2 expression were higher at 1 week compared with 3 
weeks in hDPSCs from all three donors under basal conditions (Figure 28A). 
However, in two out of three of cDPSCs donors (C2, C3), the levels of 
RUNX-2 were higher at 3 weeks compared with 1 week expression under 
basal conditions, with only cDPSCs from the second donor (C2) reached 
statistical significance (Figure 28A).  
The global analysis showed that RUNX-2 baseline expression in cDPSCs 
was lower at 1 week culture and higher at 3 weeks culture compared with 
hDPSCs . In hDPSCs, the baseline expression of RUNX-2 was higher at 1 
week compared with 3 weeks, whereas in cDPSCs, the baseline expression 
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of RUNX-2 was reversed. Nevertheless, none of these differences reached 
statistical significance (Figure 28B). 
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Figure 28: Baseline expression of RUNX-2 gene in hDPSCs and cDPSCs 
cultured under basal conditions for 1 and 3 weeks  
RUNX-2  gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, 
C2, C3) cultured in monolayers under basal conditions for 1 and 3 weeks. A: 
Individual analysis: showing the levels of RUNX-2  gene expression in individual 
donors. The expression of RUNX-2 was normalised to the house keeping gene 
(GAPDH). Data are presented as means ∆Ct ±SD of three technical replicates from 
each donor. B: Global analysis: showing an averaged expression of RUNX-2 from 
the three donors in each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P 
˂0.001. 
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B: Relative changes in RUNX-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions  
RUNX-2 was up-regulated in both cell types and at both time points in cells  
from all donors grown under osteogenic conditions compared with cells 
cultured under basal conditions (Table 16 and Figure 29A).  
Interestingly under osteogenic conditions, cDPSCs from two out of three 
donors (C1, C3) showed higher levels of RUNX-2 expression at 1 and 3 
weeks compared with hDPSCs from all three donors. However, only 
comparing cDPSCs from the first donor (C1) with hDPSCs from the second 
donor (H2) reached statistical significance (Table 16 and Figure 29A). 
However, the levels of RUNX-2 expression in hDPSCs and cDPSCs were 
higher at 3 weeks compared with 1 week under osteogenic conditions with 
only first and second donor in cDPSCs group (C1, C2) showing statistical 
significance comparing 1 and 3 week time points (Table 16 and Figure 29A).  
The global analysis showed that levels of RUNX-2 were higher at 3 weeks 
compared with 1 week in both cell types, but only the difference comparing 
cDPSCs was significant. RUNX-2 expression was higher in cDPSCs 
compared with hDPSCs at 1 and  3 weeks under osteogenic conditions 
compared with cells under basal conditions. However, these differences did 
not reach statistical significance due to variation between donors (Figure 
29B). 
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Table 16: Fold changes in RUNX-2 gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions compared with cells 
cultured under basal conditions at 1 and 3 weeks 
Duration 
of 
cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week   ↑b 1.4 ↑ 2.02 ↑ 1.3 ↑ 3.8   ↑ 1.2 ↑ 2.5 
3 weeks ↑ 3.02       ↑ 4 ↑ 2.5  ↑ 21.8 ↑ 2.5 ↑ 5.6 
             
               a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
      b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 29: Relative changes in RUNX-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in RUNX-2 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in RUNX-2 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in RUNX-2 gene expression from the three 
donors in each group of hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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 Expression of angiogenic marker genes in hDPSCs and cDPSCs  
The gene expression of angiogenic  markers (VEGFR-2 and PECAM-1) 
were investigated in hDPSCs (n=3) and cDPSCs (n=3), both cultured in 
monolayers under basal and osteogenic conditions for 1 and 3 weeks. 
 
5.2.2.2.1 Comparing the changes in VEGFR-2 gene expression in 
hDPSCs and cDPSCs  
A: Baseline expression of VEGFR-2 gene in hDPSCs and cDPSCs  
The baseline expression levels of VEGFR-2 were very low in both hDPSCs 
and cDPSCs, after 1 and 3 weeks of basal culture (Figure 30), and 
compared with the levels of osteogenic markers discussed in the previous 
section. cDPSCs showed higher levels of baseline expression of VEGFR-2 
in all three donors at week 1, and in two out of three donors (C2, C3) at 
week 3 of culture, compared with hDPSCs. However results were only 
significant at week 3 when comparing cDPSCs from the third donor (C3) with 
hDPSCs from all three donors (Figure 30A).  
Comparing the baseline expression of VEGFR-2 at the two different time 
points of culture (1 and 3 weeks), within the same cell type; hDPSCs 
revealed no significant difference. In contrast, cDPSCs from the third donor 
(C3) showed significantly higher expression at 3 weeks compared with 1 
week under basal conditions (Figure 30A).   
The global analysis confirmed largely the individual analysis. It showed a 
higher baseline expression of VEGFR-2 in cDPSCs compared with hDPSCs, 
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at  both time points with this being statistically significant only at 3 weeks. 
cDPSCs showed a higher baseline expression of VEGFR-2 at week 3 
compared with week 1, but this was not significant difference (Figure 30B). 
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Figure 30: Baseline expression of VEGFR-2 gene in hDPSCs and cDPSCs 
cultured under basal conditions for 1 and 3 weeks  
VEGFR-2  gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, 
C2, C3) cultured in monolayers under basal conditions for 1 and 3 weeks. A: 
Individual analysis: showing the levels of VEGFR-2  gene expression in individual 
donors. The expression of VEGFR-2 was normalised to the house keeping gene 
(GAPDH). Data are presented as means ∆Ct ±SD of three technical replicates from 
each donor. B: Global analysis: showing an averaged expression of VEGFR-2 from 
the three donors in each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P 
˂0.001. 
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B: Relative changes in VEGFR-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions  
The expression of VEGFR-2 in hDPSCs and cDPSCs   from all donors, 
cultured under osteogenic conditions for 1 and 3 weeks was up-regulated 
compared with cells cultured under basal conditions (Table 17 and Figure 
31A).  
 hDPSCs from the second donor (H2) showed significantly higher levels of 
VEGFR-2 expression compared with cDPSCs from all three donors, after 1 
and 3 weeks of culture under osteogenic conditions compared with cells 
cultured under basal conditions (Table 17 and Figure 31A). However, in two 
out of three donors in the cDPSCs group at 1 week (C1, C3), and at 3 weeks 
(C1, C2) showed higher levels of VEGFR-2 expression compared with 
hDPSCs from the first and third donors (H1, H3) under osteogenic conditions 
(Table 17 and Figure 31A).    
hDPSCs showed no significant difference in VEGFR-2 expression 
comparing cells cultured for 1 week or 3 weeks. cDPSCs showed slightly 
higher levels of VEGFR-2 expression at 3 weeks compared with 1 week, in 
two out of three donors (C1, C2) under osteogenic conditions (Table 17 and 
Figure 31A). 
The global analysis showed that VEGFR-2 expression was lower in cDPSCs 
compared to hDPSCs under osteogenic conditions compared with cells 
cultured under basal conditions at 1 and 3 weeks. This confirmed the results 
found in the individual comparisons of VEGFR-2 expression at the different 
time points of culture, within the same cell type (Figure 31B). 
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Table 17: Fold changes in VEGFR-2 gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions compared with cells cultured 
under basal conditions at 1 and 3 weeks 
Duration 
of 
cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week ↑b 7.03 ↑ 162.9 ↑ 5.4  ↑ 8.1   ↑ 6.1 ↑ 7.9 
3 weeks ↑ 9.6 ↑ 119.1 ↑ 5.6 ↑ 16.2 ↑ 31.04 ↑ 2.8 
          
              a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
     b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 31: Relative changes in VEGFR-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in VEGFR-2 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in VEGFR-2 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in VEGFR-2 gene expression from the three 
donors in each group of hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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5.2.2.2.2 Comparing the changes in PECAM-1 gene expression in 
hDPSCs and cDPSCs  
 
A: Baseline expression of PECAM-1 gene in hDPSCs and cDPSCs  
PECAM-1 expression levels were very low in both hDPSCs and cDPSCs 
cultured under basal conditions at 1 and 3 week time points (Figure 32). The 
baseline expression of PECAM-1 at 1 week was higher in cDPSCs from all 
three donors compared with hDPSCs from the first and third donors (H1, H3) 
(Figure 32A). 
However, at 3 weeks the baseline expression of PECAM-1 was higher in two 
out of three donors of cDPSCs (C1, C3) compared with hDPSCs from all 
donors, with only cDPSCs from the third donor (C3) showing statistically 
significant differences (Figure 32A).  
There was no significant difference in the baseline levels of PECAM-1 
expression comparing 1 and 3 weeks cultures within the same cell type, 
except in cDPSCs from the third donor (C3), which showed significantly 
higher expression of PECAM-1 at week 3 compared with week 1 (Figure 32). 
Global analysis showed a trend for cDPSCs to express higher levels of 
PECAM-1 compared with hDPSCs at 3 weeks under basal conditions 
(Figure 32B). Also, cDPSCs showed higher baseline expression levels of 
PECAM-1 at week 3 compared with week 1 (Figure 32B).  
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Figure 32: Baseline expression of PECAM-1 gene in hDPSCs and cDPSCs  
cultured under basal conditions for 1 and 3 weeks  
PECAM-1  gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, 
C2, C3) cultured in monolayers under basal conditions for 1 and 3 weeks. A: 
Individual analysis: showing the levels of PECAM-1  gene expression in individual 
donors. The expression of PECAM-1 was normalised to the house keeping gene 
(GAPDH). Data are presented as means ∆Ct ±SD of three technical replicates from 
each donor. B: Global analysis: showing an averaged expression of PECAM-1 from 
the three donors in each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P 
˂0.001. 
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B: Relative changes in PECAM-1 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions  
The levels of  PECAM-1 were up-regulated in both hDPSCs and cDPSCs 
from all donors at 1 and 3 weeks under osteogenic culture conditions. The 
only exception was the cDPSCs from the third donor (C3) at week 3, which 
demonstrated a down-regulation in PECAM-1 levels under osteogenic 
culture conditions (Table 18 and Figure 33A).  
At 1 week under osteogenic conditions, cDPSCs from two out of three 
donors (C1, C3) showed higher levels of PECAM-1 expression compared 
with expression by hDPSCs from all three donors (Table 18 and Figure 
33A). However, at 3 weeks under osteogenic conditions, cDPSCs from two 
out of three donors (C1, C3) showed lower level of PECAM-1 expression 
compared with hDPSCs (H1, H3) cultured under the same conditions, only 
cDPSCs from the third donor (C3) showed a statistically significant 
difference in comparison with hDPSCs from the first donor (H1) (Table 18 
and Figure 33A). 
The levels of PECAM-1 gene expression were higher at week 3 compared 
with week 1 in all hDPSCs donors. However, in cDPSCs, two out of three 
donors (C1, C3) showed higher levels of PECAM-1 expression at 1 week 
under osteogenic conditions compared with 3 weeks, with only third donor 
(C3) showing statistical significance (Table 18 and Figure 33A). In contrast, 
cDPSCs from the second donor (C2) showed significantly lower levels of 
PECAM-1 expression at 1 week compared to 3 weeks under osteogenic 
conditions (Table 18 and Figure 33A). 
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The global analysis showed higher levels of PECAM-1 expression in 
cDPSCs at 1 week under osteogenic conditions compared with hDPSCs 
(Figure 33B), while at 3 weeks cDPSCs showed slightly lower levels of 
PECAM-1 compared with hDPSCs under osteogenic conditions (Figure 
33B).  The level of PECAM-1 was higher in hDPSCs at 3 weeks compared 
to 1 week under osteogenic conditions (Figure 33B).   
 
 
 
 
Table 18: Fold changes in PECAM-1 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions compared with 
cells cultured under basal conditions at 1 and 3 weeks 
Duration 
of 
cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week ↑b 1.4 ↑ 1.04 ↑ 1.5   ↑  3    ↑ 1.1 ↑ 2.8 
3 weeks   ↑ 3.2 ↑     ↑ 1.7 ↑ 2.6 ↑ 1.7 ↑ 4 ↓ 4.1 
                      
              a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
     b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 33: Relative changes in PECAM-1 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in PECAM-1 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in PECAM-1 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in PECAM-1 gene expression from the three 
donors in each group of hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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 Expression of inflammatory marker genes in hDPSCs and 
cDPSCs  
The gene expression of inflammatory  markers (TLR-2 and TLR-4) were 
investigated in hDPSCs (n=3) and cDPSCs (n=3), both cultured in 
monolayers under basal and osteogenic conditions for 1 and 3 weeks. 
5.2.2.3.1 Comparing the changes in TLR-2 gene expression in hDPSCs 
and cDPSCs  
 
A: Baseline expression of TLR-2 gene in hDPSCs and cDPSCs  
The baseline expression of TLR-2 was low to moderate in both hDPSCs and 
cDPSCs, cultured under basal conditions at 1 and 3 weeks (Figure 34). 
cDPSCs from all three donors showed significantly higher levels of TLR-2 at 
both time points, compared with hDPSCs under the basal culture conditions. 
The only exception was in cDPSCs from the first donor (C1) compared with 
hDPSCs from the second donor (H2) at 1 week under basal conditionswhere 
there was no significant difference (Figure 34A) 
The  baseline levels of TLR-2 expression showed a trend to higher 
expression at 3 weeks compared with 1 week in hDPSCs from the first donor 
(H1) and in cDPSCs from the first and third donor (C1, C3), with only 
differences comparing cDPSCs from the first donor (C1) showing statistical 
significance (Figure 34A).    
Global analysis confirmed that baseline levels of TLR-2 expression were 
significantly higher in cDPSCs compared with hDPSCs at both time points. 
However, there was no significant difference in the baseline expression 
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between week 1 and 3 within the same cell type cultured under basal 
conditions (Figure 34B). 
 
 
 
 
 
Chapter 5: Results 
 
161 
 
TLR-2
A: Individual analysis
0.0000
0.0002
0.0004
0.0006
0.0008
 Healthy                                    Carious                                                  Healthy                                      Carious
1 week                                                         3 weeks
*
***
***
***
*
***
***
***
*
***
***
***
***
***
***
***
***
***
H1
H2
H3
C1
C2
C3
1
 d
e
lt
a
 C
t
B: Global analysis
0.0000
0.0002
0.0004
0.0006
0.0008
  Healthy           Carious                                                        Healthy             Carious
1 week                                                3 weeks
*** ***
Healthy
Carious
1
 d
e
lt
a
 C
t
 
Figure 34: Baseline expression of TLR-2 gene in hDPSCs and cDPSCs 
cultured under basal conditions for 1 and 3 weeks  
TLR-2  gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, C2, 
C3) cultured in monolayers under basal conditions for 1 and 3 weeks. A: Individual 
analysis: showing the levels of TLR-2  gene expression in individual donors. The 
expression of TLR-2 was normalised to the house keeping gene (GAPDH). Data 
are presented as means ∆Ct ±SD of three technical replicates from each donor. B: 
Global analysis: showing an averaged expression of TLR-2 from the three donors in 
each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P ˂0.001. 
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B: Relative changes in TLR-2 gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions  
For hDPSCs from all three donors, the level of TLR-2 expression was up-
regulated at 1 and 3 weeks under osteogenic conditions compared with cells 
cultured under basal conditions (Table 19 and Figure 35A). The only 
exception was for hDPSCs from the third donor (H3), in which the level of 
TLR-2 expression was down-regulated at 1 week under osteogenic 
conditions compared with basal conditions (Table 19 and Figure 35A).  
For cDPSCs from all three donors, the level of TLR-2 expression was up-
regulated at 1 and 3 weeks under osteogenic conditions compared with cells 
cultured under basal conditions (Table 19 and Figure 35A). The only 
exception was for cDPSCs from the first donor (C1), in which the level of 
TLR-2 expression was down-regulated at 1 week under osteogenic 
conditions compared with basal conditions (Table 19 and Figure 35A).  
hDPSCs from two out of three donors (H1, H2) showed higher levels of TLR-
2 expression compared with cDPSCs from all three donors at 1 week under 
osteogenic conditions, with only cDPSCs from the first and third donors (C1, 
C3) showing statistical significance (Figure 35A). However at 3 weeks under 
osteogenic conditions, the level of TLR-2 was significantly higher in hDPSCs 
from the second donor (H2) compared with cDPSCs from all donors (Figure 
35A).  
The levels of TLR-2 were higher at 3 weeks compared with 1 week, in two 
out of three of hDPSCs (H2, H3) and cDPSCs (C2, C3) under osteogenic 
conditions, with only hDPSCs from the second donor (H2) showing statistical 
significance (Figure 35A).       
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Although differences were not statistically significant, the global analysis 
showed that TLR-2 expression was lower in cDPSCs compared with 
hDPSCs at 1 and 3 weeks under osteogenic conditions compared with cells 
cultured under basal conditions. The TLR-2 levels were slightly higher at 3 
weeks compared with 1 week, in hDPSCs and cDPSCs cultured under 
osteogenic conditions compared with basal controls (Figure 35B). 
 
 
 
Table 19: Fold changes in TLR-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions compared 
with cells cultured under basal conditions at 1 and 3 weeks 
Duration 
of 
cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week  ↑b 3.9 ↑ 5.1 ↓ 1.6 ↓ 4.03 ↑ 2.8 ↑ 1.3 
3 weeks ↑ 2.7 ↑ 8.1 ↑         ↑ 2.04 ↑ 1.001 ↑ 3.2 ↑ 2.1 
            
              a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
     b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 35: Relative changes in TLR-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in TLR-2 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in TLR-2 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in TLR-2 gene expression from the three 
donors in each group; hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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5.2.2.3.2 Comparing the changes in TLR-4 gene expression in hDPSCs 
and cDPSCs  
A: Baseline expression of TLR-4 gene in hDPSCs and cDPSCs  
TLR-4 baseline levels of expression were low to moderate in both hDPSCs 
and cDPSCs, cultured under basal conditions at 1 and 3 weeks (Figure 36). 
cDPSCs showed significantly higher baseline levels of TLR-4 expression 
from all three donors at both time points compared with hDPSCs cultured 
under the same conditions. The only exception was in cDPSCs from the first 
and second donors (C1, C2) compared with hDPSCs from the third donor 
(H3) at 3 weeks under basal conditions (Figure 36A). The baseline levels of 
TLR-4 expression were significantly higher at 3 weeks compared with 1 
week , in hDPSCs (H3) and cDPSCs from the third donor (C3) (Figure 36A).  
The global analysis showed significantly higher baseline levels of TLR-4 in 
cDPSCs compared with hDPSCs (Figure 36B). It also showed no significant 
difference between 1 and 3 weeks within the same cell type (Figure 36B). 
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Figure 36: Baseline expression of TLR-4 gene in hDPSCs and cDPSCs 
cultured under basal conditions for 1 and 3 weeks  
TLR-4  gene expression in hDPSCs (n=3; H1, H2, H3) and cDPSCs (n=3; C1, C2, 
C3) cultured in monolayers under basal conditions for 1 and 3 weeks. A: Individual 
analysis: showing the levels of TLR-4 gene expression in individual donors. The 
expression of TLR-4 was normalised to the house keeping gene (GAPDH). Data 
are presented as means ∆Ct ±SD of three technical replicates from each donor. B: 
Global analysis: showing an averaged expression of TLR-4 from the three donors in 
each group of hDPSCs and cDPSCs. *P ˂0.05, **P ˂0.01, ***P ˂0.001. 
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B: Relative changes in TLR-4 gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions  
For hDPSCs from all three donors, the level of TLR-4 expression was up-
regulated at 1 and 3 weeks under osteogenic conditions compared with cells 
cultured under basal conditions (Table 20 and Figure 37A). For cDPSCs 
from all three donors, the level of TLR-4 expression was up-regulated at 1 
week and 3 weeks under osteogenic conditions compared with cells cultured 
under basal conditions (Table 20 and Figure 37A). The only exception was 
the third donor (C3) where the level of TLR-4 expression was slightly down-
regulated at 1 week under osteogenic conditions compared with basal 
conditions (Table 20 and Figure 37A). hDPSCs from two out of three donors 
(H1, H2) at 1 week  showed higher levels of TLR-4 expression compared 
with cDPSCs from the first and third donors (C1, C3) under osteogenic 
conditions compared with basal controls, with only cDPSCs from the third 
donor (C3) showing statistical significance (Table 20 and Figure 37A). 
However, at 3 weeks under osteogenic conditions, hDPSCs from the first 
and third donors (H1, H3) showed higher levels of TLR-4 expression 
compared with cDPSCs from all donors, with only hDPSCs from the first 
donor (H1) reached statistical significance (Table 20 and Figure 37A). 
The levels of TLR-4 expression were significantly higher at 3 weeks 
compared with 1 week in two out three of hDPSCs donors (H1, H3) (Table 
20 and Figure 37A). The level of TLR-4 expression was significantly higher 
at 1 week compared with 3 weeks in cDPSCs from the second donor (C2) 
(Table 20 and Figure 37A). 
Chapter 5: Results 
 
168 
 
The global analysis confirmed that cDPSCs showed lower levels of 
expression of TLR-4 under osteogenic conditions compared with hDPSCs, 
with statistical significance only at week 3 time point. There was no 
significant difference in levels of TLR-4 levels between 1 and 3 weeks under 
osteogenic conditions within the same cell type (Figure17B). 
 
 
 
 
Table 20: Fold changes in TLR-4 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions compared 
with cells cultured under basal conditions at 1 and 3 weeks 
Duration 
of 
cultures 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week ↑b 5.6 ↑ 4.4 ↑  2.8 ↑ 2.9 ↑ 5.8     ↓ 1.1 
3 weeks   ↑ 9.5 ↑ 2.2 ↑         ↑ 10.7 ↑ 2.9 ↑ 2.1 ↑ 2.6 
              
                a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
       b.   ↑ = up-regulation, ↓ = down-regulation 
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Figure 37: Relative changes in TLR-4 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in TLR-4 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in TLR-4 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in TLR-4 gene expression from the three 
donors in each group of  hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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5.2.3 Protein expression 
Further investigations were carried out to study the protein expression levels 
of the interleukins IL-6 and IL-8, which are known to be released following 
TLR activation. hDPSCs (n=3) and cDPSCs (n=3) were cultured under both 
basal and osteogenic conditions for 1 and 3 weeks.  
Conditioned medium (1mL) was collected from each culture at 1 and 3 
weeks. IL-6 and IL-8 concentrations in conditioned media were determined 
using the Cytometric Beads Array as described (Chapter 3, Methods, 
Section 3.2.6.2 ). The data were analysed using the flow cytometry analysis 
program (FCAP). Statistical analysis was carried out using one way ANOVA 
followed by Bonferroni multiple comparison tests, using Graph Pad Prism 
software (v 6). Differences were considered significant when P values were 
˂0.05. 
 
 Comparing IL-6 concentration in media conditioned by hDPSCs 
and cDPSCs cultured under basal and osteogenic conditions 
IL-6 was expressed in media conditioned by both hDPSCs and cDPSCs, 
cultured under basal conditions at 1 and 3 week time points (Figure 38). 
Media conditioned by cDPSCs from all three donors showed higher levels of 
IL-6 at both time points under basal conditions compared with hDPSCs 
under the same conditions (Figure 38A).  
Absolute values of IL-6 protein concentration (pg/mL) were significantly 
higher in basal media collected at 3 weeks compared with those collected at 
1 week, in hDPSCs from the first donor (H1), and cDPSCs from the first and 
third donors (C1, C3) cultured under basal conditions (Figure 38A).  
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The global analysis confirmed that concentration of IL-6 was significantly 
higher  in cDPSCs compared with hDPSCs at 1 and 3 weeks under basal 
conditions (Figure 38B). The baseline levels of IL-6 secretion were higher at 
3 weeks compared with 1 week within both cell types, but the differences 
were not statistically significant (Figure 38B). 
Osteogenic conditioned media showed much lower levels of IL-6 compared 
with basal media conditioned by hDPSCs and cDPSCs. These findings were 
confirmed in all three donors within each cell type at 1 and 3 week time 
points (Figure 38A). Figure 38A demonstrated the levels of IL-6 in 
osteogenic media collected from the different donors in both cell types, and 
between the two different time points. 
 The global analysis showed that there was no significant difference between 
media collected at 1 week compared with those collected at 3 weeks from 
both types of cells under osteogenic culture conditions (Figure 38B). 
However, there were statistically significant differences in IL-6 expression 
between cDPSCs cultured under basal conditions and cDPSCs cultured 
under osteogenic conditions at 1 and 3 week time points (Figure 38B) 
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Figure 38: IL-6 protein concentration in media conditioned by cDPSCs and  
hDPSCs 
IL-6 protein concentration in media conditioned by hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under basal (blue) and 
osteogenic (red) conditions for 1 and 3 weeks were determined by CBA. A: 
Individual analysis: showing IL-6 concentrations secreted by cells from individual 
donors. Data are presented as means ±SD of IL-6 concentrations (pg/mL) from 
three technical replicates from each donor. B: Global analysis: showing the average 
IL-6 concentrations (pg/mL) from the three donors in each group of hDPSCs and 
cDPSCs. *P˂0.05, **P˂0.01, ***P˂0.001 
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 Comparing IL-8 concentration in media conditioned by hDPSCs 
and cDPSCs cultured under basal and osteogenic conditions.  
IL-8 was expressed in media conditioned by both hDPSCs and cDPSCs , 
cultured under basal conditions for 1 and 3 weeks (Figure 39). Media 
conditioned by cDPSCs under basal conditions from all three donors 
contained higher IL-8 protein concentrations at both time points, compared 
with hDPSCs from the first and third donors (H1, H3) under the same 
conditions (Figure 39A).  
Absolute values of IL-8 protein concentration (pg/mL) were higher in basal 
media collected at 3 weeks compared with those collected at 1 week, in 
hDPSCs and cDPSCs, from all three donors. However, differences were 
only significant for cDPSCs from the first and second donors (C1, C2) 
(Figure 39A). 
The global analysis demonstrated that cDPSCs showed a trend to higher  
baseline expression of IL-8 compared with hDPSCs at 1 and 3 weeks. In 
addition, the results confirmed that IL-8 levels were higher in 3 weeks culture 
compared with 1 week culture in both cell types (Figure 39B).  
Osteogenic conditioned media showed higher levels of IL-8 compared with 
basal media conditioned by hDPSCs and cDPSCs. These findings were 
confirmed in all three donors within each cell type (Figure 39A). Figure 39A 
demonstrated the levels of IL-8 in osteogenic media collected from the 
different donors in both cell types, and between the two different time points.  
The global analysis confirmed that the levels of IL-8 were higher in 
osteogenic conditioned media compared with the basal conditioned media, 
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however, only findings at 3 weeks in both hDPSCs and cDPSCs cultures 
reached statistical significance (Figure 39B). The lL-8 levels were 
significantly higher in osteogenic conditioned media collected at 3 weeks 
compared with those collected at 1 week in both cell types (Figure 39B).  
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Figure 39: IL-8 protein concentration in media conditioned by cDPSCs and  
hDPSCs  
IL-8 protein concentration in media conditioned by hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under basal (blue) and 
osteogenic (red) conditions for 1 and 3 weeks were determined by CBA. A: 
Individual analysis: showing IL-8 concentrations secreted by cells from individual 
donors. Data are presented as means ±SD of IL-8 concentrations (pg/mL) from 
three technical replicates from each donor. B: Global analysis: showing the average 
IL-8 concentrations (pg/mL) from the three donors in each group of hDPSCs and  
cDPSCs. *P˂0.05, **P˂0.01, ***P˂0.001.   ……………………………………………
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5.3 Discussion 
In this chapter hDPSCs and cDPSCs were cultured under basal and 
osteogenic conditions and the ability of these cells to differentiate to an 
osteogenic phenotype was confirmed by the use of histochemical stains and 
the expression of osteogenic markers. In addition, the expression of 
angiogenic and inflammatory markers in hDPSCs and cDPSCs isolated from 
teeth with shallow caries were successfully investigated under basal and 
osteogenic conditions. To date, only limited studies have been performed on 
the regulation of regenerative markers in DPSCs isolated from teeth affected 
by shallow caries. The current work examined DPSCs isolated from shallow 
caries as dental pulp tissue under these conditions is capable of initiating the 
innate immune responses and reparative processes following bacterial 
invasion. In active or deep carious lesions, reparative processes might be 
absent [432].   
Prior to enamel cavitation and dentine involvement caused by bacterial 
infection,  various changes have been observed in the dental pulp [433, 
434]. In the case of caries-induced inflammation, bacterial  products diffuse 
through dentinal tubules to further stimulate the dental pulp [267]. 
In the current  study no noticeable morphological changes were apparent in 
the fibroblast-like dental pulp cells beneath shallow caries. In contrast, an 
earlier study reported that there were morphological changes in odontoblasts 
beneath carious enamel [433]. This earlier study used computerised 
histomorphometry to measure the cytosolic: nuclear volume ratio of 
odontoblasts, the odontoblast cell: dentinal tubule ratio and the adjacent pre-
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dentine area. In the current study only phase-contrast light microscopy was 
used to highlight the general morphology of hDPSCs and cDPSCs.   
This study examined the ability of cDPSCs versus hDPSCs to differentiate 
down an osteogenic lineage using qualitative and quantitative analyses. 
Osteogenic induction was carried out by culture in media containing 
dexamethasone and ascorbic acid. This has been used successfully in 
earlier studies [63, 435-437]. Other induction factors have been used, which 
were also successful in inducing osteogenic differentiation in DPSCs; these 
included enamel matrix derivatives [438], β-glycerophosphate [423, 439, 
440], epidermal growth factor [441], 1,25-dihydroxyvitamin D3 [442, 443], 
human serum [425], TNF-α [444], TGF-β [445, 446] and bone morphgenic 
proteins [447, 448]. 
The findings of this study showed that alkaline phosphatase (Figure 22) and 
Alizarin red staining (Figure 23) were more positive in both hDPSCs and 
cDPSCs under osteogenic conditions compared with basal cultures. This 
confirms that these cells could differentiate under the osteogenic conditions 
used in the current study. However, stronger staining was observed in 
cDPSCs compared with hDPSCs (Figure 22 and Figure 23). Other studies 
have also found that hDPSCs have the ability to differentiate down the 
osteogenic lineage [74, 151, 157, 220], while controversial data have been 
published regarding cDPSCs isolated from permanent teeth [175, 417, 449-
451], and deciduous teeth [177, 415] affected by deep caries. 
ALPL, OC and RUNX-2 are essential markers involved in osteogenesis. 
They were used as potentially indicative of active osteogenic differentiation 
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and mineralisation [63]. The results of the current study clearly demonstrated 
that ALPL was expressed in hDPSCs and cDPSCs (Figure 24), confirming 
several previous studies that reported the expression of alkaline 
phosphatase in dental pulp cells [452-457]. Alkaline phosphatase is normally 
found in matrix vesicles of mineralised tissues and plays a role in initial 
formation as well as early mineralisation of these tissues [458, 459]. 
Additionally, its expression in dental pulp cells is associated with the function 
of these cells in terms of dentine bio-mineralisation, where phosphate ions 
are fundamentally essential for nucleation of hydroxyapatite and crystal 
growth [460]. Furthermore, ALPL levels were increased with confluent 
cultures at the 3 week time point compared to 1 week. This suggests that 
increased culture duration and cell density established higher levels of ALPL 
expression which may also be associated with lower proliferation of dental 
pulp cells [460, 461].  
Interestingly, cDPSCs from two out of three donors showed higher levels of 
ALPL under basal conditions at both time points compared to hDPSCs under 
the same conditions (Figure 24 ). Previous observations have suggested the 
role of alkaline phosphatase in the beginning of pulp response to the 
stimulus [462, 463]. For example,  an increase in ALP activity was reported  
in reversible pulpitis although decreased ALP activity was associated with 
irreversible pulpitis [462, 464]. Different levels of ALP activity were attributed 
to cellular infiltrates, and the influx of inflammatory mediators associated with 
advanced stages of inflammation that have an inhibitory effect on the 
expression of ALP [461]. 
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ALPL is useful osteogenic marker for in vitro cell cultures [151, 465-467]. It is 
related to mineralisation and is considered as an early osteoblastic marker 
[61, 468]. In the current study, ALPL expression in hDPSCs and cDPSCs 
was up-regulated at 1 week under osteogenic conditions but returned to 
basal levels or just below at 3 weeks (Figure 25). This temporal pattern of 
ALP activity in DPSCs has been identified previously [469].  
The results of the current study showed that OC demonstrated a lower 
degree of expression in hDPSCs and cDPSCs under basal conditions at 
both 1 and 3 week time points compared with other osteogenic markers 
(Figure 26). Low levels of OC expression have previously been reported in 
hDPSCs [467]. However, in impacted third molar teeth where the 
odontoblastic layer was not included, no OCN expression was reported 
[470]. Juliana et al. (2009), suggested that the expression of OC in human 
dental pulp isolated from healthy premolar teeth indicated that primitive 
human dental pulp tissue already contains mature osteoblast cells 
irrespective of any differentiation treatment [471]. 
Interestingly, cDPSCs from two out of three donors appeared to express 
slightly higher OC under basal conditions compared to hDPSCs at 1 and 3 
week time point (Figure 26). Previous observations indicated that this 
reparative molecule is involved in the repair during pulp injury [470, 472] and 
the inflammatory-stimulated pulp response [473]. Another study reported 
higher OCN expression levels in reversible and irreversible pulpitis tissues 
compared with healthy tissues, although OCN levels in reversible pulpitis 
were found to be higher compared with irreversible pulpitis [470]. This may 
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be attributed to the decreased number of cells associated with irreversible 
pulpitis [474]. Macrophages, which are predominantly present in reversible 
pulpitis [474], are known to express OC during the final stages of 
differentiation into osteoblasts [475]. In another study, OCN was positively 
stained in cells located at the periphery of inflamed tissue and around the 
blood vessels, where stem cells are known to reside [470]. This might be an 
indication of differentiation of stem cells in response to inflammation and the 
initiation of a repair/regeneration process. 
OC is also widely used as an osteogenic marker [151, 476], and the up-
regulation that is reported in the current study has been reported previously 
during osteogenic differentiation of DPSCs [467]. OC is reported to be a 
marker for mature osteoblasts [477], and is considered a late marker for 
odontoblast differentiation [478]. This agrees with the data reported in this 
current study in that OC showed a trend of higher expression at 3 weeks 
compared with 1 week under osteogenic conditions (Figure 27). Such time 
dependant increases of OC expression have been observed previously in 
hDPSCs [467] and may be  associated with elevated levels of matrix 
mineralisation and lower osteoblast proliferation [479].  
Odontoblasts are reported to express RUNX-2 at variable levels [480, 481]. 
This current study showed that RUNX-2 was expressed in hDPSCs and 
cDPSCs under basal conditions at early and later time points (Figure 28). 
Furthermore, RUNX-2 levels were higher in cells from two out of three of 
donors in the hDPSCs group at 1 week compared with 3 weeks under basal 
conditions (Figure 28). Contrary to our findings, a separate study showed 
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increased RUNX-2 expression in hDPSCs at days 4, 7 and decreased 
expression at days 14 and 28 in these cells [481].  
RUNX-2 expression has been investigated in this study as it is a key player 
in the differentiation of odontoblasts  and osteoblasts [482]. It is a 
transcription factor whose expression is regulated by Wnt signalling during 
osteoblast differentiation [483], and β-catenin stimulates the odontoblastic 
differentiation of dental pulp cells by stimulating RUNX-2 activity [484]. This 
study showed a consistent pattern of RUNX-2 up-regulation at both 1 and 3 
week time points under osteogenic culture conditions (Figure 29). However, 
RUNX-2 demonstrated higher levels of expression at the 3 week time point 
compared with 1 week expression under osteogenic culture conditions 
(Figure 29). This suggests that both hDPSCs and cDPSCs might be still in 
an active differentiation stage, as RUNX-2 controls immature osteoblast 
production and bone formation [485], and its expression is up-regulated until 
complete maturation of functioning osteoblasts, which are able to produce 
extracellular matrix [486]. In agreement with this, up-regulation of RUNX-2 in 
in vitro stromal cell cultures resulted in matrix mineralisation [487]. 
Interestingly, two donors out of three in the cDPSCs group appeared to 
express higher osteogenic markers compared with hDPSCs at 1 and 3 week 
time points, although that applied only at 3 week time point for ALPL 
expressed under osteogenic culture conditions (Figure 25, Figure 27 and 
Figure 29). This might be due to the active reparative stage of cDPSCs, 
which is enhanced by an inflammatory environment [488].  
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Although endothelial cells express VEGFR-1, -2 and -3, angiogenic activity 
is mediated mainly through VEGFR-2 [489, 490]. VEGF is an important 
growth factor involved  in vasculogenesis (de novo formation of new blood 
vessels) and angiogenesis (the process of forming new blood vessels from 
pre-existing capillaries and vasculature) [356, 491, 492],. VEGFR expression 
is required for endothelial cell differentiation during vasculogenesis and 
angiogenesis, and it  activates the migration and proliferation of these cells 
[493]. 
This study demonstrated that VEGFR-2 was expressed at a very low levels 
in both hDPSCs and cDPSCs under basal conditions (Figure 30). Low levels 
of VEGFR-2 gene expression were reported previously in neonatal mouse 
molar-derived dental pulp [494], and both VEGF and VEGFR-2 proteins 
were found in dental pulp isolated from healthy third molars, suggesting that 
both proteins can be produced locally in pulp tissue even with no signs of 
inflammation [495]. VEGF is secreted by DPSCs, and it was suggested that 
this was important to the ability of these cells to repair induced myocardial 
infarction in a rat model by causing an increased number of vessels and a 
reduction in the infarct size [496]. Further studies suggested that VEGF 
caused this effect through activation of the PI3K-AKT and MEK-ERK 
pathway [368]. Using immunohistochemistry, VEGFR-2 was located in 
endothelial cells of the dental pulp of healthy primary teeth close to the sub-
odontoblastic layer, and in healthy incisor and premolar pulp tissue; in 
endothelial cells and throughout the pulp tissue [497]. The expression of 
VEGF and VEGFR-2 in odontoblasts and inner enamel epithelium of 
developing teeth suggests that they might have a role in maturation of the 
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odontoblasts and ameloblasts [498], although their expression throughout 
endothelial and stromal cells suggests a more widespread role in pulp 
angiogenesis [499].   
The current study showed that cDPSCs, from two out of three donors, 
showed higher expression of VEGFR-2 compared with hDPSCs grown 
under basal conditions (Figure 30). The inflammatory stimuli and their 
associated chemical mediators associated with carious lesions are known to 
modulate the microcirculatory hemodynamic and may result in a greater 
blood supply to the affected area [500]. In this regard it has been reported 
that lipopolysaccharides (LPS) derived from Gram negative bacteria [501, 
502],  and lipoteichoic acid (LTA) derived from Gram positive bacteria 
induced VEGF expression in macrophages and pulp cells [503]. High 
VEGFR expression was demonstrated in the inflammatory cell infiltrate in 
teeth affected by irreversible pulpitis, although expression was decreased 
significantly in pulp stromal cells under the same culture conditions [495, 
499] . An earlier study also found that VEGF is expressed in dentine matrix 
and suggested that this molecule may be released slowly during dentine 
injury to play a role in reparative processes [504, 505].  
Vasculogenesis has been reported to enhance differentiation of DPSCs into 
odontoblasts [360], and data from the current study suggest an increased 
expression of VEGFR-2 under osteogenic conditions in both hDPSCs and 
cDPSCs (Figure 31). VEGF is known to be highly expressed in 
osteoprogenitors, mesenchymal stem cells and in osteoblasts themselves 
[195, 506-508]. Some studies have even shown that osteoblasts release 
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higher levels of VEGF than endothelial cells [509]. VEGFR-2 is also known 
to act in both osteoblast and endotheliocyte differentiation, and it is essential 
to achieve complete differentiation and formation of mature bone [510, 511], 
although the full significance of VEGF and VEGFR-2 in the  differentiation 
and formation of bone remains controversial [356, 512]. Studies continue 
into the dual angiogenic and osteogenic functions of this growth factor [172, 
184, 205, 220, 427, 512]. 
PECAM-1 was expressed at very low levels under basal conditions in both 
hDPSCs and cDPSCs (Figure 32). However, cDPSCs from two out of three 
donors showed higher gene expression of PECAM-1 under basal conditions 
compared with hDPSCs under the same conditions (Figure 32). PECAM-1 is 
an adhesion molecule highly expressed in endothelial cells, and plays a key 
role in intercellular junctions, and in interaction of endothelial cells with 
leukocytes [513, 514]. Immunohistochemically, PECAM-1 has been 
identified in healthy dental pulp and in inflamed pulp derived from cases of 
periodontitis [515]. Supportive to our study, immunohistochemical staining 
demonstrated that the number of vessels showing positive PECAM-1 
expression was higher and more intense in inflamed pulps compared with 
healthy pulps [515]. Healthy pulps showed staining for PECAM-1 in many 
blood vessels and throughout the odontoblast layer, sub-odontoblast layer 
as well as in the pulp core [515]. 
Under the osteogenic conditions used in this study, levels of PECAM-1 
expression were up-regulated in hDPSCs from all three donors and cDPSCs 
from two out of three donors (Figure 33). An earlier study reported that 
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DPSCs isolated from healthy permanent teeth expressed VEGFR-2 and 
PECAM-1 during osteogenic differentiation of these cells in 3D cultures 
[220]. This 3D experimental model leads to the generation of structures 
similar to human adult bone with integral blood supply [220]. Simultaneous 
up-regulation of VEGFR-2 and PECAM-1 (as also found in the current study) 
under osteogenic culture conditions may indicate cell-cell communication 
between osteoprogenitors and endothelial cells [184].  
 
Toll-like receptors (TLRs) play a pivotal role in inflammatory processes and 
are activated in DPSCs during bacterial challenge [516, 517]. The 
expression of TLR-2 and TLR-4 in hDPSCs and cDPSCs, and the effect of 
osteogenic culture conditions on the expression of these receptors were 
examined in the current study (Figure 34, Figure 35, Figure 36and Figure 
37).  
The findings presented in Figure 34 and Figure 36 confirm earlier studies 
showing TLR-2 and TLR-4 expression by dental pulp cells isolated from 
healthy non-erupted third molars [155]. A separate study confirmed TLR-2 
expression in healthy dental pulp, although no protein was identified. This 
may be due to the sensitivity threshold of immunhistochmical methods used 
[89], and a subsequent study detected TLR-2 protein in healthy pulp from 
third molars [156]. For TLR-4 there is more consensus in the literature, and 
several studies have demonstrated TLR-4 gene and protein expression in 
healthy dental pulp cells [310, 311, 362, 518].  
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cDPSCs examined in this study showed higher levels of TLR-2 and TLR-4 
expression compared with hDPSCs at 1 and 3 weeks under basal conditions 
(Figure 34 and Figure 36). Generally, TLR expression remains low in healthy 
cells and would be expected to change in caries [318]. In the early 
development of caries, Gram positive bacteria infect the dentine, and as the 
lesion develops towards the pulp, the number of aerobic/facultatively 
anaerobic Gram positive bacteria decreases and the number of anaerobic 
Gram negative bacteria increases [517]. Relevant to this is that 
aerobic/facultatively anaerobic Gram positive bacteria are known to be key 
player microorganisms in shallow caries lesions [267]. TLR-2 and TLR-4 
recognize LTA and LPS respectively, which are produced by the bacteria 
[400, 519]. Increased expression of TLR-2  was reported  in odontoblasts 
isolated from mouse molar pulps which were challenged by Gram positive 
bacteria [306]. The findings of the current study are in agreement with recent 
results on the expression of TLRs in DPSCs under basal and inflammatory  
culture conditions which showed differential expression of the TLR family in 
DPSCs under basal conditions and up-regulation of TLR-2, -3, -4, -5, and -8 
following challenge with an inflammatory medium [298]. 
TLR-2 and TLR-4 expression levels were up-regulated in both hDPSCs and 
cDPSCs, in two out of three donors, at 1 and 3 weeks under osteogenic 
culture conditions (Figure 35 and Figure 37). Up-regulation of TLR-2 and 
TLR-4 is perhaps not unexpected given that osteoblasts are known to 
express TLR-2 and TLR-4 [520, 521]. It is encouraging to compare the 
results of the current study with those of another study, which demonstrated 
that prolonged exposure of osteoprogenitors to microbial infections resulted 
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in down-regulation of TLRs expression [520]. Shallow caries may indicate 
short period of exposure of DPSCs to microbial infection. This could explain 
to some extent the up-regulation of both TLR-2 and TLR-4 in cDPSCs under 
osteogenic culture conditions used in this study. However, there are some 
controversial data concerning TLRs expression and osteogenesis/ 
odontogenesis. TLR-2  activation up-regulated osteogenic mediators in 
human primary osteoblasts [522]  and osteogenesis in human bone marrow 
MSCs [336, 520]. Moreover, it has been reported that TLR-4 activation 
induces dentine synthesis, enhances DPSCs differentiation to odontoblasts 
[297], and mineralisation [523]. It also promotes bone marrow MSCs 
proliferation and osteogenic differentiation via Wnt3a and Wnt5a signalling 
[524]. Similarly, LPS-induced Wnt5a expression mediated through the TLR-
4/Myd88/PI3-kinase/AKT pathway [525], and Wnt5a participated in the 
induction of MSC osteogenesis [526]. Fischer et al. (2006), observed that 
Pam3Cys (a synthetic lipopeptide and TLR-2 ligand) enhances ALP activity 
and extra-cellular calcium deposition in bone marrow MSCs, although this 
differentiation was weak and sporadic compared with MSCs cultured under 
osteogenic induction conditions [527]. This may be related to the 
heterogeneity of the MSC population, containing only minor cell 
subpopulations able to differentiate to an osteoblasts phenotype. Activation 
of TLR-2 stimulates IL-6 secretion which may itself affect osteogenic 
differentiation [527].    
TLRs are reported to have non-pathological activity in tooth development. 
For example, activation of TLR-4 enhanced ameloblast differentiation 
although it inhibited subsequent mineralisation of enamel and dentine [335]. 
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Similarly TLR-4 down-regulated the levels of osteogenic mediators and 
osteogenesis in osteoblasts [522]. In this context, TLR-4 activation may 
decrease the ALP activity and in infected pulps, LPS may bind the Ca2+ 
decreasing its availability for enamel and dentine mineralisation [334, 528]. 
In human PDL stem cells, LPS decreased osteogenic differentiation through 
activation of TLR-4, which regulated the NF-kB pathway in these cells [291]. 
Li et al. (2014), found that blocking of TLR-4 or the NF-kB signalling pathway 
led to reversed or decreased osteogenic potential [291].  Additionally, 
studies reported that TLR-2 and TLR-4 in bone marrow MSCs activated NF-
kB dependant signalling [527]; this pathway was observed to inhibit the 
differentiation of bone marrow MSCs into osteoblasts under osteogenic 
differentiation conditions [529, 530]. Also, it has been reported that LPS from 
Porphyromonas gingivalis mediated TLR-2 activation, which resulted in poor 
differentiation of osteoblasts [531]. 
Pattern recognition receptors  such as TLRs expressed on odontoblast and 
play a crucial role in innate immunity. One major consequence of TLRs 
stimulation is the activation of the NF-kB and p38 mitogen activated protein 
(MAP) kinase intracellular signalling cascades. As a result, subsequent pro-
inflammatory mediator expression increases, including that of inflammatory 
cytokines which in turn influence the target immune cells  [271, 274, 285, 
532]. 
Cytokines are molecules that mediate inflammatory responses as a 
consequence of their biological effects on target cells. Many cytokines and 
chemokines (including IL-6 and IL-8) have been well studied in relation to 
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the inflammatory response to bacterial infection as they are expressed by a 
variety of cells, in addition to immune cells [533]. IL-6 and IL-8 proteins were 
secreted into media conditioned by all three donors from each group; 
hDPSCs and cDPSCs. Interestingly, there was a trend for higher 
concentrations of IL-6 and IL-8 in media conditioned by cDPSCs compared 
with hDPSCs under basal conditions (Figure 38 and Figure 39). These 
findings are supported by earlier studies, which found that IL-6 and IL-8 
gene expression was higher in carious pulp tissue compared with healthy 
pulp tissue isolated from human premolar and molar teeth [380, 534, 535]. In 
addition, TLR-4, IL-6 and IL-8 gene expression were each found to be up-
regulated in DPSCs isolated from third molars after treatment with LPS and 
extracts from Streptococcus mutans (a Gram positive bacterium strongly 
associated with caries) [536], and increased IL-6 protein levels were found in 
inflamed pulp with a presenting periapical lesion compared to healthy pulp 
tissue isolated from third molars [537]. The expression of IL-6 and IL-8 were 
reported to be the highest in deep caries compared with shallow caries 
[380]. 
The results of this study demonstrated that IL-6 levels were dramatically  
down-regulated in all three donors from both hDPSCs and cDPSCs at 1 and 
3 weeks under osteogenic conditions (Figure 38). Data with respect to IL-6 
and osteogenic differentiation are conflicted. IL-6  enhances the 
differentiation of pre-osteocytes within the bone marrow MSCs population 
[527], and is up-regulated in association with late bone remodelling following 
fracture and secondary bone formation [538]. IL-6 also enhanced 
osteoblastic differentiation during the process of distraction osteogenesis 
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[539]. However, it has been shown that the in vivo effect of IL-6 on bone 
homeostasis is mainly towards bone resorption rather than bone formation 
[540]. Interestingly, treatment with the synthetic glucocorticoid 
dexamethasone inhibited the endogenous production of IL-6 [271, 537, 541]. 
This may be pertinent to our study as we used dexamethasone in our 
osteogenic medium and it would be interesting in the future to use 
dexamethasone-free osteogenic induction medium and examine whether IL-
6 expression remains down-regulated.  
In contrast to IL-6, IL-8 secretion into conditioned medium increased under 
osteogenic conditions (Figure 39). Increase IL-8 expression has been 
reported previously under osteogenic conditions for human MSCs, 
progenitor cells, and osteoblasts [542]. IL-8 expression was also up-
regulated in bone marrow MSCs during osteogenic differentiation using bone 
morphogenic proteins [543]. IL-6 and IL-8 activate the NF-kB signalling 
pathway, which activates the osteogenic differentiation of several stem cells 
including those derived from adipose tissue MSCs [345] and valve interstitial 
cells [544, 545]. However, the association between the NF-kB pathway and 
the osteogenic differentiation of MSCs is still controversial [546-550]. 
 
Changes in the pulp microenvironment due to inflammatory stimuli are 
associated with the expression of several chemical mediators [551]. 
Restricting the responses of dental pulp cells to inflammatory stimuli using; 
for example, steroidal anti-inflammatory drugs inhibits the expression of pro-
inflammatory genes and increases the expression of anti-inflammatory 
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genes as well as mineralisation related genes including OC and RUNX-2  
[552]. 
During caries injury, demineralisation of dentine leads to mobilization of 
proangiogenic growth factors including VEGF [504]. Local increase in pulp 
vasculature has a crucial role to support reparative/regenerative processes 
including survival in a hypoxic environment [553], nutrition supply, gaseous 
exchange during the post-differentiation stages of DPSCs [554] as well as 
pulp cell homing [555]. Angiogenesis events can be stimulated by 
inflammatory molecules such TLR-4 mediated NF-kB and MAPK signalling 
in DPSCs, which induces VEGF expression in these cells [310, 362]. IL-6 
and IL-8 are essential in the inflammatory response, and are also pro-
angiogenic [556-559]. In addition, such inflammatory cytokines were shown 
to be generated in response to demineralised dentine matrix [271].  
Pulp response to different stimuli including dental caries suggested that the 
inflammatory process and its subsequent signaling might be essential 
initiators for dental repair [322, 488]. Shallow caries is capable of initiating 
changes in expression of regenerative molecules including osteogenic, 
angiogenic and inflammatory markers in DPSCs under different culture 
conditions.     …
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  Results 
 
IGF axis expression in dental pulp cells 
6.1 Introduction 
The insulin-like growth factor (IGF) axis comprises two polypeptide growth 
factors (IGF-1 and IGF-2), two cell surface receptors (IGF-1R and IGF-2R) 
and six high affinity, soluble binding proteins (IGFBP-1, IGFBP-2, IGFBP-3, 
IGFBP-4, IGFBP-5 and IGFBP-6) [560]. The IGF axis is known to play a role 
in  the differentiation of stem and progenitor cells into skeletal and dental 
mineralised tissue [561-563]. This molecular axis is also involved in 
induction of enamel bio-mineralisation [564], differentiation of dental pulp 
cells [565], and reparative dentinogenesis [566]. IGF-1 is important for 
osteogenesis, and when delivered by liposomes into the tooth socket [563], 
it enhanced deposition of osteodentine-like matrix around implants in 
combination with calcium hydroxide [221]. IGF-1 in combination with platelet 
derived growth factor (PDGF) and calcium hydroxide, improved healing of 
apical tooth perforations in a canine model [567]. Further evidence 
suggested that IGF-1 regulated the balance between odontogenesis and 
osteogenesis in apical papilla stem cells [568]. IGF-1 is expressed by dental 
pulp cells and enhances odontogenic differentiation and deposition of 
extracellular matrix [565, 569]. IGF-2 was also expressed by dental pulp 
cells both gene and protein levels, although its function in this tissue is still 
largely unknown [570]. 
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IGF-1R showed higher expression in teeth with incomplete root 
development, suggesting the role of IGF-1 in root development [212]. 
IGFBP-1, -3, -5, and -6 have also been detected in DPSCs isolated from 
healthy premolars and third molars [571]. IGF axis expression is influenced 
by different culture conditions including treatment with pharmacological 
doses of dexamethasone [572], 3D culture conditions [573], exogenous 
treatment by antagonistic analogues of growth hormone releasing hormone 
(GHRH) [574], and different concentrations of glucose and amino-acid 
supplements [575].   
In this chapter,  the changes in the IGF axis gene and protein expression in 
dental pulp stromal/stem cells isolated from healthy (hDPSCs) and carious 
(cDPSCs) teeth grown under osteogenic culture conditions in vitro were 
successfully investigated. In addition, expression data were used to test the 
hypothesis that members of IGF axis were causally involved in the 
osteogenic differentiation of hDPSCs.  
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6.2 Results 
6.2.1 Gene expression   
The changes in the gene expression of IGF axis members in hDPSCs and 
cDPSCs cultured under basal and osteogenic conditions for 1 and 3 weeks, 
were investigated using qRT-PCR as previously described (Chapter 3, 
Methods, Section 3.2.5). The relative changes in the expression of the IGF 
axis genes in both hDPSCs and cDPSCs cultured under osteogenic 
conditions were carried out to determine the changes in the expression of 
this molecular axis in both cell types under osteogenic culture conditions, 
compared with their baseline expression under basal conditions. The 
expression of the genes of interest in both hDPSCs and cDPSCs cultured 
under osteogenic conditions were normalized to controls from the same cells 
cultured under basal conditions. The ∆∆Ct method was used to calculate the 
relative change in the gene expression (Chapter 3, Methods, 
,Section 3.2.5.6). The mean 2-∆∆ct  ±SD were plotted (log 10 scale) to show 
the relative changes in gene expression at the two time points (1 and 3 
weeks). Fold changes in the gene expression  were calculated.  All 
experiments were repeated three times from three different donors in each 
group; hDPSCs and cDPSCs. Results from individual donors (individual 
analysis) as well as the average results of all donors together in each group 
(global analysis) were plotted for all genes of interest.   
Statistical analysis 
Statistical analysis was carried out for individual donors and for global gene 
expression data using one way ANOVA followed by Bonferroni multiple 
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comparison tests, using Graph Pad Prism software (v 6). Differences were 
considered significant when P values were ˂0.05.  
 
 Relative changes in the expression of IGF axis genes in hDPSCs 
and cDPSCs under osteogenic culture conditions  
In hDPSCs, expression of IGF-1 and  IGFBP-1 genes was down-regulated 
by ~2-fold at week 1 and showed up-regulation by ~34-fold and ~2-fold, 
respectively, at week 3 under osteogenic culture conditions compared with 
the same cells cultured under basal conditions (Figure 40). IGF-2 and 
IGFBP-4 levels were up-regulated by ~2-fold and ~4-fold respectively at  
week 1, and were down-regulated by ~1-fold and ~2-fold, respectively, at 
week 3 under osteogenic culture conditions compared with the same cells 
cultured under basal conditions. IGF-1R and IGF-2R gene levels were up-
regulated at both 1 and 3 weeks by ~2-fold under osteogenic culture 
conditions compared with the same cells cultured under basal conditions 
(Figure 40). IGFBP-2 gene expression was up-regulated at both1 week (~4-
fold) and 3 weeks (~6-fold) (Figure 40). In contrast, the expression of  
IGFBP-3,  BP-5 and BP-6 were down-regulated by ~16-fold, ~3-fold and ~2-
fold, respectively, at week 1. However, less down regulation was 
demonstrated at week 3 under osteogenic culture conditions compared with 
the same cells cultured under basal conditions. The fold changes at 3 weeks 
under osteogenic culture conditions compared with the same cells cultured 
under basal conditions were as follows; for IGFBP-3: ~11-fold; IGFBP-5: ~2-
fold; and IGFBP-6: ~1-fold (Figure 40).  
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In cDPSCs, IGF-1 and IGFBP-4 gene expressions were down-regulated by 
~2-fold at 1 week and showed up-regulation by ~13-fold (IGF-1) and ~1-fold 
(IGFBP-4) at week 3 under osteogenic culture conditions compared with the 
cells cultured under  basal conditions (Figure 40). IGF-1R and IGFBP-6 
gene expression were down-regulated by ~2-fold at 1 week and were up-
regulated by ~5-fold at 3 weeks under osteogenic culture conditions 
compared with the same cells cultured under basal conditions (Figure 40). 
The levels of IGF-2R and IGFBP-5 were down-regulated by ~1-fold and ~8-
fold, respectively, at week 1 and were up-regulated at week 3 by ~4-fold and 
~1-fold, respectively, under osteogenic culture conditions compared to the 
same cells cultured under basal conditions (Figure 40). On the other hand, 
IGF-2,  IGFBP-1, and BP-2 expressions were up-regulated by ~3-fold, ~1-
fold and ~3-fold, respectively, at week 1 under osteogenic conditions. 
However, greater increases were demonstrated in the gene expression of 
IGF-2, IGFBP-1 and BP-2 at week 3 (~27-fold, ~6-fold, ~11-fold, 
respectively) under osteogenic culture conditions compared with the same 
cells cultured under  basal conditions (Figure 40). In cDPSCs, all members 
of the IGF axis were up-regulated at the 3 week time point compared with 1 
week expression, except for IGFBP-3. IGFBP-3 was down-regulated at week 
1 (~18-fold) and week 3 (~3-fold) under osteogenic culture conditions 
(Figure 40). 
IGF-1 displayed its highest level of gene expression in hDPSCs at week 3 
under osteogenic culture conditions compared with cDPSCs. IGFBP-2 and 
IGFBP-3 were the only two members of the IGF axis which showed 
consistent pattern of expression with changing culture conditions and 
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changing time points (1 and 3 weeks) in both hDPSCs and cDPSCs (Figure 
40 red and blue columns, respectively).  
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Figure 40: Relative changes in the expression of IGF axis genes in hDPSCs 
and cDPSCs cultured under osteogenic conditions for 1 and 3 
weeks  
Relative changes in the expression IGF axis genes in hDPSCs (n=1) and cDPSCs 
(n=1) cultured in monolayers under osteogenic conditions for 1 and 3 weeks. The 
relative gene expression was normalised to corresponding control cultured under 
basal conditions. Data are presented as mean 2-∆∆ct  ± SD for three technical 
replicates.  
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 Comparing the changes in IGFBP-2 and IGFBP-3 gene 
expression in hDPSCs and cDPSCs under osteogenic culture 
conditions  
The results in the previous section have shown reproducible and consistent 
up-regulation of IGFBP-2 and down-regulation of IGFBP-3 gene expression 
in both hDPSCs and cDPSCs under osteogenic culture conditions compared 
with the basal culture conditions at 1 and 3 week time points. Therefore, 
further investigations were carried out to confirm and compare the changes 
in the gene expression of IGFBP-2 and IGFBP-3 in DPSCs from six different 
donors, hDPSCs (n=3) and cDPSCs (n=3), both cultured in monolayers 
under basal and osteogenic conditions for 1 and 3 weeks. 
 
A: Relative changes in IGFBP-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions  
For hDPSCs cultured under osteogenic conditions at 1 and 3 weeks, all 
three donors showed up-regulation of IGFBP-2 expression compared with 
cells cultured under basal conditions (Table 21 and Figure 41A). However, 
the levels of IGFBP-2 expression were higher at week 3 compared with 
week 1 under osteogenic conditions (Table 21 and Figure 41A). The 
increases were statistically significant comparing  the two time points under 
osteogenic conditions in hDPSCs from the third donor (H3) (Table 21 and 
Figure 41A). 
For cDPSCs cultured under osteogenic conditions for 1 and 3 weeks, all 
three donors showed up-regulation of IGFBP-2 levels compared with cells 
cultured under basal conditions (Table 21 and Figure 41A). The levels of 
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IGFBP-2 expression appeared to be higher at week 3 compared with week 1 
under osteogenic conditions, in cDPSCs from two (C1, C2) out of three 
donors, with only cDPSCs from the first donor (C1) showing statistically 
significant difference (Table 21 and Figure 41A).  
Comparing both cell types cultured under osteogenic conditions, the levels 
of IGFBP-2 expression were higher in cDPSCs from two out of three donors 
at 1 week (C2, C3), and 3 weeks (C1, C2), compared with hDPSCs from the 
first and second donors (H1, H2) under the same culture conditions (Table 
21 and Figure 41A). The levels of IGFBP-2 expression were higher at both 
time points under osteogenic conditions in hDPSCs from the third donor (H3) 
compared with cDPSCs from all three donors under the same culture 
conditions. However, results were significant in cDPSCs from the first donor 
(C1) at 1 week, and in cDPSCs from all three donors at 3 weeks under 
osteogenic conditions when comparing cDPSCs with hDPSCs (Table 21 and 
Figure 41A). 
Global analysis showed a trend for cDPSCs to express lower IGFBP-2 levels 
compared with hDPSCs at 1 and 3 week under osteogenic conditions 
(Figure 41B). The levels of IGFBP-2 expression were higher within the same 
cell type at 3 weeks compared with 1 week under osteogenic conditions. 
Nevertheless, none of these differences reach statistical significance (Figure 
41B).  
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Table 21: Fold changes in IGFBP-2 gene expression in hDPSCs and cDPSCs 
cultured under osteogenic conditions compared with cells 
cultured under basal conditions at 1 and 3 weeks  
 
Duration of 
culture 
Fold change in gene expression in DPSCs from donor a: 
H1 H2   H3 C1 C2 C3 
1 week ↑b 3.7 ↑ 3.2   ↑ 12   ↑ 2.6 ↑ 7.6  ↑ 7.3 
3 weeks   ↑ 6.2 ↑ 4.2 ↑ 19.6 ↑ 11.4 ↑ 8.2 ↑ 2.1 
                
           a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
  b.   ↑ = up-regulation 
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Figure 41: Relative changes in IGFBP-2 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in IGFBP-2 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in IGFBP-2 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes  in IGFBP-2 gene expression from the three 
donors in each group; hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001. 
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B: Relative changes in IGFBP-3 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions  
For hDPSCs cultured under osteogenic conditions at 1 and 3 weeks, all 
three donors showed down-regulation of IGFBP-3 expression compared with 
cells cultured under basal conditions (Table 22 and Figure 42A). However, 
the levels of IGFBP-3 gene expression appeared to be lower in hDPSCs at 1 
week compared with 3 weeks under osteogenic  culture conditions (Table 22 
and Figure 42A).   
For cDPSCs cultured under osteogenic conditions at 1 and 3 weeks, all 
three donors showed down-regulation of IGFBP-3 gene expression 
compared with cells cultured under basal conditions (Table 22 and Figure 
42A). However, the levels of IGFBP-3 expression were lower at 3 weeks 
compared with 1 week under osteogenic conditions, in cDPSCs from two 
(C2, C3) out of three donors, with only cDPSCs from the second donor (C2) 
showing statistically significant difference (Table 22 and Figure 42A) 
Comparing both cell types, the levels of IGFBP-3 expression were 
significantly lower at 1 week under osteogenic conditions, in hDPSCs from 
all three donors compared with cDPSCs from two out of three donors (C2, 
C3). The only exception was when comparing the IGFBP-3 levels in cells 
from the second donor in each group (H2 and C2), the difference did not 
reach statistical significance (Table 22 and Figure 42A). At 3 weeks under 
osteogenic conditions, the levels of IGFBP-3 were lower in hDPSCs from the 
first and third donors (H1, H3) compared with cDPSCs from all three donors 
(Table 22 and Figure 42A). However, the levels of IGFBP-3 in hDPSCs from 
the second donor (H2) was higher compared with cDPSCs from the first and 
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second donors (C1, C2) at 3 weeks under osteogenic conditions, with only 
cDPSCs from the second donor (C2) reached statistical significance (Table 
22 and Figure 42A).  
The global analysis showed a trend for cDPSCs to express higher IGFBP-3 
levels compared with hDPSCs at 1 and 3 weeks under osteogenic 
conditions (Figure 42B). However, the results of the global analysis did not 
reach statistical significance comparing 1 and 3 weeks within the same cell 
type (Figure 42B).   
 
 
 
Table 22: Fold changes in IGFBP-3 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions compared with 
cells cultured under basal conditions at 1 and 3 weeks  
Duration 
of culture 
Fold change in gene expression in DPSCs from donor a: 
H1 H2 H3 C1 C2 C3 
1 week ↓b 18.3 ↓ 3.2 ↓ 10 ↓18.2 ↓  2   ↓ 1.2 
3 weeks   ↓ 11.4   ↓  2 ↓         ↓ 7.3 ↓ 3.2 ↓ 7 ↓ 1.3 
              
                a.    hDPSCs donors (H1, H2, H3), cDPSCs donors (C1, C2, C3)  
       b.   ↓ = down-regulation 
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Figure 42: Relative changes in IGFBP-3 gene expression in hDPSCs and 
cDPSCs cultured under osteogenic conditions for 1 and 3 weeks  
Relative changes in IGFBP-3 gene expression in hDPSCs (n=3; H1, H2, H3) and 
cDPSCs (n=3; C1, C2, C3) cultured in monolayers under osteogenic conditions for 
1 and 3 weeks. A: Individual analysis: showing relative changes in IGFBP-3 gene 
expression in individual donors. The relative gene expression was normalised to 
corresponding control cultured under basal conditions. Data are presented as 
means 2-∆∆ct  ± SD of three technical replicates from each donor. B: Global analysis: 
showing an averaged relative changes in IGFBP-3 gene expression from the three 
donors in each group; hDPSCs and cDPSCs. *P˂0.05, **P˂0.01, ***P ˂0.001.  
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6.2.2 Protein expression 
The results in the previous section have shown reproducible and consistent 
up-regulation in IGFBP-2 expression and down-regulation in IGFBP-3 
expression in both hDPSCs (n=3) and cDPSCs (n=3) under osteogenic 
conditions compared with controls from the same cells, cultured under basal 
conditions for 1 and 3 week time points. Therefore, further investigations 
were carried out to confirm and compare the changes in the protein levels of 
IGFBP-2 and IGFBP-3 in DPSCs from six different donors,  hDPSCs (n=3) 
and cDPSCs (n=3).  
Conditioned medium (1mL) was collected from each culture at 1 and 3 
weeks.  IGFBP-2 and IGFBP-3 concentrations in conditioned media were 
determined using ELISA as described (Chapter 3, Methods, Section 3.2.6). 
Statistical analysis was carried out using one way ANOVA followed by 
Bonferroni multiple comparison tests, using Graph Pad Prism software (v 6). 
Differences were considered significant when P values were ˂0.05. 
 
A: Comparing IGFBP-2 concentration in media conditioned by hDPSCs 
and cDPSCs cultured under basal and osteogenic conditions  
For hDPSCs and cDPSCs, IGFBP-2  protein concentration (ng/mL) were 
higher in media conditioned by cells cultured under osteogenic conditions 
compared with basal cultures at both time points in cells from all three 
donors (Figure 43A). Absolute values of IGFBP-2 protein concentration were 
significantly higher in media conditioned by hDPSCs and cDPSCs from all 
donors cultured under basal and osteogenic conditions at 3 weeks 
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compared with 1 week in culture. The only exception was for cDPSCs from 
the second donor (C2), which showed no statistical significant difference 
comparing the two time points under basal conditions (Figure 43A). The 
levels of IGFBP-2 in basal and osteogenic media collected from the different 
donors in both cell types, and comparing the two different time points are 
demonstrated in Figure 43A. 
The global analysis showed that the levels of IGFBP-2 were higher in 
osteogenic media compared with basal media conditioned by hDPSCs and 
cDPSCs at 1 and 3 weeks, with only 3 weeks data reached statistical 
significance (Figure 43B). The levels of IGFBP-2 were significantly higher in 
osteogenic media conditioned by cDPSCs compared with hDPSCs at 3 
week time point (Figure 43B). However, within the same cell type, the levels 
of IGFBP-2 in both basal and osteogenic conditioned media were higher at 3 
weeks compared with 1 week cultures, with only osteogenic media 
conditioned by cDPSCs reached statistical significance (Figure 43B).  
 
.  
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Figure 43: IGFBP-2  protein concentration in media conditioned by cDPSCs 
and   hDPSCs  
IGFBP-2 protein concentration in media conditioned by hDPSCs (n=3; H1, H2, H3) 
and cDPSCs (n=3; C1, C2, C3) cultured in monolayers under basal (blue) and 
osteogenic (red) conditions for 1 and 3 weeks were determined by ELISA.                 
A: Individual analysis: showing IGFBP-2 concentration in individual donors. Data 
are presented as means ±SD of IGFBP-2 concentrations (ng/mL) from three 
technical replicates from each donor. B: Global analysis: showing the average 
IGFBP-2 concentrations (ng/mL) form the three donors in each group. *P˂0.05, 
**P˂0.01,***P˂0.001 
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B: Comparing IGFBP-3 concentrations in media conditioned by 
hDPSCs and cDPSCs cultured under basal and osteogenic 
conditions   
For hDPSCs and cDPSCs, IGFBP-3 concentrations (ng/mL) were lower in 
media conditioned by these cells cultured under osteogenic conditions 
compared with basal cultures at both time points, in cells from all donors 
(Figure 44A). Absolute values of IGFBP-3 concentrations were higher in 
media conditioned by hDPSCs and cDPSCs from all donors, cultured under 
basal and osteogenic conditions at 3 weeks compared with 1 week cultures 
(Figure 44A). The levels of IGFBP-3 in basal and osteogenic media collected 
from the different donors in both cell types, and comparing the two different 
time points are demonstrated in Figure 44A. 
The global analysis showed that the levels of IGFBP-3 were lower in 
osteogenic media compared with basal media conditioned by hDPSCs and 
cDPSCs at 1 and 3 weeks, with only cDPSCs at 3 weeks reached statistical 
significance (Figure 44B). However, the levels of IGFBP-3 within the same 
cell type were higher at 3 weeks compared with 1 week in both basal and 
osteogenic conditioned media, with only basal media conditioned by 
cDPSCs reached statistical significance (Figure 44B). 
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Figure 44: IGFBP-3  protein concentration in media conditioned by cDPSCs 
and   hDPSCs  
IGFBP-3 protein concentration in media conditioned by hDPSCs (n=3; H1, H2, H3) 
and cDPSCs (n=3; C1, C2, C3) cultured in monolayers under basal (blue) and 
osteogenic (red) conditions for 1 and 3 weeks were determined by ELISA.              
A: Individual analysis: showing IGFBP-3 concentration in individual donors. Data 
are presented as means ±SD of IGFBP-3 concentrations (ng/mL) from three 
technical replicates from each donor. B: Global analysis: showing the average 
IGFBP-3 concentrations (ng/mL) form the three donors in each group. *P˂0.05, 
**P˂0.01,***P˂0.001 
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6.2.3 IGFBP-2 and IGFBP-3 biological activity 
Although we have shown reproducible and reciprocal changes in IGFBP-2 
and IGFBP-3 mRNA and protein expression following osteogenic 
differentiation of hDPSCs. The hypothesis that either/both of these proteins 
played a causative role in the osteogenic differentiation process of DPSCs 
has also been tested in the current study. IGFBPs can have a direct IGF-
independent effect on cell physiology or an IGF dependant effect where they 
act to inhibit or enhance the activity of IGF(s). To take account of this we 
examined the effects of IGFBP-2 and IGFBP-3 when co-incubated at a fixed 
concentration (10nM) with varying concentrations (0-100nM) of IGF-1 or 
IGF-2. As a marker for osteogenic differentiation, ALP enzyme activity was 
investigated as it showed up-regulation under osteogenic culture conditions 
used in the current study (Chapter 5).  
Figure 45 shows that ALP activity is increased after 7 days. Differential ALP 
activity under basal and osteogenic conditions was maximal at 14 days 
which was the final time point of this assay. Accordingly in the current study, 
a 14 day time point was used to examine the effect of IGFs ± IGFBP-2/-3 on 
osteogenic differentiation of hDPSCs. The results of such an experiment are 
shown in Figure 46. For IGF-1 (upper panel); data shows that co-incubation 
with IGFBP-2 enhances the osteogenic activity of IGF-1 whereas co-
incubation with IGFBP-3 has an inhibitory effect on IGF-1 action. At the 
highest concentrations of IGF-1 (100 nM), ALP activity reaches the highest 
level and there is no enhancing or inhibitory effect(s) of IGFBP-2 or IGFBP-3 
respectively. hDPSCs appear to be less sensitive to IGF-2 with respect to 
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increased osteogenesis and there is no effect on of co-incubation with either 
IGFBP-2 or IGFBP-3 on IGF-2  osteogenic activity.  
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Figure 45: ALP enzyme activity  
ALP enzyme activity was monitored over the period 0-14 days in hDPSCs treated 
under osteogenic (red) or basal (black) conditions (red). Data are presented 
nmol/µg DNA and represent the mean ± SD of three technical replicates of 
duplicate wells at each time point for both basal and osteogenic cultures. **P ≤ 0.01 
basal v osteogenic.  
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Figure 46: Effect of co-incubation with IGFBP-2 or IGFBP-3 on the osteogenic 
activity of IGF-1 and  IGF-2  
Effect of co-incubation with IGFBP-2 (blue) or IGFBP-3 (green) on the osteogenic 
activity of IGF-1 (red – top panel) or IGF-2 (red- bottom panel). DPSCs were 
incubated in osteogenic medium containing IGFs (0-100nM) ± IGFBPs at a fixed 
concentration of 10nM. Incubations were conducted for 14 days before assay of 
ALP activity. Data are presented as mean ± SD nmol/µg DNA and represent 
technical triplicate repeats from duplicate wells for each condition. *P˂0.05, 
**P˂0.01.   ……………………………………
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6.3 Discussion 
In this study, hDPSCs and cDPSCs have been cultured under basal and 
osteogenic conditions; the ability of both cells to differentiate into osteogenic 
lineage has been confirmed in Chapter 5 of this thesis. In the current 
chapter, the IGF axis profile has been investigated in hDPSCs and cDPSCs 
cultured in monolayers under basal and osteogenic conditions. The 
expression of the entire IGF axis under osteogenic conditions in both 
hDPSCs and cDPSCs has not yet been fully investigated in dental pulp cells.   
The current study showed that IGF-1 was down-regulated in both hDPSCs 
and cDPSCs at 1 week, although it was up-regulated at 3 weeks under 
osteogenic conditions compared with the same cells cultured under basal 
conditions (Figure 40). An earlier study investigated IGF-1 expression in vitro 
in differentiated normal rat osteoblasts and reported that IGF-1 gene 
expression increased from day 5 in culture, reached a maximum level at day 
11 and declined thereafter [576]. A subsequent study showed a biphasic 
change in IGF-1 expression as the osteoblast cultures progressed through 
the developmental stages of proliferation, matrix maturation, and 
mineralisation [577]. Decreased levels of IGF-1 were also observed prior to 
mineralisation of the cultures [577].  
IGF-2 and IGFBP-1 demonstrated consistent up-regulation in cDPSCs under 
osteogenic conditions at 1 and 3 week time points compared with 
inconsistent patterns in hDPSCs under the same conditions (Figure 40). IGF-
2 is known to enhance cell proliferation and differentiation [578], and is 
particularly active during embryonic development [579]. This growth factor 
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may be sequestered in dentine matrix during dentine formation and released 
during demineralisation of dentine. This may to some extent explain the 
pattern of IGF-2 gene expression in cDPSCs observed in the current study. 
Supportive of the current results, the expression IGF-2 and IGFBP-1 genes 
were highly expressed in dental pulp cells isolated from deciduous teeth 
where the pulp was exposed during the removal of proximal caries 
compared to the level of expression in healthy premolar teeth [580].   
IGFs act through cell surface IGF receptors which are expressed in 
osteoblasts and play a role in osteoblastic differentiation in combination with 
other members of the IGF axis [581]. The current study showed that IGF-1R 
and IGF-2R were both up-regulated in hDPSCs at both time points (1 and 3 
weeks) under osteogenic conditions compared with basal conditions. These 
findings confirm to some extent previous reports by Reichenmiller et al. 
(2004), reporting an association between mineralised nodule formation and 
increased expression of IGF-1R [582].  
IGFBP-5 is one of the most abundant IGFBPs in bone. In our study, IGFBP-
5 gene expression was down-regulated in hDPSCs and cDPSCs cultured 
under osteogenic conditions at the 1 week time point compared with the 
basal conditions. IGFBP-5 has been implicated as a pro-osteogenic factor in 
several studies but, conversely, it has been shown to act as an inhibitor of 
bone formation, as it might interfere with IGF actions on osteoblasts [244]. In 
contrast to the findings of the current study, Mori et al. (2011), demonstrated 
that the IGFBP-5 gene was up-regulated during the osteogenic 
differentiation of dental pulp cells isolated from healthy third molars. They 
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used microarray analysis to demonstrate an 8-fold increase in IGFBP-5 gene 
expression in dental pulp cells following 10 days osteogenic treatment [583] . 
Although their methods were almost similar to here, they isolated pulp tissue 
from the crown and root of the tooth through cutting around the cementum–
enamel junction, which might lead to possible contamination by cells from 
the gingiva and periodontal ligament. Such contamination of the cell 
population might have led to the variation in the outcomes of that study 
compared to the current study [583]. In primary osteoblast cultures, IGFBP-5 
is secreted by pre-osteoblasts but decreases in abundance during their 
differentiation and maturation [577]. IGFBP-5 gene expression is induced by 
IGF-1 in cultured osteoblasts [584]. In the current study, though IGF-1 gene 
levels were up-regulated in hDPSCs under osteogenic conditions at 3 
weeks, IGFBP-5 gene levels were down-regulated at both time points. 
IGFBP-5 may be regulated by proteolysis before binding to IGF-1 under 
osteogenic conditions [585] and the results of this study also showed that 
IGFBP-5 level was lower in cDPSCs compared with hDPSCs after 1 week in 
culture. Indeed, an earlier study revealed that IGFBP-5 expression was 
inhibited in stem cells isolated from inflamed periodontal tissue compared 
with healthy periodontal tissue. This suggested that inflammation itself might 
potentially down-regulate the local expression of IGFBP-5 [586]. 
It has been clearly demonstrated in the results of this study, that there was 
consistent,  reproducible up-regulation of IGFBP-2 gene expression in both 
hDPSCs and cDPSCs under osteogenic conditions at 1 and 3 week time 
points. These findings were mirrored in the results for protein concentrations 
in conditioned medium. The first report describing IGFBP-2 gene and protein 
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expression in osteogenic cultures was in osteoblast-like cells isolated from 
neonatal rat calvariae [587]. In later studies, IGFBP-2 expression at protein 
level was reported in both human and mouse osteoblast cell lines [588, 589]. 
Involvement of IGFBP-2 in enhanced osteogenesis was suggested by the 
observation of skeletal thickening associated with elevated serum IGFBP-2 
levels in hepatitis-associated osteosclerosis [590]. Despite two reports of 
inhibitory effects of IGFBP-2 on bone size, mass and proliferation of rat 
calvarias derived cells [591, 592], consensus opinion appears to favour an 
anabolic role of IGFBP-2 in osteogenesis either complexed with IGFs or 
acting independently of the growth factor [593, 594].   
It has been clearly demonstrated in the results from this part of the study that 
there was reproducible down-regulation of IGFBP-3 at gene and protein 
levels of in both hDPSCs and cDPSCs under osteogenic conditions at 1 and 
3 week time points. IGFBP-3 is a key component of the IGF axis and is the 
most abundant IGFBP in serum [595]. Although IGFBP-3 has been reported 
to have a direct role on bone formation at the growth plate [595], there 
remains a considerable debate concerning the effects of IGFBP-3 in bone 
[596]. IGFBP-3 overexpression was observed to be associated with 
enhanced osteogenesis and decreased osteoclastogenesis [597, 598]. 
Additionally, systematic treatment of ovariectomized rats with recombinant 
human IGF-1 (rhIGF-1)/IGFBP-3 complexes led to enhanced cortical bone 
formation [599]. Furthermore, Lee et al. (2014), demonstrated a reduction in 
bone marrow derived macrophage osteoclastogenesis when rhIGFBP-3 was 
used independently of IGF-1 [598]. IGFBP-3 and a non-IGF binding mutant 
IGFBP-3 reduced the osteoclast numbers and suppressed cell activity in 
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mice with collagen induced arthritis [598]. In contrast to these reports, 
overexpression of IGFBP-3 (in the presence of IGF-1) in transgenic mice led 
to increase in osteoclast activity and bone resorption together with 
diminished osteoblast proliferation and led eventually to decreased cortical 
and trabecular bone mineral density. This suggests that expression of 
IGFBP-3 that is largely bound to IGF-1, might sequester the IGF-1 from 
being delivered to the tissue, which can  impair its osteogenic function [596].  
Early studies suggested that the expression of IGFBP-3 can be regulated by 
glucocorticoids such as dexamethasone. Glucocorticoids inhibit IGFBP-3 
expression in hepatocytes [600] and fibroblasts [601], although these 
steroids are also reported to up-regulate IGFBP-3 expression in vivo [602]. 
Based on these reports, the levels of IGFBP-3 in the current study might be 
down–regulated due to the effect of dexamethasone in the osteogenic 
differentiation cultures. Another group who investigated the IGFBP-3 gene 
expression in an odontoblast-like cell line cultured in non- dexamethasone 
containing medium confirmed the expression of IGFBP-3 at later stages (25 
days) of differentiation [603]. However,  Jia et al. (2002), reported that 
IGFBP-3 gene expression was lower in dexamethasone-treated cultures at 
day 20, while at days 8 and 14, IGFBP-3 expression levels were higher in 
dexamethasone-treated cultures compared to non- dexamethasone controls 
in osteoprogenitor cells derived from the vertebral explants [604]. The use of 
dexamethasone free differentiation medium may, therefore, be indicated for 
future experiments and it would be interesting to compare the results of such 
experiments with those reported in the current study.  
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In contrast to the current findings, Reichenmiller et al. (2004), reported  that 
IGFBP-2 concentrations decreased slightly, while IGFBP-3 increased during 
differentiation of human pulp cells isolated from healthy third molars [582]. 
There are several possible explanations for this contradiction, Reichenmiller 
et al. (2004) assayed the cell extracts (and thus intracellular IGFBPs) to 
determine the protein concentration of IGFBP-2 and IGFBP-3, whilst in the 
current study, these proteins were measured in conditioned media. IGFBPs 
are essentially secreted proteins and therefore media conditioned by dental 
pulp cells are considered more appropriate sources to investigate IGFBP-2 
and IGFBP-3 concentrations in vitro.  Additionally, Reichenmiller et al. 
(2004), did not treat the cells with dexamethasone, or ascorbic acid but 
simply allowed confluent cells to differentiate in basal medium [582]. 
Furthermore, the current findings regarding IGFBP-2 (protein and gene) up-
regulation in osteogenic differentiation medium containing dexamethasone 
was confirmed by a previous study [604].  
In the current study, media conditioned by cDPSCs showed higher levels of 
IGFBP-2 and IGFBP-3 compared with hDPSCs in two out of three donors 
(Figure 41, Figure 42, Figure 43 and Figure 44). Inflammatory processes 
might explain such findings as it is considered a  key player in cDPSCs. The 
predominant inflammatory environment could activate NF-kB [605]. NF-kB 
translocation into the nucleus leads to expression of numerous target genes 
including IGFBPs [606]. 
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However the most exciting and novel data described in this chapter of the 
thesis relates to the functional interaction of IGFs and IGFBP-2/-3 and how 
this affects osteogenic differentiation of hDPSCs (Figure 46). IGF-1 clearly 
stimulated ALP activity in a dose dependant manner and this function in 
hDPSCs is enhanced by IGFBP-2 or inhibited by IGFBP-3 (Figure 46). The 
significance in these observations is that they integrate with the expression 
data of IGFBP-2 and IGFBP-3 in this chapter, which showed up-regulation of 
IGFBP-2 and down-regulation of IGFBP-3 under osteogenic culture 
conditions. These experiments designed where  the ratio of IGFs: IGBPs 
would vary as 0.1, 1 and 10 thus allowing study of IGFBP effects at below 
equimolar, at equimolar and above equimolar concentrations with respect to 
IGFs. The enhancing and or inhibiting actions of IGFBP-2 and -3 
respectively are not seen at the highest ratios of IGF: IGFBP and this was 
interpreted simply due the fact that the large excess of IGF-1 present under 
these conditions allows maximum levels of stimulation to be achieved 
irrespective of the presence of either IGFBP (Figure 46). hDPSCs appear to 
be less sensitive to the action IGF-2, although ALP stimulation still occurs at 
the highest concentration of this growth factor (Figure 46). 
In conclusion, this part of the  current  study showed consistent changes in 
gene and protein expression of IGFBP-2 and IGFBP-3 under osteogenic 
conditions compared with basal conditions, indicating that they could be key 
players in the osteogenic differentiation process of DPSCs, and have a role 
in the regenerative process.  
Using an in vitro functional assay the effects of IGFBPs were confirmed and  
consistent with the changes in gene and protein expression seen under 
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osteogenic culture conditions in hDPSCs. The regulatory roles of IGF axis in 
osteogenic/odontogenic differentiation processes and the interactions of IGF 
axis with other hormones, growth factors, extracellular matrix and 
inflammatory molecules raises more questions that need to be answered in 
context of basic and clinical research. In the next Chapter, details are 
provided for initial and preliminary experiments aimed at knocking out 
IGFBP-2 expression in hDPSCs in an attempt to further confirm a role of  
this gene in  osteogenic differentiation of  these cells.  ………………………...              
………………………...  ……………………………………….                                                          
.
  
223 
 
 Results 
 
Role of the IGFBP-2 in osteogenesis 
IGFBP-2 Knock down 
7.1 Introduction  
The results outlined in earlier chapters have clearly demonstrated that 
IGFBP-2 was consistently up-regulated in both hDPSCs and cDPSCs under 
osteogenic conditions compared with similar cells cultured under basal 
conditions. This opened a question to whether these changes in IGFBP-2 
profile were causally associated with the osteogenic differentiation of 
DPSCs, or whether they could be regarded as the result of differentiation to 
an osteogenic lineage. Evidence was presented in Chapter 6, Section 6.2.3 
that demonstrated IGFBP-2 did indeed play a functional role in the 
enhancement of the osteogenic activity of IGF-1. To further investigate the 
role of IGFBP-2 in osteogenic differentiation of hDPSCs, a gene knock down 
strategy was employed. These experiments were designed to determine 
whether IGFBP-2 knock-down in hDPSCs would down-regulate the ability of 
these cells to go down the osteogenic differentiation lineage. A short or small 
hairpin RNA (shRNA)-based knock down strategy was employed (Methods, 
Chapter 3, Section 3.2.8) with puromycin selection of stably transfected cell 
colonies. …………………………………… 
………………………………………………
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7.2 Results 
7.2.1 Lipid-based transfection 
Determination of the optimum puromycin concentration for selection of stably 
transfected clones was performed for hDPSCs at passage 4, in 6 well plates 
and a range of puromycin concentrations of 0-10 µg/mL (Figure 47); 
cDPSCs were not included in this experiment. The results demonstrated that 
the minimal concentrations of puromycin required to achieve 100% cell 
death in hDPSCs were between 4 and 6µg/mL. This range was therefore 
used for all subsequent lipid-based transfection experiments. 
In order to knock down IGFBP-2 gene expression in hDPSCs at passage 4,  
transfections of target and control plasmids were performed in 6 well plates, 
in which the concentration of plasmid was held constant at 1µg, while the 
ratio of concentration of transfection reagent varied between 1:1 and 1:6. 
Scrambled sequence shRNA was used as a negative control. The 
experiment was performed according to the manufacturer’s instructions 
(Methods, Chapter 3, Section 3.2.8). However, puromycin resistance could 
not be achieved by hDPSCs after three weeks. Observations showed that 
there was no indication of cell growth or proliferation using light microscopy 
(Figure 48). The puromycin optimisation experiment was therefore repeated 
to include a lower range of puromycin concentrations, 0-2.5 µg/mL. In a 
repeat experiments,  it was demonstrated that the minimum concentration of 
puromycin required to achieve 100% cell death was between 1 and 
1.5µg/mL, and this range was therefore used in all subsequent lipid-based 
transfection experiment. Then the knock down experiment was repeated as 
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described previously, and the observations again confirmed that hDPSCs 
showed no sign of growth or proliferation using light microscopy.   
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Results 
 
226 
 
 
 
Figure 47: Puromycin optimization 
hDPSCs  were treated with different concentrations of puromycin within the range 
0-10 µg/ml. The images show the appearance of hDPSCs after treatment with 
different concentrations of puromycin for (A) two days and (B) eight days hDPSCs 
were cultured in monolayers under basal conditions. Scale bar =100 µm 
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Figure 48:  Knock down of IGFBP-2 in 4µg/mL puromycin containing medium 
hDPSCs were treated with (A) control scrambled shRNA or (B) IGFBP-shRNA in 
transfection medium. Transfections of IGFBP-2 shRNA plasmid and control plasmid 
were performed in 6 well plates in which the concentration of plasmid was held 
constant at 1µg, while the concentration of transfection reagent varied between a 
ratio of 1:1 and 1:6. ,Scale bar= 100 µm 
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7.2.2 Electroporation-based transfection 
 Previous observations suggested that lipid-based transfection 
methodologies were unsuccessful to transfect hDPSCs. As an alternative, 
electroporation-based methodology was used. Electroporation is known to 
create transient pores in the cellular membrane and these permit nucleic 
acid to pass into the cells [387]. copGFP (green fluorescent protein cloned 
from copepod Pontellina plumata) control plasmid was used in this 
experiment as a positive control.  
Determination of the optimum puromycin concentration for selection of stably 
transfected clones was repeated for hDPSCs at passage 4 in 6 well plates 
and a range of puromycin concentrations of 0-2.5 µg/mL. The cells were 
exposed to different concentrations of puromycin after they had been 
exposed to an optimised electric voltage to demonstrate any changes can be 
caused by electroporation to the optimum puromycin concentration. The 
minimal concentrations of puromycin required to achieve 100% cell death in 
hDPSCs were between 1 and 1.5 µg/mL. These concentrations were used in 
all subsequent electroporation-based transfection experiments. 
In electroporation-based transfection experiment, hDPSCs at passage 4 
were used with either positive control (copGFP control plasmid), negative 
control (control shRNA plasmid) or IGFBP-2 shRNA plasmid in 
electroporation buffer. The protocol was adapted from a previous study, 
which optimised the electroporation conditions for transfection of dental pulp 
stem cells [388] (Chapter 3, Methods, Section 3.2.8 ). After 24 and 48 hours, 
the cells were checked using fluorescence microscopy and the results were 
completely negative, as the green fluorescence of copGFP (positive control) 
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could not be detected inside the cells, indicating failure of the electroporation 
process  to transfect this plasmid into the cells. …………………………………      
……………………………………
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7.3 Discussion  
In order to investigate whether the alteration in IGFBP-2 expression under 
osteogenic conditions in hDPSCs was causal or as a result of osteogenic 
differentiation, a number of attempts were carried out to knock down the 
gene expression of IGFBP-2 in hDPSCs. This part of the study aimed to 
generate a stably transfected cell line in which IGFBP-2 was targeted to be 
knocked down using a well-established route. Gene silencing allows 
investigation of gene function in primary cells [607, 608], and shRNA 
technology used in the current study has previously been successfully used 
to knock down IGFBP-2 in breast cancer cells [609]. Studies have shown for 
the first time that RNA interference is an active pathway in mammals [610], 
and this suggested a reverse genetic approach using RNA interference in 
mammalian systems. The RNA interference approach depends on the 
formation of double-stranded RNA, in which the antisense strand is 
complementary to the transcript of the gene of interest. Figure 49 illustrates 
how RNA silencing becomes functional using stem loop constructs encoding 
hairpin RNA, resulting in intracellular production of siRNA-like species [608].      
Lipid-based chemical transfection is commonly used, in which a lipid 
transfection reagent allows the shRNA plasmid to pass into the cells.  
Among gene delivery systems, viral-based vector methods are known to be 
highly efficient in stable transfection over a prolonged period. Although 
chemical methods result in lower transfection efficiency, these are simpler to 
use and are considered biologically safe in comparison to virus-based 
vectors [611-613]. 
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To select a stably transfected cell line, an antibiotic (puromycin) resistance 
system has been used in the present study as a selection marker introduced 
to the cells after transfection. Only those cells which have integrated the 
plasmid survive, and these contain the drug-resistant gene. 
 
 
 
Figure 49: Mechanism of shRNA based gene silencing  
Gene silencing using micro RNA designed hairpin RNA. An enzyme known as Dicer 
cleaves the hairpin RNA and generates small RNA called short interference 
molecule. The RNA-induced silencing complex (RISC) uses siRNA as a guide in 
the sequential specific cleavage of the target RNA transcript. 
(Santa Cruz Biotechnology, RNA interference, www.scbt.com/gene_silencers.html) 
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This current study has demonstrated the difficulty in transfecting dental pulp 
cells as a mixed primary population using a lipid-based chemical transfection 
technique. hDPSCs in the present study were unable to develop puromycin 
resistance after lipid-based transfection, indicating the failure of these cells 
to take up the plasmid. Although chemical-based transfection techniques are 
simple to apply and require no special equipment, they are relatively 
expensive and showed  insufficient transfection of primary cells in our hands. 
This might be related to the sensitivity of hDPSCs and the problem of the 
cytotoxicity of such reagents also remains an issue [614]. 
 It was therefore decided to use the alternative transfection technique of 
electroporation [615].  This is based on the application of high voltage pulses 
which can cause transient pores in the cellular membrane and allow the 
transfection materials to access the intracellular compartment [387, 616]. 
This technique has been successful to transfect MSCs from different 
sources [617]. In addition, other groups have studied the difference between 
electroporation and alternative commercially available transfection reagents 
[613], based on the human dental follicle cells isolated from human impacted 
third molars, and have concluded that electroporation results in relatively 
higher transfection efficiency, with higher cell viability compared with 
chemical transfection techniques [613].  
 In the current study, the optimised electroporation parameters have been 
adapted from the studies of Rizk et al. (2012), who examined dental pulp 
stem cells isolated from sound healthy premolars. They reported that the 
highest transfection efficiency was achieved under 100V, 20msec and one-
pulse square-wave conditions [388]. In contrast to the studies of Ahmed Rizk 
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et al. (2012), the current observations showed no evidence of successful 
transfection proved by using copGFP as positive control. Although similar 
conditions to those described by Rizk et al. (2012), have been used, 
transfection of hDPSCs was not successful in the current study. There may 
be several reasons why this is the case; for example, this inconsistency may 
be the result of differences in the electroporation buffer or culture conditions. 
The degree of permeablisation can be manipulated by the ionic strength of 
the buffer in which the cells are electroporated [618]. Commonly, a high ionic 
strength buffer (low resistance) is used in electroporation [387], and serum-
free growth media have been used in the present study as electroporation 
buffer. However, we cultured the cells after electroporation in complete 
growth medium (containing 20% FBS), although the earlier study did not 
indicate the culture conditions following electroporation. Studies on 
transfection of dental follicle cells using electroporation have demonstrated 
that adding BSA or FBS in the electroporation buffer significantly improved 
cell viability and increased the number of transfected cells [619]; this could 
be worth considering in the transfection of DPSCs in the future. 
When a specific cell type is difficult to transfect, this might indicate that its 
membrane is difficult to penetrate. The properties and composition of  the 
cell membrane show considerable variation in different types of cells. The 
charge offered by the plasma membrane of a given cell type, its thickness 
and the orientation of its molecules, together with its chemical interaction 
with the transfection reagent, will all have a role in the efficiency of 
transfection. For example, Glycocalyx, which is glycoprotein-polysaccharide 
located in the outer cell membranes of certain bacteria, epithelia and other 
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cells [620], has a negative charge, and this plays an effective role in the 
uptake of lipoplexes into the cells [621]. It has however been reported that 
cationic species can readily pass through the negatively charged cell 
membrane [621]. This can serve to explain why certain virus protein coat 
which is simply a sequence of positively charged amino acids can 
successfully perform cell transfection. Cationic liposome-based gene 
delivery has proved successful in cell transfection [621]. Lipoplexes larger 
than 200nm may internalize through caveolin-mediated endocytosis, 
although smaller complexes can also be internalized via endocytosis [622]. 
These methodologies may be worth further investigation to achieve 
successful transfection of hDPSCs. The lipid structure may also play a role 
in achieving a high level of effectiveness in transfection [623]. Additionally, 
helper lipids can be used in lipofection, and are responsible for forming the 
inverted hexagonal structure in liposomes which results in the release of  
DNA from lipoplex into the cytoplasm [624]. This also promotes optimum 
fluidity of bilayer of lipoplexes that improves the interaction of vector with cell 
membrane [625].  
Interestingly, a recently developed nucleofection protocol has been used 
successfully to deliver transfection reagent to the nucleus. Nucleofection is a  
physical method based on electroporation and uses a combination of 
electrical parameters applied by a nucleofector with specific reagents [626]. 
It can therefore be used for non-dividing cells such as neurons [627] and 
resting blood cells, in addition to other cells known to be difficult to transfect 
such as human umbilical vein endothelial cells [628].  
Chapter 7: Results 
 
235 
 
It might be necessary to optimise the electroporation parameters on a sorted 
population of dental pulp cells to achieve an adequate level of transfection 
efficiency including cell concentration, electroporation media, DNA 
concentration, pulse type and voltage [387, 388, 613]. The differences in 
published electroporation protocols suggest that minor variations need to be 
adapted to each type of cell .  
Developing techniques to transfect dental pulp stromal/stem cells as a mixed 
primary population is an important step in the further investigation of gene 
function for future tissue engineering.      ……………………………………….
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 General Discussion 
8.1 General discussion 
 Dental caries and the consequent pulp inflammation cause major changes 
in the dental pulp tissue caused by bacterial invasion into the dentine-pulp 
complex [175, 177, 462, 629, 630]. It is now well-acknowledged that DPSCs 
can be successfully isolated and cultured from teeth with deep caries, 
although there are controversial data published regarding their ability to 
retain stem cell surface marker expression and tissue regeneration potential 
[175, 177]. However, none of the previous studies have performed thorough 
investigations of DPSCs isolated from teeth with shallow caries (i.e. 
cDPSCs), including the expression of stem cell markers, osteogenic, 
angiogenic and inflammatory markers, as well as the expression of IGF axis. 
This project set out to better characterise and identify changes in the 
expression of stem cell and other selected markers in cDPSCs under basal 
and/or mineralisation conditions compared with hDPSCs. The IGF axis, 
which plays a crucial role in mineralised tissue formation, was profiled for the 
first time in this study in cDPSCs. All markers were investigated in each 
donor in the cDPSCs group and then compared with the donors in the 
hDPSCs group, which were cultured under exactly the same conditions. 
Understanding of the inflammation-regeneration processes might help to 
determine whether the cDPSCs can be used for mineralised tissue 
regeneration, either in situ for dentine/pulp complex, or as a source of 
autologous stem cells for bone regeneration 
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In this study, hDPSCs and cDPSCs showed the classic features of MSCs; 
they were found to express the following stem cell markers: CD146+, 
CD105+, CD90+, and were negative for the following markers: CD45- and 
CD31- . They both demonstrated remarkable colony-forming ability, plastic 
adherence and osteogenic differentiation potential. An earlier studies 
observed that cDPSCs isolated from teeth with deep caries expressed 
comparable stem cell surface markers compared with DPSCs isolated from 
healthy teeth [175, 177, 414]. The multi-lineage differentiation potential of 
these cells has also been investigated earlier [175].  
The findings of the current study concluded that cDPSCs exhibited a higher 
potential to differentiate into an osteogenic lineage compared with hDPSCs. 
This was confirmed in two out of three donors in almost all marker genes. 
Although the pattern of changes in the selected markers under basal and  
mineralisation culture conditions was comparable in both hDPSCs and 
cDPSCs, the level of expression in cDPSCs were apparently affected by the 
inflammatory micro-environment. Two members of the IGF axis; IGFBP-2 
and IGFBP-3, demonstrated consistent changes under mineralisation culture 
conditions in both hDPSCs and cDPSCs; however, the expression of these 
members appeared to be influenced by inflammation in cDPSCs cell 
cultures. Interestingly, earlier studies observed that early pro-inflammatory 
cytokines promoted the mineralisation of DPSCs [631]. Dentine extracellular 
matrix expresses a range of bioactive molecules that have previously been 
reported to influence differentiation of dental pulp cells and mineralisation 
[632-635]. These bioactive dentine extracellular matrix molecules are 
released as a result of degradation of dentine extracellular matrix due to the 
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action of acids and proteolytic enzymes derived from both invading bacteria 
and immune response cells [636, 637]. Dentine extracellular matrix 
breakdown products have been previously shown to be essential and involve  
powerful signalling molecules such as basic fibroblast growth factor (bFGF), 
Insulin-like growth factor (IGF), transforming growth factor-β (TGF-β) [205, 
638-640]. The ability of different molecules to stimulate dentine formation in 
vitro and in vivo has been proven earlier [108]. The expression of angiogenic 
factors in dental pulp cells was up-regulated during pulp inflammation. It has 
been suggested that this observation is due to the role of inflammatory 
cytokines that are released into the pulp interstitial fluid during inflammation 
[641, 642]. In addition, activation of TLRs has been observed to stimulate 
the neoangiogenesis processes along with inflammatory responses [274, 
285, 325]. The angiogenic growth factor; VEGF [643, 644], was observed to 
be expressed by inflammatory cell infiltrates,  including neutrophils, 
eosinophils and lymphocytes in profound dental pulp inflammation [499], and 
it was expressed by monocytes and macrophages [645]. An earlier study 
suggested that VEGF is potentially valuable in repairing inflamed pulp tissue 
through angiogenic activity, which is required at the sites of injury [499]. 
Tissue reparative events will favourably occur when the infection and 
inflammation are under control, either due to an effective immune response 
that eliminates the infection or as a result of clinical treatment that aims to 
resolve the disease and restore the function of the tissue [25]. Fine-tuning 
and balance between defence and repair processes is basically the key 
factor in regulating such complex events [25]. Interesting studies 
demonstrated that the immune- and repair-related stem/progenitor cells 
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expressed the same receptors; for example, C-X-C receptor 4 (CXC4) was 
expressed on both cell types [646, 647], stromal cell derived factor-1 (SDF-
1) and its ligand CXCL12 were reported to be expressed within the dentine-
pulp complex [648]. Sharing of receptors between immune and repair-
related cells can be explained by the parallel needs of both immune and 
stem cells during caries infection, in attempt to repair the damaged tissue 
[649].     
The cross talk between inflammation and mineralised tissue formation is a 
controversial and interesting area to discuss. Lipopolysaccharide- activated 
TLR-4 can promote odontogenic differentiation of human DPSCs isolated 
from healthy teeth via ERK and p38 MAPK signalling pathways but not NF-
kB signalling [297]. On the other hand, another study reported that NF-kB  
potentially activates the osteogenic transition and promotes the ectopic 
mineralisation of aortic valves [544]. It has also been reported that TLR-4 
signalling was down-regulated during the mineralisation stage of murine 
odontoblast-like cells [650]. TLR-4 inhibits bone marrow MSCs differentiation 
into osteoblasts through its inhibitory effect on the Wnt signalling pathway 
[651]. The inflammatory cytokines as well demonstrated controversial role 
during mineralised tissue repair. For example, IL-6 levels were increased in 
response to mechanical strain, indicating that this cytokine might have an 
anabolic effect during distraction osteogenesis, although it was also reported 
to have a catabolic effect during fracture repair [539]. 
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8.2 Conclusion 
This research characterised DPSCs isolated from teeth with shallow caries. 
The data generated confirmed that cDPSCs exhibited a higher potential than 
hDPSCs to differentiate into an osteogenic lineage, with a higher trend to 
express stem cell, osteogenic, angiogenic and inflammatory markers under 
basal culture conditions. These findings (along with the observed differences 
in the expression of selected markers in cDPSCs under mineralised culture 
conditions compared with hDPSCs) may shed light on the cDPSC . These 
cells in particular are almost always extracted and discarded; however, they 
may prove potential for future applications for mineralised tissue repair and 
regeneration. Changes in the expression of osteogenic, angiogenic and 
inflammatory markers in both hDPSCs and cDPSCs under basal and 
osteogenic conditions are summarized in Table 23 and     Table 24 .  
 
8.3 Limitations  
Variability of cell behaviour and response may due to donor variation as well 
as to true differences between cells. Unfortunately, it is almost impossible to 
isolate healthy and carious DPSCs from the same patient and same type of 
tooth. Furthermore, the available samples for hDPSCs and cDPSCs were 
generally collected from the tissue bank with very restricted information 
about patients’ medical or dental history. These are important features in 
examining and interpreting the behaviour of the cells. Efforts were made to 
restrict the variability within DPSCs population by including only Wisdom 
teeth. However, there still remained concerns of donor variation in respect of 
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age, gender and patient’s history, which might explain some reported 
variations in the gene and protein expression seen across the results from 
all three donors in each group.  Nonetheless, the findings presented in this 
study demonstrated to a great extent very good reproducibility between the 
donors in each group, as at least two out of three donors showed the same 
pattern of gene and protein expression in each category under both culture 
conditions and different time points. 
Finally, this study showed unsuccessful attempts to establish stably 
transfected DPSC lines. The development of stably transfected cell lines is a 
pre-requisite for our mechanistic studies, due to the lengthy time course(s) 
associated with most differentiation protocols and particularly with the use of 
cells in tissue engineering protocols; it is believed that such studies are 
worth revisiting drawing on the expertise of members within the group, 
department and indeed elsewhere. 
 
8.4 Future work 
A more extensive use of dental tissue material to include stem cells isolated 
from PDL or SHED may prove informative and it would be interesting to 
compare the behaviour of cells isolated from these tissues with DPSCs 
reported in the current study. The development of methodologies to screen 
larger groups of the population would be useful, particularly if combined with 
3D culture methodologies.  
The use of flow cytometry as an analytical tool in experiments with DPSCs 
has been demonstrated in the current study. An access to FACS also as a 
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preparative tool (via a cell sorter) is also available and the use of the FACS 
data in this thesis as guide to design an appropriate cell sorting experiments 
will lead to the isolation of enriched stem cell populations, which can led to 
more successful transfection experiments. An enriched or purified stem cell 
population will permit testing the hypothesis that subpopulations of cells may 
show a preference for differentiation down a particular phenotypic lineage 
and may be a good basis for future investigation, which would allow 
development of customised tissue engineering strategies.                             .   
………………………………………. 
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Table 23: Summary for regenerative marker expression in both hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) under basal conditions  
                         + , + + and + + + indicate low, moderate and high level of expression         ↑  and  ↓  indicate increase or decrease with time          
 
  Osteogenic markers          Angiogenic markers                                 Inflammatory markers 
 
 ALPL OC RUNX-2 VEGFR-2 PECAM-1 TLR-2 TLR-4 IL-6 IL-8 
H1 
1W 
+ + + + + + + + + + + + 
3W ↑ ↓ ↓ ↑ ↑ ↑ + ↑ ↑ 
H2 
1W 
+ + + + + + + + + + + + + 
3W ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↑ ↑ 
H3 
1W 
+ + + + + + + + + + + + 
3W ↑ ↑ ↓ + ↑ ↑ ↑ ↑ ↑ 
C1 
1W 
+ + + + + + + + + + + + + + + + 
3W ↑ ↑ ↓ ↓ ↓ ↑ ↓ ↓ ↑ 
C2 
1W 
+ + + + + + + + + + + + + + + + 
3W ↑ ↑ ↑ ↓ ↓ ↓ ↓ ↓ ↑ 
C3 
1W 
+ + + + + + + + + + + + + + + + 
3W ↑ ↓ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
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    Table 24: Summary for regenerative marker expression in both hDPSCs (H1, H2, H3) and cDPSCs (C1, C2, C3) under osteogenic    
conditions.          
                                                 ▲  and  ▼ indicate up-regulation and down-regulation under osteogenic conditions   
  Osteogenic markers          Angiogenic markers                                 Inflammatory markers 
 
 ALPL OC RUNX-2 VEGFR-2 PECAM-1 TLR-2 TLR-4 IL-6 IL-8 
H1 
1W 
▲ ▼ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
3W 
▼ ▲ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
H2 
1W 
▲ ▼ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
3W 
▼ ▲ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
H3 
1W 
▲ ▼ ▲ ▲ ▲ ▼ ▲ ▼ ▲ 
3W 
▼ ▲ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
C1 
1W 
▲ ▲ ▲ ▲ ▲ ▼ ▲ ▼ ▲ 
3W 
▲ ▲ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
C2 
1W 
▲ ▼ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
3W 
▲ ▲ ▲ ▲ ▲ ▲ ▲ ▼ ▲ 
C3 
1W 
▲ ▲ ▲ ▲ ▲ ▲ ▼ ▼ ▲ 
3W 
▼ ▲ ▲ ▲ ▼ ▲ ▲ ▼ ▲ 
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